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Abstract 
Background Vaccination of pregnant women with conserved group B Streptococcus 
(GBS) surface proteins has the potential to confer serotype independent protection 
against invasive GBS disease. Susceptibility to early onset (<7 days of age) GBS 
disease in infants is associated with maternal recto-vaginal colonisation, low circulating 
maternal antibodies and reduced trans-placental transfer of antibodies specific to GBS 
capsular polysaccharides (CPS). Additionally, invasive GBS disease beyond infancy has 
been reported in individuals with underlying conditions associated with 
immunosuppression including HIV infection. In this study we undertook retrospective 
analysis of serum IgG titres against select GBS surface proteins in relation to invasive 
GBS disease risk factors. 
Methods Multiplex Luminex immunoassay was used to measure serum IgG titres 
against GBS capsular polysaccharides of serotype Ia, Ib, III and V and surface proteins 
Fibrinogen binding surface Antigen (FbsA), GBS Immunogenic Bacterial Adhesin 
(BibA), Surface immunogenic protein (Sip), gbs0393, gbs1356, gbs1539, gbs0392; and 
lipoproteins gbs0233, gbs2106 and Foldase PsrA. Furthermore, in vitro expression of 
Sip, gbs2106, gbs0393 and gbs1356 proteins on the surface of clinical GBS isolates was 
assessed by flow cytometry using protein specific polyclonal antibodies generated in 
rabbits.  
Results Retrospective analyses of serum antibody titres against GBS surface proteins 
and CPS were measured in children between 4-7 years of age who were either HIV-
infected (n=68) or HIV-uninfected (n=77). Lower geometric meant titres (GMT, U/mL) 
against Sip and gbs2106 were detected in HIV-infected children (77.03 and 53.10) 
compared to HIV-uninfected children (196.41 and 139.11, p<0.001) respectively. 
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Similar results were observed for antibodies against CPS, with HIV-infected children 
having lower IgG GMC for serotype Ib (p=0.012) and V (p=0.005). 
Protein specific antibody titres were measured in pregnant women at 20-25 and ≥37 
weeks of gestation age who were either non-colonised or colonised with GBS in the 
rectal and/or vaginal tract. Acquisition of GBS colonisation in the vagina was associated 
with higher antibody titres compared to colonisation in the rectum for proteins Sip 
(p=0.049), Foldase (p=0.0094), gbs0233 (p=0.0039), gbs0393 (p=0.027), gbs1539 
(p=0.0004) and gbs1356 (p=0.039). The likelihood of acquiring GBS colonisation 
during pregnancy was lower in women having median IgG titres against gbs0233 ≥200 
U/mL (adjusted OR=0.47 [95% CI: 0.25-0.89], p=0.021) and gbs1539 ≥85 U/mL 
(adjusted OR=0.44 [95% CI: 0.24-0.82], p=0.01).   
The influence of maternal HIV infection on trans-placental transfer of antibodies against 
GBS surface proteins was evaluated by comparing IgG titres between 83 HIV-infected 
and 81 HIV-uninfected mother-newborn dyads. Maternal HIV infection was associated 
with reduced trans-placental transfer of antibodies, demonstrated by the difference in 
cord-maternal antibody ratios between HIV-infected and HIV-uninfected mother-
newborn pairs for Sip (25.8%, p<0.001), Foldase (30.4%, p<0.001), gba0392 (36.5%, 
p=0.006), gbs0393 (32.9%, p<0.001), gbs1539 (39.2%, p<0.008), gbs2106 (35.7%, 
p<0.001) and BibA (19.4%, p=0.004). 
A case control study was used to evaluate the association of protein specific IgG titres 
and invasive disease in neonates and young infants born to GBS colonised mothers, 
including 116 with healthy infants and 66 with invasive GBS disease at <90 days of 
age. Lower IgG GMT were detected in neonates who developed early-onset disease 
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compared to control infants for Sip (65.48 vs 145.43, p<0.001), Foldase (50.45 vs 
109.87, p=0.005), gbs0393 (106.42  vs 221.81, p=0.006) and gbs1356 (45.34 vs 94.52, 
p=0.01). Similarly, young infants with late-onset disease had significantly lower IgG 
GMT (U/mL) compared to healthy controls for Sip (43.72 vs 79.69, p=0.04) and 
gbs2106 (30.46 vs 65.35, p=0.003). Infants born to women with Sip specific antibody 
titres ≥150 U/mL antibodies titres against Sip were 66% less likely to develop invasive 
disease. 
Of the 82 GBS isolates collected from mothers who deliverd term babies (39 with 
invasive GBS disease and 43 healthy controls) that were assessed for in vitro expression 
of specific proteins, Sip, gbs2106 and gbs0393 were expressed in 70.7% 93.9% and 
87.8% GBS isolates respectively. The expression of gbs2106 on the surface of GBS was 
more frequent in strains of women with infants who developed invasive disease 
compared to those with healthy infants (100% vs 88.4%, p=0.028). The distribution of 
Sip and gbs0393 expression between GBS isolates from women of infants with invasive 
GBS disease and healthy controls was similar, 71.8% vs 69.8% (p=0.84) and 89.7% vs 
86.0% (p=0.61) respectively. Among women carrying GBS strains expressing gbs2106, 
having antibody titres ≥100 U/mL was associated with 90% lower likelihood for 
delivering infants that develop invasive GBS disease (OR=0.11 [95% CI: 0.02-0.54], 
p=0.002).  
Conclusion Vulnerability to invasive GBS disease in HIV-infected 
immunocompromised individuals is possibly due to reduced antibody levels against 
CPS, Sip and gbs2106. Also, susceptibility to invasive GBS disease in infants may be 
exacerbated by maternal HIV-infection, which was associated with reduced trans-
placental transfer of antibody against GBS surface proteins. 
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Higher maternal antibodies titres against Sip and gbs2106 proteins were associated with 
reduced odds of their infants developing invasive GBS disease. These data support 
consideration of Sip and gbs2106 proteins as possible vaccine candidates in pregnant 
women to protect their infants against invasive GBS disease. Furthermore, reduced GBS 
colonisation during pregnancy can be achieved by maternal immunisation of gbs0233 
and gbs1539, which may subsequently result in lower rates of GBS transmission to 
newborns and thereby decreasing their risk for invasive GBS disease.  
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1.1 Study rationale 
An estimated 6.3 million deaths occur in children ≤5 years of age, of which 44% of 
these deaths occur during the neonatal period (1). Group B streptococcus (GBS) is the 
most common infectious cause of neonatal morbidity and mortality with the highest 
incidence rate reported in sub-Saharan Africa (2). The strongest independent risk factor 
associated with development of invasive GBS disease in infants is maternal recto-
vaginal colonisation during pregnancy (3). The prevalence of GBS colonisation in the 
recto-vaginal tract of pregnant women is 10-30%, resulting in 30-50% vertical 
acquisition of GBS in utero or at intrapartum in newborns, of whom 1-3% develop 
invasive disease (4).  
Thus, administration of intrapartum antibiotic prophylaxis (IAP) in pregnant women 
identified to be at risk of transmitting GBS to their infants has been adopted in 
industrialised countries as an intervention strategy (5,6). Although this method of 
prevention has successfully reduced the incidence of GBS early onset disease in high 
income countries, cost and logistical problems has impeded the adoption of this strategy 
in low-income countries where the burden of invasive GBS disease is the highest 
(2,6,7). The majority (75-90%) of early onset disease in the absence of IAP occurs 
within 24 hours of birth; hence, limiting opportunity for an effective intervention once 
the baby is born (6,8). 
The ascertainment that high maternally derived GBS capsular polysaccharide (CPS) 
antibodies in newborns are associated with reduced incidence of serotype-specific 
invasive GBS disease has prompted immunisation of pregnant women as an alternative 
prevention strategy (9–14). Current clinical studies have focussed on the development 
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of multivalent serotype-specific polysaccharide vaccines inclusive of a highly 
immunogenic protein conjugant (15–17). A limitation of this, however, includes 
geographic and temporal differences in serotypes associated with GBS colonisation and 
invasive disease.  
Alternatively, a vaccine formulation strategy would be to use epitopes which are 
genetically conserved and shared among all GBS serotypes and strains as vaccine-
targets. Protein antigens are highly conserved among GBS serotypes and therefore can 
confer serotype-independent protection. The prevalence of GBS-protein antibody titres 
in women and their respective neonates, and their association with invasive GBS 
disease in neonates has been shown for pilus island proteins, however, protective 
antibody threshold has not been established (18). Therefore, measuring antibody titres 
induced by surface proteins that are correlated with disease protection is warranted for 
identifying vaccine candidates that are capable of broad-serotype coverage.  
Furthermore, maternal antibodies directed against GBS surface proteins induce antibody 
mediated opsonophagocytic killing associated with a reducing GBS colonisation in 
pregnant women (19). Therefore, consideration to investigate the potential role of GBS 
surface proteins in preventing and/or clearance of GBS colonisation is warranted. 
Identifying GBS proteins capable of eliminating GBS colonisation in pregnant women 
could reduce the risk of vertical acquisition of GBS in newborns. 
Recently it has been reported that intrauterine HIV-exposure increases the risk of 
developing invasive GBS disease in HIV-exposed uninfected infants compared to HIV-
unexposed uninfected infants (20,21). Reduced efficiency of placental transfer of 
protective antibodies against CPS epitopes are postulated to play a role in increased 
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susceptibility to invasive GBS disease in HIV-exposed uninfected infants. This suggests 
that increased GBS disease in infants may be mediated by the impaired ability to 
transfer maternal antibody in HIV infected mothers, and therefore further studies are 
required to investigate the effect of maternal HIV-infection on protein antibody titres 
and the trans-placental transfer thereof. 
Moreover, invasive GBS disease has an unconventional age distribution that rarely 
occur in children >3 months of age when maternal derived antibodies have waned. 
About 6% of invasive GBS disease occur among 1 month to 17 year old children, with 
all cases having underlying comorbid conditions associated with immunosuppression 
such as diabetes mellitus, cancer and HIV infection (22). Therefore, immune-
suppression is associated with an increased risk of invasive GBS disease in older 
children and adults (22,23); however, the particular mechanism that causes this 
increased risk is unclear.  
1.2 Aims and Objectives 
The aim of this study was to identify and produce highly immunogenic GBS surface 
proteins; and measure the natural induced antibody response specific to the selected 
GBS surface protein antigens in relation to maternal GBS colonisation, invasive GBS 
disease in infants, in utero HIV exposure in newborns and HIV infection in older 
children. 
Objectives 
1. Clone, express and purify GBS surface proteins identified in silico as highly 
immunogenic. 
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2. Measure the natural induced antibody response to GBS surface proteins and 
capsular polysaccharides in relation to: 
a. HIV status in children: compare antibody titres in HIV-uninfected 
and HIV-infected children against GBS surface proteins and capsular 
polysaccharides. 
b. GBS colonisation in pregnant women: 
i. Measure serum IgG titres in women at 25 weeks of gestation age 
and association with subsequent risk of GBS recto-vaginal 
acquisition during pregnancy. 
ii. Determine protein specific antibody titres associated with 
clearance of GBS colonisation by comparing antibody tires in 
women who are persistently colonised with GBS throughout 
pregnancy and those who clear GBS colonisation during 
pregnancy. 
c. In utero HIV exposure: Compare antibody titres in HIV-infected and 
HIV-uninfected mother-newborn dyads, to determine the effect of 
maternal HIV status on the efficiency of protein specific trans-
placental antibody transfer during pregnancy. 
d. Invasive GBS disease in infants: Determine the association of 
maternal antibody titres specific to GBS surface proteins in relation 
to the odds of developing invasive GBS disease in infants born to 
GBS colonised women.  
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2.1  Streptococcus agalactiae 
Streptococcus agalactiae is a Gram-positive, β-haemolytic facultative anaerobe visible 
as short cocci chains and belonging to the Streptococcaceae family. S. agalactiae is also 
known as Lancefield group B streptococcus (GBS) according to the Lancefield 
classification based on the encapsulating polysaccharides (24). GBS is classified into 
ten serotypes (Ia, Ib, II through to IX) based on the chemistry of encapsulating 
polysaccharides (CPS), which are antigenically distinct (24–26).  
Capsular serotyping is the classical GBS characterisation or typing technique, albeit 
additional molecular typing techniques for classifying GBS have been used, such as 
multi-locus enzyme electrophoresis, pulse-field gel electrophoresis, restriction 
endonuclease digestion pattern, restriction fragment length polymorphism and multi-
locus sequence typing (MLST) (27). These techniques are used to distinguish GBS into 
clonally related strains and similar genetic structures in order to identify genotypes 
associated with invasive GBS disease. MLST is the least ambiguous typing technique 
utilising seven housekeeping gene sequences to define non-overlapping sequence types 
(ST) (28). The major sequence types identified are ST1, ST19, ST17, and ST23. ST-17 
has been observed to be associated with hypervirulent clones, whilst ST1 and ST19 are 
associated with asymptomatic colonisation and ST23 is associated with both invasive 
and colonising clones (28).  
GBS isolates can be further differentiated based on surface localised proteins: α-C, β-C, 
epsilon, alpha-like protein and Rib encoded by genes acp, bac, epsl, apl and rib 
respectively (29).  The expression of these proteins occurs commonly in certain 
serotypes and thus in turn are associated with either colonising or invasive GBS isolates 
(29–32). Additionally, clinical isolates have been characterised based on pilus island 
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genes (PI) that express flagellin proteins that function as bacterial adhesions (33). The 
type or various combinations of PI genes expressed by a particular GBS isolate have 
been shown to be associated with either colonisation or invasiveness of the bacterial 
infection (34).  
2.2 Clinical manifestation of group B streptococcus   
GBS is the leading infectious cause of morbidity and mortality in neonates; causing 
pneumonia, meningitis and septicaemia (2,35). GBS disease among children clinically 
presents as a bimodal distribution in early-infancy, and hence classified as either early-
onset disease (EOD, <7 days of age) or late-onset disease (LOD, 7-90 days of age).  
EOD manifests mainly as pneumonia or septicaemia and has a case fatality ratio of 2%-
21% (2). EOD usually results from vertical acquisition of GBS, in which recto-
vaginally colonised mothers infect the neonate either in utero or intrapartum. In 
industrialised countries, the introduction of intrapartum antibiotic prophylaxis (IAP) in 
GBS colonised women has resulted in  >80% decrease in the incidence of EOD  (36). 
LOD mostly manifests as septicaemia or meningitis and has a case fatality ratio of 2-
20% (2,37,38). Furthermore, 10-50% of infants who survive meningitis will develop 
permanent neurological sequelae such as mental retardation, blindness, deafness or 
severe disability (39). Although the mode of LOD infection is poorly understood, it is 
thought to be horizontally transmitted from mother to child, since the majority of cases 
have identical GBS isolates in the mother and infant (40). LOD has remained fairly 
constant in USA and elsewhere over the past decades, and is not prevented through  IAP 
treatment during labour (2).  
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GBS infection also accounts for maternal morbidity among pregnant women causing 
bacteraemia, chorioamnonitis, endometritis and urinary tract infections (23,41,42). This 
subsequently results in pregnancy complications that are associated with prematurity, 
low-birth weight and also GBS-related stillbirths (43,44). Furthermore, a continued 
increase in the proportion of invasive GBS disease among the elderly especially in the 
population >65 years has been reported (23,45). Invasive GBS disease among the 
elderly commonly manifests as bacteraemia with no focus, pneumonia, urinary tract 
infections (UTI) and meningitis, in most cases occurring in patients with underlying 
conditions (45). 
2.3 Epidemiology of invasive GBS disease 
There is an estimate of 2.7 million deaths per year that occur during the neonatal period 
(1), with neonatal sepsis, pneumonia and meningitis accounting for approximately 20% 
of these cases, and GBS being a leading bacterial cause of death during the neonatal 
period (1,2,46). The burden of neonatal invasive GBS disease is highest in African 
countries with an estimated incidence of 1.21 cases per 1000 live births compared to 
0.67 in the Americas, 0.57 Europe, 0.35 Eastern Mediterranean, 0.15 Western Pacific 
and 0.02 in South-East Asia (2). 
Overall, the major invasive serotypes of GBS are type-Ia, Ib, II, III and V (2,37). 
Serotype Ia, and III account for 40% and 37% of EOD cases, while serotype III is the 
predominant (53%) cause of LOD (2). However, the prevalence and distribution of 
invasive GBS serotypes differ according to geographical region, where serotype V 
predominantly occurs in some industrialised countries, (47) and with type VI and VIII 
being frequent colonisers of pregnant women in South-East Asia (48). Additionally 
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non-typeable GBS strains that cause invasive disease in the neonatal period have been 
isolated in 3-15% of cases (2,49).  
Molecular epidemiological classification of neonatal isolates showed that ST-17 
belonging to serotype III was more frequent among LOD cases (75.3%) compared to 
63.5% EOD cases (49). GBS isolates of ST-17 cause meningitis more frequently than 
sepsis, particularly for LOD cases (50). The hyper-virulence of ST-17 has been linked 
with an allelic variant of bacterial adhesion protein A (BibA) that mediates invasion of 
blood brain barrier and is expressed exclusively among ST-17 isolates (51). 
Furthermore ST-17 is associated with a specific combination of pilus island genes, such 
as PI-1 and PI-2b that frequently occur in LOD cases (52). ST-19 which is associated 
with maternal colonisation and accounts for 18-30% of GBS related EOD cases, almost 
exclusively expresses PI-1 and PI-2a combination (49,50,52,53). 
Maternal morbidity due to GBS infection occurs in 0.04-0.12 cases per 1000 women-
years (23,41). The distribution of invasive GBS serotypes among pregnant women is 
more heterogeneous than that observed in infants, with serotypes Ia to V occurring in 
similar percentages (9%-22%) (41). In non-pregnant adults, particularly the elderly, 
serotype V predominates among invasive isolates and accounts for 27.5% of cases (45).  
The implementation of IAP has resulted in a significant reduction in EOD, effectively 
decreasing the number of cases from 1.8 to 0.26 cases per live births from 1990s to 
2010 in the USA (6). However, in low income countries, particularly sub-Saharan 
African region, where cost and logistical problems limit implementation of IAP-like 
preventative strategies, the prevalence of EOD has remained high at 1.3 cases per 1000 
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live births (7). Furthermore, the incidence of LOD has remained unchanged in USA,  
despite successful adoption of IAP as a standard of care (6).  
Given that the probability of introducing a multivalent GBS CPS serotype Ia, II, III and 
V vaccine could result in 50-90% neonatal invasive GBS disease case reduction (54), 
factors such as socio-economic status, geographic and temporal variation of invasive 
serotypes and the occurrence of non-typeable invasive isolates could result in residual 
cases. This could be partly overcome by the inclusion of GBS surface protein epitopes 
that are universally expressed and capable of conferring protection independent of 
serotype. 
2.4 Risk factors associated with GBS colonisation and invasive disease 
2.4.1 Maternal colonisation 
The frequency and severity of GBS infection is age dependent (55). The greatest 
proportion of invasive GBS disease occurs in newborns (<7 days of age; 48.2%), with a 
lower percentage of cases occurring in the 7-90 day age group (38.02%) and rarely in 
infants >90 days (13.7%) (56). This onset of invasive GBS invasive disease early in life 
limits strategies that would alter the potential fatal progression in infants, hence the 
need for prevention being  targeted during pregnancy or labour (8).  
The strongest independent risk factor associated with invasive GBS disease in infants is 
maternal colonisation (3). Pregnant women are commonly colonised with GBS in the 
recto-vaginal tract, with higher prevalence reported from African countries, Table 2.1. 
Maternal colonisation status is in turn influenced by other factors such as maternal age, 
ethnicity, parity and previous GBS-related pregnancy complications (57,58). Women  
<20 years of age and/or of African ethnicity with previous spontaneous abortion are 
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observed to be frequently colonised with GBS (59–61), although these observations are 
restricted to  specific study settings, Table 2.1.  
Recto-vaginal colonisation of women during pregnancy has been reported to result in 
30-70% GBS acquisition rate by their respective newborns’, transmitted vertically in 
utero or intrapartum.  About 2% of  newborns’ that acquire GBS colonisation will 
develop EOD, >90% of which occurs within  24 hours of life (4). Predisposing risk 
factors associated with neonatal invasive GBS disease include intrapartum fever, 
prolonged rapture of membranes (PROM) >18 hours, chorioamnonitis, prematurity and 
low birth weight (62–64). Premature infants (<37 weeks of gestation) and those born 
with a birth weight <2.5 kg are reported to be at an increased risk of invasive GBS 
disease, including being  more likely to develop LOD (64,65). Maternal GBS 
colonisation has also been associated with stillbirth, with up to 12.1% stillbirth cases 
associated with  GBS infection (44).  
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Table 2.1 Group B Streptococcus recto-vaginal colonisation in pregnant women between the years 2000-2015. 
 
Region Country Prevalence 
(%) 
Samples collected Risk factors Gestational 
week 
Year Ref 
A
fr
ic
a 
Zimbabwe 60.3 Lower vaginal and rectal 
swabs 
Rural area setting 20-delivery 2003-2005 (66) 
Tanzania 23.0 High vaginal and rectal 
swabs 
ND ≥37 2008-2009 (67) 
Malawi 21.0 Low vaginal and rectal 
swabs 
ND ≥24 2008-2010 (68) 
Nigeria 11.3 Vaginal introitus ND 35-40 2010 (69) 
South Africa 49.7 Lower vaginal and rectal 
swabs 
Parity and gravidity 20-37+ 2010-2011 (58) 
South Africa 10.0 Vaginal swabs C. albicans, sexual intercourse, frequent sex 
worker, chlorehexidine vaginal washes and 
cervical ectopy 
≥14 
 
2010-2011 (70) 
Kenya 14.3  
DRC 20 Vaginal swabs Low education, history of UTI , prematurity or >24 2012-2013 (71) 
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abortion and HIV-infection 
Gambia 33.7 Recto-vaginal swabs and 
breast milk 
Maternal haemoglobin < 10 g/dL, previous 
stillbirth, delivery assisted by midwife and 
delivering during the wet or hot dry season 
Delivery 2014 (64) 
Egypt 25.3 Vaginal swabs ND 35-40 2007-2008 (72) 
E
u
ro
p
e 
Denmark 36 Vaginal and anorectal 
swab 
ND ≥16 1999-2001 (73) 
Netherlands 21.0 Vaginal introitus and rectal  
(through anal sphincter) 
swabs 
African origin 35-37 2000-2002 (74) 
Hungary 23.2 Distal vaginal and rectal 
swabs  
ND 32-34 1995-2011 (75) 
Italy 20 Low vaginal and rectal 
swabs 
ND 35-37 2008-2010 (76) 
UK 19.0 Lower vaginal, rectal and 
throat 
ND 34-40 2011 (77) 
A
m
er
ic
a
s 
Brazil 17.0 Vaginal and rectal swabs ND 35-37 2002-2004 (78) 
Chile 14.4 Vaginal and rectal swabs ND 35-37 2010-2012 (79) 
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USA 18.6 Vaginal-anal swab ND >36 2002 (80) 
A
si
a 
Taiwan 6.2 Upper vaginal swabs ND ≥37 2005-2006 (81) 
Korea 8.3 Urine 
Vaginal and rectal swabs 
Geographical region (hospital) 35-37 2006-2008 (82) 
India 16 Vaginal and rectal swabs ND 35-37 2008 (83) 
Bangladesh 18.3 Vaginal and rectal swabs Rapture of membrane ≥8h and PROM ≥30 2011 (84) 
Iran 25.4 Rectal and vaginal swabs History of UTI 35-37 2013-2014 (85) 
China 7.1 Recto-vaginal swabs ND 35-37 2011-2013 (86) 
ND = not determined, DRC=Democratic Republic of Congo, UTI=urinary tract infection
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2.4.2 Maternal GBS serotype specific capsular antibody levels 
The risk of invasive GBS disease in neonates is associated with the level of maternal 
serum serotype specific capsular antibodies, where neonates born to mothers with 
higher serotype specific CPS antibody titre have reduced risk of developing invasive 
GBS disease. Newborns of mothers ≥34 weeks  gestation age with serotype Ia anti-
capsular specific IgG ≥5 µg/mL were less likely to develop  EOD (11), whereas in other 
studies maternal IgG concentrations >2 µg/ml for serotype III was associated with 
protection against type-III EOD (9,10). Inter-study variation among the reported 
antibody threshold correlated with invasive GBS disease might be due to the lack of 
standardised immunological assays being used between studies. Furthermore, reference 
serum with high avidity compared to the test samples tend to underestimate antibody 
levels detected (87), and therefore the reported antibody threshold may vary depending 
on the study sample and reference serum used. 
Lin et al. noted a 91% risk reduction in EOD incidence for infants born to mothers with 
≥ 10 µg/mL IgG antibodies against CPS serotype-III (12). Recently, a risk reduction of 
70-90% in GBS EOD cases has been reported in infants born to mothers with > 0.5 
µg/mL IgG antibody concentration specific for GBS CPS serotype Ia, III and V (13). 
Furthermore, a study from South Africa reported a decrease in the risk of invasive GBS 
disease in infants with increasing maternal antibodies against CPS serotype Ia and III.  
The study demonstrated that antibody concentrations of  ≥ 6 µg/mL and ≥ 3 µg/mL 
against GBS CPS serotype Ia and III respectively, result in < 10% risk for GBS invasive 
disease in infants (14). Therefore, increasing maternal GBS capsular antibodies by 
vaccination could reduce the incidence of invasive GBS disease in infants.  
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Currently, there are limited studies reporting changes in antibody levels against GBS 
surface proteins during pregnancy. The protective maternal antibody levels that have 
been determined are specific to GBS polysaccharide epitopes. β-C protein specific 
antibodies were detected in 99% of women evaluated, however, maternal  antibody 
concentrations against β-C protein did not differ according to maternal GBS 
colonisation status, gestational age nor was associated with the risk of invasive GBS 
disease in their neonates (88). Moreover, no associations were observed between higher 
antibody concentration to surface immunogenic protein (Sip), bacterial adhesion protein 
A (BibA), fibrinogen binding protein (FbsA) and pilus island proteins for either 
neonatal invasive GBS disease or  maternal vaginal colonisation (89,90). Studies by 
Larsson et al. and Fabbrini et al., however, reported that low concentrations against α-
C, Rib and pilus island proteins were associated with invasive GBS disease in neonates 
(18,91). This indicates that antibodies specific to some GBS surface proteins might be 
involved in protection against invasive disease and warrant consideration as possible 
vaccine candidates.   
There is currently no established protective antibody threshold for GBS protein specific 
antibodies in pregnant women or their respective newborns (88–90,92),  this is despite 
evidence of protein specific antibodies conferring protection in murine models and 
capable of inducing opsonophagocytic killing (93–97). These studies, however, either 
had a limited sample size or the quantification of antibody specific level was not 
correlated with invasive GBS disease from isolates expressing the target protein. 
Further studies evaluating the association between GBS protein antibodies with 
maternal GBS colonisation during pregnancy and invasive GBS disease in infants could 
identify a potential role of such proteins as vaccine candidates. 
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2.4.3 HIV infection and intrauterine exposure 
The prevalence of HIV among pregnant women in South Africa is 30.2% (98). 
Improved management of HIV-infected pregnant women with antiretroviral treatment 
(ARV) has reduced the prevalence of  HIV transmission from mother-to-child (99). This 
has resulted in a decrease of HIV-infected infants, however, a high proportion of 
children remain HIV-exposed, albeit uninfected with HIV (HEU). Maternal colonisation 
by GBS is similar between HIV-infected and HIV-uninfected pregnant women 
(100,101). HEU infants, however, have a higher incidence of EOD and LOD compared 
to infants born to HIV-uninfected mothers (20,21,102). 
Increased morbidity and mortality among HEU infants may be due to  severity of 
maternal HIV disease; increased exposure to opportunistic pathogens in early life, 
maternal antibody levels and reduced trans-placental transfer of maternal antibodies 
(102–104). Lower IgG antibodies against GBS CPS serotype Ia, Ib, II, III and V were 
reported in HIV-infected compared to HIV-uninfected pregnant women (105,106). 
These studies also reported significant reduction in trans-placental transfer of CPS-
specific antibodies to newborns of HIV-infected women. Therefore, intrauterine HIV 
exposure may in part increase the risk of invasive GBS disease in HEU neonates by 
impairing the transfer of protective antibodies from mother to the foetus/newborn.      
Antibodies induced by protein antigens are preferentially transported across the placenta 
(107,108), and are impaired in HIV infected women during pregnancy (109,110). Such 
an association has not been reported between maternal HIV infection and GBS surface 
protein specific antibodies. A study by Dangor et al. reported that HIV-infected 
pregnant women have low IgG antibodies against FbsA and pilus island proteins 
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compared to HIV-uninfected pregnant women, however, there was no significant 
reduction in the ratio of trans-placental antibody transfer from mother to newborn (106). 
Further studies to identify GBS surface proteins that are associated with reduced 
transfer in HIV-infected compared to HIV-uninfected mother-newborn dyads, could 
identify GBS surface proteins that contribute to the increased risk of invasive GBS 
disease among HEU infants; which might also lead to the identification of potential 
GBS vaccine epitopes. 
2.5 Group B Streptococcus virulence factors 
GBS is a commensal bacterium that colonises the gastrointestinal and genitourinary 
tract of healthy adults (35). Development of invasive GBS diseases underlines the 
species evolution, enabling the utilization of extracellular matrix factors such as 
laminin, glycosaminoglycan’s, fibronectin and fibrinogen to mediate pathogenesis by 
adhering and invading host epithelial and endothelial cells (111). Some of the surface 
virulence factors described have dual roles, enabling GBS invasion and evading 
immunological recognition and/or clearance.  
2.5.1 Capsular polysaccharides 
The encapsulating GBS polysaccharides identified by Lancefield to possess the ability 
to confer protection in murine immunisation models, have been subject of vaccine 
development (112). GBS CPS are key virulence factors, mediating GBS pathogenesis 
and immune-evasion (113). The chemical composition of CPS possesses sialic acid 
similar to that present on the surface of host epithelial cells. This molecular mimicry 
prevents deposition of C3 complement factors on the surface of GBS and therefore 
escapes opsonisation by phagocytic cells (114).  
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Serotype Ia and III share a similar oligosaccharide structure that only differ by the 
linkage of the galactose and sialic acid to the oligosaccharide backbone (115). This 
difference has been shown to have a similar anti-phagocytic capability but was 
quantitatively less for serotype Ia  and hence CPS serotype-III predominantly occurs in 
both colonising and invasive clinical isolates (116). 
2.5.2 Surface proteins 
GBS surface proteins play an important role in mediating pathogenesis of invasive GBS 
disease. Proteins are involved in adhesion to epithelial cells, interaction with host 
extracellular matrix and also in evading immunological recognition (29). Figure 2.1 
shows a pictorial summary of GBS surface proteins as virulence factors that enable 
GBS adherence and invasion of host epithelial cells to cause symptomatic infection. 
 
Figure 2.1 Mechanisms of group B Streptococcus pathogenesis using surface virulence factors to mediate 
cellular adherence and invasion by binding host extracellular matrix ligands/receptors  (111). 
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β-haemolysin/cytolysin and CAMP factor 
β-haemolysin is a pore-forming toxin secreted by GBS which has been shown to cause 
damage to lung epithelial cells and brain epithelium resulting in pulmonary infection 
and meningitis (117,118). Similarly, CAMP factor is another pore-forming toxin 
secreted by GBS to mediate damage to host epithelial cells (119). The potential role of 
antibodies to these toxins in protecting against GBS disease has not been evaluated, 
mainly due to the toxins being non-immunogenic and non-essential during pathogenesis 
(120,121). 
C protein  
Antibodies specific to C protein antigens that are identified on selected GBS strains 
were shown to be capable of conferring protection in immunised mice (112). The C 
protein antigen consists of two forms designated α- or β-C proteins based on trypsin 
digestion sensitivity. GBS strains that express the C protein are found to express either 
of the proteins or both except for isolates expressing CPS belonging to serotype-III 
(122). Further investigation on GBS serotype-III strains identified the Rib protein that 
was present in GBS strains not expressing the C protein (123). Molecular 
characterisation of αCP and Rib revealed that these proteins consist of highly identical 
tandem repeats and thus belong to a family of surface localised proteins denoted alpha 
like proteins (Alp)  (124,125). The Alp family is comprised of αCP, Rib, R28 and Apl2 
proteins which promote invasion by interacting with host cell’s glycosaminoglycans 
(126). Alp are essential virulence factors and their ability to induce protective antibodies 
makes then suitable GBS vaccine candidates, however, these proteins are 
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heterogeneously distributed among GBS serotypes and therefore would require a multi-
peptide vaccine to enhance coverage. 
FbsA 
Fibrinogen, present on the extracellular matrix, interferes with activation of complement 
mediated opsonophagocytosis and thus certain pathogens have developed mechanisms 
to accumulate fibrinogen on their surface to evade the immune system (127). Fibrinogen 
binding protein (FbsA) is a GBS surface anchored protein that consists of repeating 
units comprised of 16 amino acids that interact with fibrinogen during bacterial 
adhesion (128). FbsA interaction with fibrinogen also triggers polymer aggregation of 
fibrinogen on the surface of GBS that interferes with opsonophagocytosis by 
macrophages (129). 
Another protein co-transcribed with FbsA, analogously designated FbsB, binds human 
fibrinogen in a dose dependant and saturable manner (130) and thus cumulatively 
increases the virulence of GBS. Interaction of FbsB and fibrinogen are, however, not 
essential during bacterial adhesion since deletion of the fbsb gene deletion does not 
influence adherence to epithelial cells. Furthermore, IgG antibody levels against FbsA 
were reported not to be associated with protection against invasive GBS disease during 
infancy (90). 
Serine protease C5a peptidase (ScpB) 
Cell-surface-associated protein ScpB is a serine protease that cleaves the complement 
factor C5a as a mechanism of immuno-evasion (131,132). C5a is a component of the 
complement system which functions as a chemoattractant of polymorphonuclear 
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leucocytes (PMNL). Cleavage of C5a by ScpB inactivates its ability to stimulate the 
influx of PMNL to the infection site hence contributing to GBS pathogenesis (132). 
ScpB also interacts with fibrinogen and thus serves as an adhesin during GBS bacterial 
invasion (133,134). Other similar proteases localised on the surface of GBS have been 
described such as cell surface associated protein (CspA) that cleaves a panel of  CXC 
chemokines essential for recruiting neutrophils to the site of infection (135). CspA is 
also capable of binding to human fibrinogen (136). These proteases are highly 
conserved among GBS strains and therefore are ideal as cross-protective vaccine 
candidates (131,137).  
Lmb protein 
Present on the extracellular matrix of mammalian cells are a fibrous network of high 
molecular weight glycoproteins called laminins (138). These proteins form the major 
part of the basement membrane of the epithelium layer and serve as structural 
organisation of tissue, cell differentiation and adhesion. Spellerberg et al. (1999) 
identified a GBS surface protein that is capable of binding to immobilised laminin, and 
as such designated as laminin binding protein (Lmb) (139). 
 Lmb protein is homologous to other streptococcal LraI (lipoprotein receptor antigen I) 
protein family that have been extensively characterised to mediate pathogenicity by 
adhering to laminin of damaged epithelial cells. The lmb gene encoding Lmb protein is 
situated immediately upstream of the scpb gene. Lmb protein is expressed by all GBS 
strains isolated from humans and binds to laminin on the surface of endothelial cells 
during colonisation and bacterial invasion. Deletion mutant studies of the lmb-scpb 
gene demonstrated that Lmb is also capable of binding to human brain endothelial cells 
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to promote the development of meningitis (140). Thus Lmb is an essential virulence 
factor of GBS pathogenesis expressed by most if not all GBS strains, making it a 
possible vaccine candidate. 
BibA protein 
GBS immunogenic bacterial adhesion protein A (BibA) is a cell wall anchored protein 
identified in silico and shown to possess epithelial cell adherence properties (141). BibA 
is also capable of immunological evasion by inhibition of C4bp (complement regulator) 
and thereby resisting opsonophagocytosis (141). Analysis of the hyper-virulence ST-17 
clone identified an allelic biba gene that only occurs in ST-17 isolates (28,51). Further 
characterisation of the genetic diversity of the biba gene revealed that the protein is 
encoded by alleles occurring in three major phylogenetic clusters designated clusters A, 
B and C based on sequence types with shared biba gene homology (51). Cluster A and 
B are more related whilst cluster C was exclusively comprised of alleles belonging to 
ST-17, Figure 2.2. The BibA protein; belonging to cluster C, was shown to mediate 
specific adherence to intestinal epithelial cells and brain microvascular endothelial cells 
enabling migration through the blood brain barrier to cause meningitis and as such 
designated hypervirulent GBS adhesin (HvgA) (142).  
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Figure 2.2 Structural depictions of the allelic forms of the biba genes in each phylogenetic cluster. S1-S11 
represent identical gene segments present in more than one GBS strain.S1, S7 and S8 present in all 
clusters represent the flanking N-terminal signal peptide (S1), the KPEA amino acid repeats (S7) and the 
sorting signal with the LPxTG motif followed by the hydrophobic domain and the positively charged tail 
(S8) with > 90% identity (51). 
Pilus island proteins 
Analysis of the GBS genome sequences from different serotypes revealed the presence 
of genetic pilus island-like structures that encode pilus island proteins (PI) on the 
surface of GBS (143,144). Among the GBS strains, three structurally similar but 
phylogenetically distinct loci encode the PI proteins; the PI-1, PI-2a and PI-2b. Each PI 
encode for three different pili proteins; the backbone protein (BP) and two ancillary 
proteins (AP), and for two sortase proteins that enzymatically attach the pili to the 
peptidoglycan layer on the surface of GBS, Figure 2.3 (33,143,145). 
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Pili proteins are covalently polymerised proteins that form filamentous structures and 
extend on the surface of bacteria essential for motility (146). GBS pilus proteins play an 
essential role during bacterial adherence and invasion of lung and cervical epithelial 
cells (147). The pilus proteins also have the capacity to interact with brain 
microvascular endothelial cells to invade the blood brain barrier causing meningitis 
(148). Pilus backbone proteins of both PI-1 and PI-2a enable GBS paracellular 
trancytosis through the epithelial cells as demonstrated with cervical, pulmonary and 
intestinal cell lines (149). 
  
Figure 2.3 Schematic representation of the pilus island proteins assembly, inclusive of the backbone 
protein (BP) and the two ancillary proteins (AP) for PI-1, PI-2a and PI-2b. The sequence diversity of 
genes encoding pilus proteins are depicted with the sortase encoding region shown in grey (33).   
2.6 Natural immune response to group B Streptococcus 
2.6.1 Immunity to polysaccharides  
The high density of CPS on the surface of GBS triggers a thymus independent (TI) 
immune response that mounts an immunological clearance of the pathogen independent 
of T lymphocytes (150). There are two types of TI immune responses that can be 
triggered depending on the nature of the antigen; the type I (TI-1) and the type II TI (TI-
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2) that result in the activation of the B cell and subsequent secretion of pathogen 
neutralising antibodies (151). TI-1 immune response is induced by bacterial products 
mostly lipids that stimulate the B cell. The 1st signal is mediated by the interaction of 
the B cell receptors (BCR) with the antigen and the 2nd signal results from the Toll-like 
receptors (TLR) binding the antigen which then stimulates polyclonal activation of the 
B cell. TI-2 immune response is induced by large molecular weight polymers with 
repetitive epitope such as polysaccharides that encapsulate GBS (152). The stimulatory 
signals that result in B-cell activation are mediated by extensive cross-linking of surface 
antibodies due to a repeating epitope presented by the polysaccharide antigen, Figure 
2.4. The GBS pathogen thus triggers a TI-2 immune response that requires mature B 
cells that are capable of extensive cross-linking of membrane-bound antibodies (153). 
Once activated, these B cells are incapable of mediating clonal expansion into memory 
B cells (152) and predominantly secrete IgG2 (154). 
 
Figure 2.4 Schematic depiction of TI-2 immunological response that results in the activation of B 
lymphocytes from the extensive cross-linking of BCR by repeating epitopes of the antigen. 
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This particular type of immune response is not evident in neonates since they have a 
delayed ontogeny for TI immune response (155). The inability of neonates to recognise 
and mount an immune response against CPS (156), makes them highly dependent on 
the placental acquisition of maternal antibodies for protection against invasive GBS 
disease. Maternal transfer of antibodies to the foetus gradually increases and reaches a 
peak during the third trimester of gestation (108). This increases the vulnerability of 
preterm infants since they have low protective antibodies against GBS. Moreover 
amongst the IgG subclasses, IgG2 is less efficiently transported across the placenta and 
only found in trace amounts in cord blood even during the third trimester (107). Since 
IgG2 is the predominant antibody secreted by maternal B-cells against CPS antigens, 
this further increases the risk of susceptibility to invasive GBS disease in neonates 
(108). Thus a combination of these factors results in neonates exhibiting an 
immunodeficiency state towards GBS, due to a deficit in protective antibodies against 
the GBS CPS because of the delayed maturity in TI immune response and limited trans-
placental transfer of maternal antibodies.  
2.6.2 Immunity to proteins 
Protein antigens trigger a thymus dependent (TD) immune response that requires 
activating signals from T lymphocytes (152). This particular type of immune response is 
more advantageous in neonates and their mothers than the TI immune response; since 
neonates are capable of producing antibodies towards these antigens and TD immune 
response result in inducing memory B cells. Moreover, the predominating subclass 
secreted is the IgG1, (157) that has an increased efficiency of crossing the placenta-
barrier than IgG2 isotype (107). This results in an increased ability of neutralising the 
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invading pathogen in neonates, thus presenting an ideal class of potential vaccine 
antigens against GBS. 
Peptides are either endogenously processed, presented complexed with human 
leukocyte antigen (HLA) class I, or exogenously recognised (presented by HLA class 
II) as epitope by B lymphocytes. Class II antigens comprise mainly of surface exposed 
peptides and are presented to CD4+ T lymphocytes, which then aid in stimulating 
antibody production by B lymphocytes (158). HIV gp120 (viral-envelope glycoprotein) 
recognises the CD4 molecule as a receptor during infection into T lymphocytes. This 
results in these lymphocytes having defects in soluble antigen processing and 
presentation (159–161). Contrary to these studies Woc-Colburn (162) maintains that 
antigen presentation is preserved in HLA class II restricted T cells and that HIV 
infection marginally affects the presentation of antigens. Nevertheless, the particular 
type of immune response induced by GBS surface protein in HIV infected individuals 
has not been fully elucidated. Thus, by determining the antibody dynamics toward GBS 
protein antigens and how it is affected by underlying HIV infection could help identify 
potential vaccine epitopes against invasive GBS disease. Moreover pregnant women 
exhibit an immuno-attenuated state due to the interaction between the endocrine and the 
immune system, where a shift towards humoral immunity away from cell mediated 
immunity is observed at the maternofoetal interface (163). Therefore, the design and 
development of an efficacious vaccine against invasive GBS disease has to incorporate 
the plasticity of the immune system during pregnancy, the maternofoetal relationship 
together with the influence of HIV infection. 
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2.7 GBS vaccines 
Currently, the recommended GBS prevention strategy is the use of IAP in pregnant 
women who are identified to be at high risk of transmitting GBS to their infants. The 
implementation of the IAP method has successfully reduced the incidence of EOD in 
high-income countries, however, due to cost and logistical problems its adoption in low-
income countries has not been considered  (6). IAP also does not protect against LOD, 
GBS-related prematurity and stillbirth.  Moreover, the use of IAP could  result in the 
emergence of antibiotic-resistant bacteria, which may  necessitate  alternative strategies 
(164).  
The use of vaccines as a prevention strategy against invasive GBS disease has been a 
subject of extensive research.  This has been primarily based on the findings that the 
probability of invasive GBS disease decreases with increasing maternal serotype 
specific capsular antibodies in the women and newborns (9–11).  Hence, maternal 
immunisation could provide immunity to the physiologically immunocompromised 
infants that might persist during infancy. Therefore, development of a GBS vaccine is 
an alternative approach to IAP for the prevention of invasive GBS disease in infants and 
possibly reducing GBS colonisation and associated morbidity in pregnant women. The 
characteristics of an ideal GBS vaccine candidate is that the antigen: (i) must be 
immunogenic, (ii) the antigen specific antibodies must efficiently cross the placenta, 
(iii) able to confer protection to both the mother and the infant, (iv) antigen specific 
antibodies must persist into infancy and (iv) possess a broad-spectrum target against the 
various strains of the pathogen (89). 
  
31 
 
2.7.1 Polysaccharide antigens 
GBS encapsulating polysaccharides play a major role as virulence factors capable of 
eliciting an immune response that triggers the production of protective antibodies (25). 
The antigenicity of the CPS serotypes has been exploited to synthesise vaccines that 
provide immunity against GBS. CPS-based vaccines have been shown to provide a 
significant level of protection against other encapsulated bacteria such as H. influenzae 
type b and S. pneumoniae  (165).  
The major problem encountered in GBS vaccine development is the antigenic variation 
amongst the serotypes (166), and with the prevalence and distribution of the serotypes 
varying according to geographical region (48). Kotloff et al. (16) evaluated a tetravalent 
CPS (Ia, Ib, II and III) vaccine potential to confer broad-spectrum serotype protection. 
The vaccine was modestly immunogenic and well tolerated among recipients, but none 
of the recipients had responses to all four antigens and responders had lower IgG GMC 
than those who were immunised with the monovalent CPS. Furthermore, to induce a ≥ 
4-fold IgG GMC post-vaccination, vaccine recipients had to have CPS specific IgG 
prior immunisation, with higher dosing concentrations unable to enhance the vaccine 
immunogenicity.  
To date, several clinical trials have investigated GBS CPS vaccines candidates to assess 
their immunogenic potential. Table 2.2 provides a detailed summary of GBS vaccine 
clinical trials that have been conducted. The majority of the clinical trials have primarily 
focused on the safety and tolerability of the multivalent polysaccharide vaccine in non-
pregnant and pregnant women. Given that CPS are poor immunogens, most potential 
vaccine constructs have incorporated a highly immunogenic peptide such as tetanus 
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toxoids (TT) or cross-reactive material (diphtheria mutant protein; CRM197) that 
stimulates a TD immune response, and enhances the immunogenicity of CPS. 
Overall, the limitations of CPS-based vaccines include (i) limited serotype cross-
reactivity, (ii) poor immunogenicity on its own, which requires protein conjugation 
process to increases its immunogenicity and (iii) inefficient materno-foetal transfer of 
predominantly IgG2 antibodies produced. 
Recently the use of GBS molecular characterisation techniques such as MLST and 
pulse-field gel electrophoresis has revealed that within the hyper-virulent clonal 
complex there is capsular switching (167). The switch involved the dominant disease 
causing serotype-III switching to serotype-IV, which could impact on vaccine design 
(56).   
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Table 2.2 Clinical studies that reported the safety and immunogenicity of group B Streptococcus capsular polysaccharides based vaccines. 
Antigen Population Objective Study phase and setting Finding Ref 
Tetravalent CPS 
(Ia, Ib. II and III) 
Healthy adults with pre-
existing antibodies prior 
vaccination. 
Assess the safety and 
immunogenicity of the 
vaccine. 
Phase Ia, USA Vaccine was well tolerated among 
participants. Immune response did not vary 
with increased dosage. Seroconversion (≥4 
fold) was observed in 17-70% participants.  
No participant had detectable antibodies to all 
four CPS serotype. 
(16) 
CPS serotype-III 
conjugated to TT 
Healthy non-pregnant adults 
(n=100) between 18-40 
years. 
Evaluation of the safety and 
immunogenicity of vaccine 
Randomised, placebo 
controlled phase, USA 
Dose dependent immune response was 
observed with CPS type-III specific 
antibodies being highest when immunised 
with III-TT (50.1-fold increase) compared to 
uncoupled CPS type-III (8.8-fold increase) at 
8-weeks post-immunisation. 
 
(168) 
CPS serotype-Ia 
and -Ib 
conjugated to TT 
Healthy non-pregnant women 
(n=105 for type-Ia and n=85 
for type-Ib) between 18-40 
years. 
Determine safety, 
immunogenicity and optimal 
dose. 
Randomised, placebo 
controlled phase 1 or 2, USA 
GBS CPS specific IgG increased post-
vaccination in a dose dependent manner and 
was higher in participants immunised with 
TT conjugated vaccine formulations that 
resulted in higher OPA killing. 
(15) 
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CPS serotype-III 
conjugated to TT 
with or without 
alum as adjuvant 
60 Non-pregnant adults 
randomised to receive four 
doses of CPS with or without 
aluminium hydroxide and 36 
adults who previously (> 21 
months) received CPS-type 
III-TT vaccine. 
Evaluate the effects of 
aluminium hydroxide 
adsorption and inclusion of a 
booster dose on the 
immunogenicity of CPS. 
Randomised, blinded (alum 
adjuvant effect) and open 
label (booster dose response) 
phase I, USA 
Similar CPS-III specific IgG concentrations 
at 4 weeks post-vaccination between 
participants immunised with or without alum 
adjuvant. IgG decreased 21 months post 
initial vaccine dose. Booster effect was 
achieved in 22% participants with IgG 
increasing 3-fold higher compared to 2-
months post initial dose.  
(169) 
CPS serotype-III 
conjugated to TT 
Pregnant women between 30-
32 weeks of gestation who 
delivered ≥37 weeks of 
gestation. Their respective 
infants were followed up for 
6-months. 
Evaluate the safety and 
immunogenicity of vaccine, 
efficiency of placental 
transport and durability in 
infancy. Correlate antibody 
level to OPA killing. 
Randomised, double-blind, 
placebo controlled phase I, 
USA 
No vaccine-associated AE were noted. A 
>50-fold increase in type-III specific IgG 
GMC persisted 2 months postpartum in 
infants. 
(170) 
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Bivalent CPS 
(serotype-II and –
III) conjugated to 
TT 
Healthy adults (n=75) 
between 18-45 years. 
Compare immune elicited by 
the bivalent vaccine 
formulation to that elicited 
by either of the monovalent 
vaccines. 
Randomised, double blind 
phase II, USA 
Bivalent vaccine formulation induced ≥4-fold 
increase of both CPS type-II and –III specific 
antibodies 4-8 weeks post-immunisation with 
no statistical difference to the monovalent 
vaccines. However, OPA killing was not 
observed in serum of recipients of the 
monovalent CPS type-III vaccine as 
compared to the recipient of the bivalent 
vaccine. 
(171) 
CPS serotype-V 
conjugated to TT 
Healthy adults between 65-85 
years old. 
Assess the reactogenicity and 
immunogenicity and also 
determine the durability and 
functional activity of the 
CPS type-V specific 
antibodies induced. 
Randomised, double blind, 
Td controlled phase I, USA 
Vaccine was well tolerated with no AE 
reported.  Vaccine induced ≥4-fold increase 
in CPS type-V specific IgG, IgM and IgA in 
68%, 76% and 59% of recipients 8-weeks 
post-immunisation which persisted for 52-
weeks with increasing avidity. Higher OPA 
was achieved in recipients who had ≥1 
µg/mL type-V specific antibodies prior-
immunisation.  
(172) 
CPS serotype-V 
conjugated to 
either TT or 
CRM197 
35 Nonpregant adults 
receiving type V-TT, V-
CMR or placebo. 
Evaluate immunogenicity 
and OPA activity 
Randomised, double blinded 
placebo controlled phase I, 
USA 
A ≥4-fold increase in CPS-V specific IgG 
concentration in 93-100% participants 26 
weeks post-immunisation which persisted in 
85-93% 2 years post vaccination. IgA and 
(173) 
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IgM also increased post-immunisation, 
peaking at 8-weeks and persisted until 26-
weeks post-immunisation. 
CPS serotype-V 
conjugated to TT 
Healthy non-pregnant adults Determine the dose of 
vaccine with optimum 
immunogenicity and 
functional activity. 
Phase I open label,  USA Unconjugated vaccine modestly increased 
type-V specific GMC but was significantly 
lower than TT conjugated vaccine. 
Significantly less OPA killing was observed 
for the unconjugated compared to the TT 
glycoconjugate. 
(174) 
CPS serotype-Ia, 
III and V 
conjugated to TT 
or CRM197 
33 Healthy adults who had 
low antibody concentrations 
pre-immunisation. 
To determine the persistence 
of functional activity of GBS 
CPS specific antibodies.  
Phase I and II, USA Significant increase in IgG post-
immunisation that declined by 40-50% at 
104 weeks post-immunisation. OPA activity 
persisted 104 weeks post-immunisation 
although lower compared to 4 weeks post-
immunisation. 
(175) 
Trivalent CPS 
(serotype-Ia, -Ib 
and -III) 
conjugated to 
CRM197 
Pregnant women between 24-
35 weeks of gestations with 
or without HIV infection and 
their respective infants. 
Assess placental transfer of 
antibodies specific to CPS in 
infants relative to HIV in 
utero-exposure. Compare 
vaccine safety and 
immunogenicity in pregnant 
women with or without HIV 
Non-randomised open-label 
phase II, Malawi and South 
Africa 
CPS type specific antibody GMC increased 
following vaccination and was significantly 
higher in HIV-uninfected mothers compared 
to HIV-infected mothers. Placental antibody 
transfer was similar between the HIV-
uninfected and HIV-infected mother-infant 
dyads. Antibody GMC in infants decreased 
(176) 
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infection.  to 28-58% atfter 42 days compared to those 
recorded at birth. 
Trivalent CPS 
(Ia, Ib and III) 
conjugated to 
CRM197 with or 
without 
aluminium 
hydroxide or 
MF59 as adjuvant 
340 Non-pregnant women 
followed for 2 years 
(longevity) and 338 pregnant 
followed for 61 days 
(immunogenicity). 
Determine optimal dosage, 
vaccine formulation and 
injection schedule. 
Randomised, observer blind 
phase Ib, Belgium 
Higher antibody GMC in all vaccine 
formulations compared to the placebo group 
but no additional benefit from higher 
dosage, adjuvanted vaccine or injection of 
second dose. 
(177) 
Trivalent  CPS 
(Ia, Ib and III) 
conjugated to 
CRM197 with 
aluminium 
hydroxide as 
adjuvant 
Healthy non-pregnant and 
pregnant women (32- 
gestation week) were 
followed post-vaccination 
together with their respective 
newborn infants. 
Asses safety and 
immunogenicity in pregnant 
and non-pregnant women 
together with antibody trans-
placental transfer to 
newborns 
Randomised, observer blind 
placebo controlled phase 
Ib/II, South Africa 
Specific IgG against all GBS CPS serotype 
was significantly high 1year post 
vaccination compared to the non-pregnant 
women who received the placebo. Similarly, 
higher IgG specific to CPS serotypes were 
observed in immunised pregnant women 
resulting in 49-79% antibody transfer to 
their newborns. 
(17) 
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2.7.2 Protein antigens 
Protein antigens have several advantages to polysaccharide antigens as vaccine 
candidates; including  eliciting a TD response that results in immunological memory, 
being immunogenic without conjugation to other molecules and can also be produced 
inexpensively in large quantities by employing DNA recombination techniques (166). 
Several GBS surface proteins have been identified as potential vaccine epitopes against 
invasive GBS disease, based on their virulence potential and antibody reactivity, Table 
2.3. Investigation to elucidate the immunogenicity of these proteins has, however, been 
limited to murine models with only few studies in humans.  
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Table 2.3 Virulence and immunogenic properties of GBS surface proteins considered as potential vaccine candidates.  
Protein name Virulence Cohort and sample size Immunogenic potential Ref 
Sip Unknown Pregnant women (n=644) between 35-37 
weeks of gestation who were either GBS 
colonised or non-colonised and their newborns 
(n=176) 
GBS colonised women were detected to 
have higher IgG specific to Sip compared 
to non-colonised women. IgG levels in 
newborns were correlated to that of 
maternal levels. 
(89) 
BibA Complement inhibitor and adhesion protein, 
occurs in three allelic variants, with HvgA 
associated with hypervirulence 
Studies limited to murine models and 
uncategorised human sera 
BibA specific IgG is capable of 
conferring up to 69% protection against 
GBS disease in pups born to mice dams 
immunised with BibA protein. 
Recombinant BibA protein N-terminal is 
recognised by human IgG and IgA.  
(51,95,141) 
FbsA Induces fibrinogen aggregation, masking GBS 
from opsonophagocytosis  
Cervical and ano-rectcal culture confirmed 
colonisation in pregnant women. 
FbsA is highly immunogenic and 
recognised by IgA obtained from cervical 
secretions 
(96,129)  
ScpB Cleaves complement component C5a to 
attenuate recruitment of polymophornuclear 
leukocytes to site of infection. Binds to 
fibronectin as an adhesin during infection. 
Pooled sera form asymptomatic adults     Natural occurring IgG inhibits activity of 
soluble C5a-ase, however GBS surface 
anchored C5a-ase is masked by the 
encapsulating polysaccharide from 
neutralisation by antibodies  
(133,178) 
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Rib Unknown Culture confirmed neonates (1week post-
partum) and their respective maternal serum 
(26-48 gestation weeks) 
Neonates and their mothers with blood 
negative cultures were used as case controls 
Colonisation with Rib expressing GBS 
elicits an antibody response associated 
with maternal gestational age. Low IgG 
levels against Rib were associated with 
invasive GBS disease and there were 
correlation between maternal IgG levels 
and neonate IgG levels 
(91,166) 
Alpha C 
protein 
(αCP) 
Binds to integrin of fibronectin on epithelial 
cells to mediate GBS invasion. 
Sera of pregnant women collected at delivery 
together with neonatal cord blood (n=570). 
Colonised women were culture confirmed 
with vaginal and rectal swabs (n=156). 
α-C specific IgG titre was similar in both 
non- and colonised women, however, 
women presenting with peripartum GBS 
bacteraemia had elevated IgG titre 
together with their respective healthy 
neonates. Neonates with invasive disease 
had half the IgG level required for 
effective opsonophagocytic killing. 
(19,179) 
 Beta C 
protein 
(βCP) 
 Sera from 570 pregnant women was collected 
of which 156 were colonised with GBS and 16 
had βCP expressing strains. 
IgA and IgG GMCs were similar 
between colonised and non-colonised 
pregnant women, however, bacteremic 
women (n=2)  had significantly elevated 
IgA and IgG GMCs. 
(92) 
Pilus Island GBS adhesion and invasion in epithelial cells, 
with serotype Ia and III showing greater 
Maternal sera was collected for 984 colonised 
women who delivered healthy infants, 153 
Maternal IgG specific to the three pilus 
proteins BP-1, AP1-2a and BP-2b were 
(18,147,148) 
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proteins invasion capability. from those who delivered infants with 
invasive GBS disease and 473 who were non-
colonised together with their respective 
infants. 
significantly higher in women colonised 
with GBS expressing the respective 
protein compared to those non-colonised 
or colonised by strains not expressing the 
respective PI protein. Significantly lower 
maternal IgG titres to PI-1 and 2a were 
reported for women who delivered EOD 
infants. 
R protein Trypsin resistant protein sub-classified into 4 
distinct genetic types with R4 most prevalent 
in isolates recovered from humans 
Sera of 40 GBS II/III colonised mothers and 
26 non-colonised mothers were assayed for 
presence of antibodies to R4. Furthermore 
cord blood of 14 mother-infant pairs were 
assayed. 
R4 specific antibodies were present in 
92.5% of colonised mothers compared 
with 54% of non-colonised mothers. A 
correlation of 0.68 antibody 
concentration was observed between 
mothers and their newborns suggesting 
materno-fetal transfer of antibodies 
across the placenta. 
(180) 
Laminin 
binding 
protein 
(Lmb) 
Adhesion protein that binds to human laminin 
to mediate bacterial attachment during 
infection. Lmb plays an important role in 
transcytosis of brain microvascular endothelial 
cells. 
Lack of relevant data on the immunogenicity 
of the protein, which is further enunciated by 
the protein’s inability to stimulate neutrophil 
to secrete cytokines. 
 (139,140) 
Luecine rich LrrG is homologous to PsaA a choline binding Mice immunisation study was performed by LrrG immunisation provided 91% (181) 
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repeat 
protein 
(LrrG) 
protein of S. pneumoniae in which its C-
terminal region adheres to epithelial cells. 
injecting s.c the recombinant mixture with 
alum adjuvant and a booster dose after 28 
days to a group of 12 mice of 6-7 weeks old. 
Challenge lethal dose was administered 3 
weeks post-booster dose.  
protection and a substantial increase of 
IgG1 > IgG2 consistent with 
administration of protein antigens in 
immunisation models. No further 
progress has been made regarding LrrG 
immunogenicity. 
Ornithine 
carbamoyltr
ansferase 
(OTK) and 
Phosphoglyc
erate kinase 
(PGK) 
Outer membrane localised GBS proteins with 
unknown virulence properties. 
Anti-sera collected from rabbits immunised 
with recombinant protein were mixed with 
GBS challenge dose that was subsequently 
injected i.p to 24 h old mice. Sample size was 
48-54. 
Anti-sera provided 46% and 35% 
protection in neonatal mice for OTK and 
PGK relative to 64% protection conferred 
by whole cell anti-sera. 
(182) 
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Other factors which could influence the immunogenicity of proteins e.g., surface 
accessibility and/or masking effect of CPS and their genetic variability, have not been 
fully studied. These factors may limit the potential of a GBS protein antigen from 
serving as a vaccine candidate capable of conferring  protection against invasive disease 
(183). Fluegge et al. noted a pronounced genetic variability in the distribution of 
virulence conferring surface proteins among invasive and non-invasive strains isolated 
from neonates (49). Figure 2.5 highlights that 21% of the invasive strains did not 
contain genes encoding any of the known virulence surface proteins. Therefore, factors 
such as the physiological and physiochemical properties that play complex roles in the 
immunogenicity of GBS should be considered during the selection of peptides as 
vaccine antigens for the prevention of invasive GBS disease. 
 
Figure 2.5 Distribution of group B Streptococcus surface protein genes in A, neonatal invasive strains and 
B, neonatal non-invasive strains(49). 
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2.7.3 Polysaccharide-protein glycol-conjugate 
Proteins are considered to be more immunogenic than polysaccharides, although the 
polysaccharide capsule is the major virulence factor of GBS, making it the ideal target 
for the immune system. The immunogenicity of CPS conjugated to tetanus toxoid (TT) 
has been extensively evaluated in several clinical trials. The conjugated vaccines, 
inclusive of the major invasive serotypes (Ia, Ib, II-III and V), were well tolerated and 
elicited immunological responses with functional antibodies that mediated 
opsonophagocytic killing (15,168,174,184).  The immunogenicity of each vaccine in 
pregnant and non-pregnant adults was dose dependent, with the highest dose resulting in 
≥ 4-fold increase in CPS specific antibody geometric mean concentration (GMC) that 
persisted for almost a year post immunisation. A recent clinical trial by Leroux-Roels et 
al., however, reported that there was no additional benefit when increase vaccine dose 
>5 µg/mL (177). The predominant antibody isotype elicited by the conjugate vaccines 
was IgG, except for type V conjugants in which IgM was the predominantly secreted 
isotype. For CPS III-TT and the CPS-III unconjugated vaccines; IgG2 was higher, with 
insignificant levels of the other IgG subclasses observed in immunised sera (168). The 
unconjugated vaccines were less immunogenic, eliciting antibody concentrations that 
peaked 2 weeks post-immunisation and declined after 8-26 weeks, which highlights the 
role of TT in activating cell mediated immunity that subsequently serves as immune 
modulators into polarising clonal expansion of plasma B cell to memory cells.  
Only five serotypes account for 95% of invasive GBS disease isolates globally, hence a 
pentavalent conjugate vaccine could possibly result in substantial disease reduction. 
Evaluation of the immunogenicity of a bivalent type II and III-TT conjugate showed 
that in 80-90% individuals,  ≥ 4-fold increase in IgG GMC was retained 8-weeks post-
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immunisation, which  persisted for 26 weeks (171). Although there is some cross-
reactivity between serotype II and III, this cross-reactivity was not associated with ≥ 4-
fold GMC increase inter-serotype specific IgG; and insignificant level of OPA killing 
occurred with the heterologous GBS serotype. Furthermore, the functional activity of 
the antibodies elicited by the bivalent conjugate vaccine mediated similar OPA killing 
as the monovalent conjugate of either type II or III resulting in 1.6-1.8 log10 reduction of 
colony forming units. Substituting the conjugate protein by a highly immunogenic GBS 
protein, such as in Table 2.4, could increase the vaccine’s potential as a universal GBS 
vaccine, and possibly mitigate against replacement disease by non-vaccine serotypes. 
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Table 2.4 Studies investigating group B Streptococcus capsular polysaccharide protein glyco-conjugates 
Conjugate protein Serotype Finding Ref 
TT IV and 
VII 
Despite the CPS type-IV and -VII having a similar structure each vaccine induced CPS-type 
specific antibody response with no cross-reactivity. CPS type-IV and –VII specific antibodies 
conferred protection to 93% and 100% of pups challenged with a homotypic GBS strains 
respectively. 
(185) 
C5a peptidase III Immunisation with C5a-III provided greater bacterial clearance compared to TT-III conjugate due 
to independent serotype protection. 
(137) 
Cα Administration of 20 µg conjugate to mouse dams resulted in 95% and 60% protection of pups 
when challenged with type-III GBS or Cα positive GBS, results comparable to TT-III vaccine. 
(186) 
Cβ Cβ-III immunisation triggers serotype independent opsonophagocytic killing in rabbit sera. Pups 
from mouse dams immunised with conjugate vaccine resulted in 93% and 76% survival when 
challenged with either type-III or Ia GBS lethal dose. 
(187) 
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Recombinant alpha like 
protein (rAlp) 
Vaccine formulation induced dose dependent antibodies titres against serotype-III and rAlp. 
Protection was conferred to 94% of pups born to immunised dams when challenged with a lethal 
dose of GBS expressing CPS type-III.  However, survival was reduced to 23% when pups were 
challenged with GBS expressing Alp3 but not the CPS type-III. 
(188) 
Duck hepatitis B core 
antigen 
Serotype-III specific IgG GMC increased to 22.6 µg/ml on mouse dams administered the 
conjugate vaccine which conferred protection to 97% of neonates when challenged with a lethal 
dose of GBS. 
(189) 
Diphtheria toxin CPS type-III specific IgG GMC increased from baseline level (0 µg/mL) to 42.4 µg/mL on mouse 
dams administered the conjugate vaccine which conferred protection to 98% of neonates when 
challenged with a lethal dose of GBS. 
(189) 
Cross-reactive material 
(diphtheria mutant 
protein) 
V Conjugate vaccine triggered a ≥ 4-fold increase of type-V specific IgG concentration that persisted 
26 weeks post vaccination with 95% of recipients having ≥ 1µg/ml type-V specific IgG 
concentrations. Other Ig subtypes were higher than IgG post-immunisation. 
(173) 
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Pilus protein (PI-1)  II Conjugate vaccine induced both type-II and PI-1 specific antibodies capable of OPA killing in 
immunised dams. Antibodies were trans-placental transferred to their respective pups which 
conferred protection when challenged with lethal dose of GBS expressing either type-II CPS or PI-
1 proteins. 
(190) 
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2.8 Reverse vaccinology 
The use of vaccines as a strategy for disease prevention has been successfully used for 
over two centuries to eradicate or cause near elimination of several invasive pathogens 
such as variola-virus, rubella virus, poliovirus, C. diphtheriae etc. The conventional 
methods used in vaccine development involved in vitro cultivation of the pathogen 
which is then inactivated by killing or attenuated and with the whole-organism used as a 
vaccine. Alternatively, subunits of the cultivated pathogen could be isolated one at a 
time to be analysed for their immunogenic properties, Figure 2.6a (191). This method of 
vaccine development involves a laborious task which is time consuming and proves 
ineffective when the pathogens cannot be cultured in vitro. Additionally most pathogens 
occur in variant strains that have mutated their virulence factor to avoid immunological 
clearance, hence, increasing the complexity of designing and developing a vaccine for 
all possible variable strains (192). Other detrimental effects are also observed when the 
whole organism is used as a vaccine; either it may re-activate upon immunisation or 
consist of toxic chemicals. Consequently, there is a need for more reliable and feasible 
methods in developing vaccines. 
Reverse vaccinology, a term coined by Rappuoli (191), refers to a technique that use the 
high-throughput genomic data available to select for potential antigenic molecules with  
potential to be vaccine targets. Computational algorithms are used to analyse and access 
for conserved sequences and/or motifs within the pathogen’s genome to select for 
peptides that are potentially immunogenic, Figure 2.6b. The in silico identified antigens 
are then cloned and expressed in E. coli or a suitable host and assayed for their 
immunogenic capabilities both in vivo and ex vivo.  
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Figure 2.6 Schematic representation of approaches used to develop vaccines, A, conventional methods 
and ,B, reverse vaccinology  (164). 
The process of reverse vaccinology in vaccine development has been used successfully 
in identifying essential virulence factors of N. meningitidis and S. agalactiae which are 
conserved amongst several serotypes thus making them possible universal vaccines 
(193,194). A limitation of reverse vaccinology is that it can only be used to identify 
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protein antigens and unable to identify other essential virulence factors such as 
polysaccharides and glycolipids. 
Proteins anchored on the surface of the bacteria are easily accessible and are targeted by 
the antigen presenting cells, which subsequently activate an immune response to clear 
the evading pathogen. The primary structure of proteins contains conserved intragenic 
sequences that determine subcellular localisation of the particular protein. These 
conserved sequences are used to construct computational algorithms that can be used to 
predict subcellular localisation of hypothetical proteins of related bacterial genomes 
(195). Available GBS genomes of strains isolated from humans are listed in table 2.5, in 
which reverse vaccinology to identify immunogenic GBS peptides may be executed.  
Table 2.5 List of group B Streptococcus strains with complete genome sequences. Only GBS strains 
isolated from human subjects are included. 
Strain Serotype Size (Mb) Genes Proteins Ref 
2603V/R V 2.2 2279 2127 
(196) 
A909 Ia 2.1 2150 2026 
(197) 
COH1 III 2.1 2067 1929  
CNCTC 
10/84 V 2.0 2031 1903 
(198) 
GBS6 II 2.2 2222 2079  
GBS2-NM II 2.2 2198 2057 
(199) 
GBS1-NY II 2.2 2223 2083 
(199) 
SS1 V 2.1 2100 1977 
(200) 
H002 III 2.1 2140 2008 
(201) 
GBS85147 
 
2.0 1982 1876  
SG-M1 III 2.1 2169 2037 
(202) 
NGBS128 III 2.1 2077 1914 
(203) 
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NEM316 III 2.2 2217 2103 
(204) 
515 Ia 2.09 2110 1886 
(197) 
18RS21 II 2.19 2238 2146 
(197) 
H36B Ib 2.2 2382 2376 
(197) 
CJB111 V 2.11 2114 1917 
(197) 
 
S. agalactiae NEM316 strain isolated from a fatal case of septicaemia (204) is a 
representative genome of the major invasive serotype-III and colonising ST-23. The 
genome is comprised of 14 putative pathogenic islands of which one is triplicated in the 
genome and saturated by open reading frames for protein coding. Comparative 
genomics reveals that the GBS pan-genome consist of approximately 1806 core genome 
and 33 strain specific genes (197). Almost one third of the core genome is comprised of 
hypothetical proteins and the functions of the vast majority of the dispensable genes are 
unknown, Figure 2.7, which enunciates the necessity of reverse vaccinology in further 
elucidating the virulence and immunogenic proteins with vaccine potential. 
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Figure 2.7 Schematic representation of group B Streptococcus core genes and dispensable genes of the 
eight GBS strains isolated from humans (192). 
Therefore, using in silico identified GBS surface proteins together with those with 
known virulence capacity; the objectives of my study were: 
i.  Determine the association between natural occurring antibodies and prevention of 
GBS acquisition and/or clearance of colonisation during late pregnancy; 
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 (ii) Evaluate the effect of maternal HIV infection on trans-placental transfer of IgG 
specific to GBS surface proteins from mother to newborn; 
iii. Evaluate the association of GBS surface protein specific IgG titres with risk of 
disease against invasive GBS disease in infants; 
iv. Explore the possible immunological characteristics associated with the increased 
likelihood of invasive GBS in older children by comparing IgG titres in HIV-infected 
and HIV-uninfected children against CPS with that induced by GBS surface proteins. 
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Chapter Three Methods 
Methods 
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3.1 In silico surface protein selection 
Surface proteins were predicted using an adaptation of the Giombini et al.  protocol 
designed to automatically identify surface localised proteins using query genomic 
sequences (205). A systemic cycle-process was adopted rather than the filtration system 
to analyse all proteins for potential cell surface features. A cut-off ≤ 3 membrane helices 
per protein was permitted since proteins with more than 3 membrane spanning regions 
tend to be insoluble (194). Proteins supplied by Valneva Austria GmbH were removed 
prior to selection of immunogenic proteins. Additional bioinformatics tools: SignalP 
and TargetP, were used to decrease the level of false positives, Figure 3.1. Proteins that 
were identified as extracellular and/or cell wall surface anchored proteins were screened 
for B-cell epitpope regions using BepiPred and an average threshold score of 0.4 was 
considered significant for immunogenic proteins (206). Ideal immunogenic proteins 
were further selected based on the presence of repeating proline residues (peptidase 
resistance), repeating serine residues (family of adhesins in Gram positive bacteria) and 
LysM domain (surface anchor motif).  
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Figure 3.1 Extracellular surface protein selection methods, A: Giombini et al filtration protocol, B: 
systemic cycle-process that analyse each protein with all the available bioinformatics tools. 
3.2 Protein structure and immunogenic domain prediction 
Protein structure of the in silico identified protein was predicted using Swiss Model 
database available at http://swissmodel.expasy.org which uses known protein structures 
that are homologous to the query protein sequence. The modelled structure was then 
accessed for distinguishable domains using domain linker prediction database (DLP) 
(128). The database identifies domains based on the presence of a consensus sequence 
of residues that are highly associated with linking protein domains. The domain 
structures were superimposed onto the complete protein structure using Superimpose 
CERPROXY software and the respective immunogenicity of each domain accessed 
with DISCOTOPE (129). 
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3.3 Gene cloning, expression and protein purification 
GBS serogroup III (CDC) was grown overnight on 5% sheep blood agar and 
subsequently cultured in Todd Hewitt broth (Merck, South Africa) at 37oC with 
shaking. The genomic DNA was extracted and purified with the QIAgenDNAamp kit 
according to manufactures instruction, and DNA concentration and purity determined 
spectophotemtrically with the A260/280 ratio. Genes encoding putatively immunogenic 
proteins were amplified with manually designed and optimised primers, Table 3.1, with 
the PCR mixture inclusive of 1.0 µM of each primer (Inqaba Biotec, South Africa), 25-
50 ng gDNA and Phusion Flash Enzyme mix (2.5 U DNA polymerase, DMSO, 50 µM 
MgCl, 400 µM per dNTPs) (Thermo Scientific) and the reaction cycles were: an initial 
denaturation cycle at 98oC for 2 min, 30 cycles of 98oC for 5 sec, 50-55oC for 30 sec, 
72oC for 15 sec/kb and a final extension cycle at 72oC for 5 min. The PCR product was 
then purified with QIAgen PCR purification kit and cloned into the pETite C-His vector 
(Lucigen, USA) and propagated in HI E. Coli competent 10G cells (Lucigen, USA) 
according to manufactures instructions. 
Table 3.1 Primer sequences (5’-3’) flanked by att-L/R homologous oligonucleotides 
 Forward primer Reverse primer 
Foldase protein* GAAGGAGATATACATATGGTTGTTA
CAATGAAGGGCGACAC 
GTGATGGTGGTGATGATGTTGTGAT
AAGATGCCTGCAAATGC 
Sip GAAGGAGATATACATATGGCACAA
GAAACAGATACGACGTGG 
GTGATGGTGGTGATGATGTGATACG
TGAACGTGGTCATAGTG 
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gbs0392 GAAGGAGATATACATATGGTCATCC
CAGTAGACCCAGCAGTACC 
GTGATGGTGGTGATGATGTGGGAGC
GTCTTTTCAGCACCTG 
gbs0393 GAAGGAGATATACATATGGCTGTTA
CAACCACACCTGCAGTTAATC 
GTGATGGTGGTGATGATGTGGCAGT
CCTTTAGCTGGAGC 
gbs1356 GAAGGAGATATACATATGGTAGGG
AGAACTGTTGCGACAAGTG 
GTGATGGTGGTGATGATGACCGTCC
GCATTTTCATTGTCCTT 
cell wall protein GAAGGAGATATACATATGGCTGATA
CAAGTGATAAGAATACTGAC
ACG 
GTGATGGTGGTGATGATGTCCCGTA
GATGCTATTACAGTATCTG 
immunogenic secreted 
proteins 
GAAGGAGATATACATATGGAAACT
GCTTCACCTTCAGCCG 
GTGATGGTGGTGATGATGTTGTGCA
GCTTGTGCTGAACT 
gbs2106 GAAGGAGATATACATATGGCAGAT
AAAGTTCGCGTAGCC 
GTGATGGTGGTGATGATGCCAAGCT
GATAAACCTTGAGCACG 
LysM domain protein GAAGGAGATATACATATGACCGTG
AAATCAGGTGATACCTTATCA
GC 
GTGATGGTGGTGATGATGAAATGAT
AGCGCTGCCGACC 
pEtite vector TAATACGACTCACTATAGGG CTCAAGACCCGTTTAGAGGC 
 
Positive recombinant colonies were identified by colony PCR, which were then cultured 
in YT broth Kan+ for ~6hr at 37oC with shaking (220rpm). The culture recombinant-
clones were diluted to a final concentration of 30% glycerol and stored in 1 ml aliquots 
at -70oC. Plasmids isolated from the recombinant-clones were sequenced to confirm 
correct ORF orientation prior to protein expression.  
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Sequence confirmed plasmids were subsequently transformed into E. coli BL21(DE3) 
competent cells (Lucigen, USA) by heat shock at 42oC in a water bath (Scientific, South 
Africa) and cultured overnight in YT agar plates supplemented with 30 µg/ml 
kanamycin and 0.5% glucose at 37oC. The overnight culture was diluted 1/100 to 100 
ml YT broth and cultured for ~ 3 h at 37oC after which protein expression was induced 
by adding IPTG (Sigma Aldrich) to a final concentration of 1 mM. After induction of 
protein expression, the culture was allowed to continue to grow at 37oC with shaking 
(220 rpm), and 1 ml samples were collected every half an hour for 3 h. The collected 
samples were centrifuged and the pellet re-suspended in 100 µl SDS sample loading 
buffer (250 µM Tris-HCl pH 6.8, 10% SDS, 30% glycerol, 5% β-mercaptalethanol and 
0.02% bromophenol blue) (Biorad), incubated for 5 min at 95oC and stored at -20oC for 
SDS-PAGE analysis. The remaining culture was used to access the solubility of the 
protein. The pellet was suspended in 4 ml of PBS, sonicated at 6-10 pulses of 10 s. The 
lysed cells were centrifuged at 18514g for 30 min at 4oC and the supernatant mixed with 
SDS sample buffer in a 1:1 ratio. The pellet was re-suspended in 4 ml of 8 M urea with 
vigorous vortexing, and subsequently centrifuged at 12857g for 30 min and the 
supernatant mixed with the sample buffer in a 1:1 ratio, similarly with the PBS re-
suspended pellet. The collected samples were visualised by SDS-PAGE analysis.  
Proteins were purified by fast performance liquid chromatography (FPLC) that utilised 
an immobilised metal ion affinity column. Overnight cultures were diluted 1/100 in 1 L 
YT broth Kan+, grown to an OD600 nm
 0.5 and protein expression induced with 0.1 mM 
IPTG (Sigma, Germany) and further cultured for an additional 3 h. The culture was 
centrifuged at 2000g for 10 min and the pellet re-suspended in either 20 mM phosphate 
buffer pH 7.4, 0.5 M NaCl, 20 mM imidazole (soluble proteins) or 20 mM phosphate 
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buffer pH 7.4, 0.5 M NaCl, 20 mM imidazole, 8 M urea (insoluble proteins) and were 
lysed by a cycle of freezing (-20oC) and thawing. The cells were further lysed by 
sonication and the cell lysate purified by centrifugation at 18514g for 30 min at 4oC. 
The histidine tag on the C-terminal of the recombinant proteins was allowed to bind to 
immobilised Ni2+ cations of the resin column. A step gradient elution was performed to 
remove protein with low column binding affinity with 50 mM imidazole and with a 
subsequent elution of His-tagged protein by 500 mM imidazole. Purity of eluted 
proteins was chromatographically analysed at 254 nm and visualised by SDS-PAGE 
analysis. 
3.4 Multiplex immunological assay 
3.4.1 Conjugation of recombinant proteins to microsphere beads 
Purified proteins were desalted by gel filtration using PD-10 desalting columns (GE 
healthcare, Germany) with an exclusion limit of 5 KDa and eluted with 3.5 ml PBS pH 
7.2 in 1 ml aliquots. Desalted proteins were immobilised to carboxylated beads using a 
2-step carbodiimide reaction, with each protein being conjugated to a unique bead 
region (207). Beads were homogenised by vortexing for 1 min and transferred to 1.5 ml 
eppendorf tube where they were centrifuged for 5 min at 15000g. The supernatant was 
discarded and the bead pellet was washed with PBS pH 6.1 and re-centrifuged. Binding 
site of the beads was activated by adding PBS pH 6.1, 20 mg 1-ethyl-3 (3-
dimethylamino-propyl) carbodiimide-HCl and 20 mg N-Hydroxysulfosuccinimide 
which was incubated at room temperature with shaking at 100 rpm for 20 min in the 
dark. Afterwards the beads were washed twice with PBS pH 7.2 and the beads 
suspended in 50 µg/ml proteins at room temperature with shaking at 100 rpm overnight. 
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Quantification of optimal protein conjugation concentration to the beads is described in 
appendix 10.5.1. 
3.4.2 Reference serum, controls and sample analysis 
Purified immunoglobulin G pooled from human adults (Polygam, National Bioproducts, 
South Africa) was used as a reference serum to measure IgG titres. Polygam was diluted 
1:50 in PBS, 10% fetal bovine serum, 0.05% NaN3 (PBSFN) and serially diluted 4-fold 
to obtain 7 standards. The lowest dilution standard (1:50) was arbitrarily assigned a 
value of 100 U/mL IgG titre. IgG titres to the Polygam standards were measured in true 
duplicates by adding 50 µL of each standard to 50 µL of protein-bead mixture (3500 
beads per unique bead region) and incubated at room temperature for 1 h with 300 rpm 
to allow for antibody-antigen coupling. The samples were washed 3× using PBS, 0.05% 
Tween-20, 0.02% NaN3 (PBSTN). Bound antibodies were quantified by adding 50 µL 
goat anti-human IgG conjugated to R-phycoerythrin (Jackson ImmunoResearch, USA) 
diluted 1:100 in PBSFN. The sample mixture was incubated for 30 min at room 
temperature with 300 rpm followed by washing 3×with PBSTN. IgG titres were 
measured using Bioplex 200 (Bio-Rad) instrument. Linearity, specificity and correlation 
between the singleplex and multiplex assay for Polygam are described in appendix 
10.5.2.     
In house controls were prepared by pooling sera from pregnant women with high IgG 
titres against the proteins (high control) and sera from those that had low IgG titres (low 
control). The pooled sera were diluted 1:100 in PBSFN, and IgG titre to the controls 
was measured similar to Polygam standards. Levey-Jennings plots of the controls were 
used to assess inter-assay reproducibility (appendix 10.4.2). 
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Collected serum samples were diluted 1:100 in PBSFN and IgG level determined 
similar to Polygam standards. Antibody titres were extrapolated using the reference 
serum and reported as U/mL. Serum samples with IgG higher than the upper limits of 
detection of the reference serum were re-analysed at 1:200 dilutions. Those below the 
lower limit of detection (LLD) were arbitrary assigned a value 4× lower than LLD for 
the respective antigen. All duplicate samples with coefficient of variation ≥30% were 
re-analysed. Use of all archived human serum samples was approved by the Human 
Research Ethics Committee of the University of Witwatersrand (approval letters 
included in appendix 10.1). 
      
3.5 Generation of specific GBS surface protein antibodies 
Specific polyclonal antibodies were generated in 6 weeks old New Zealand white 
female rabbits. Purified cell wall anchored proteins Sip, gbs0393, gbs1356 and 
lipoprotein gbs2106 were dialyzed in sterile PBS solution (pH 7.2) at 4oC with the PBS 
solution changed three times every 2 h, and then overnight. Prior immunisation, 5 mL 
blood was collected from the lateral ear artery of each rabbit and was used as control. 
After which, 1 mL of the recombinant proteins (250 µg/mL) were emulsified in 
complete Freud’s adjutant at a 2:1 ratio and administered subcutaneously (s.c) at the 
dorsal thoracic area of the rabbit. 
Two booster doses of 250 µg/ml antigen mixed with incomplete Freud’s adjuvant (2:1 
ratio) were administered s.c at days 28 and 42 post-immunisation. To see if the rabbits 
were responding to the antigen, 5 mL blood was collected from the lateral ear artery a 
week later after each booster dose. Finally, at day 56 post-immunisation 20 mL blood 
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was collected via cardiac puncture on fully anaesthetised animals which were 
subsequently euthanized using sodium pentobarbital administered intravenously at a 
dose of 2 mL/kg. Table 3.2 gives a summary of the rabbit immunisation schedule 
performed in the study. Animal use for generating polyclonal antibodies was approved 
by the Witwatersrand University animal ethics screening committee (AESC number: 
2015/05/20/B, approval letter included in appendix 10.1). 
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Table 3.2 Overview of the immunisation schedule used to generate protein specific polyclonal-antibodies 
using New Zealand white rabbits. 
Day Event Procedure Specifications 
1 Collection of control 
serum 
5 ml of blood from the lateral ear 
artery 
Pre-immunisation bleed 
1 Primary Immunisation Subcutaneous injection at 4 sites at 
the back of the neck (250 µl/injection 
site) 
Immunised with 250 µg/ml  
antigen in of CFA 
28 1st Booster 
Immunisation 
35 Collection of test sera 5 ml from lateral ear artery Test bleed for ELISA 
analysis 
42 2nd Booster 
Immunisation 
Subcutaneous injection at 4 sites (250 
µl/injection site) 
Immunise with 250 µg/ml  
antigen in IFA 
56 Exsanguination Heart puncture and withdrawal of 
blood (~20 ml) 
Anesthetise with ketamine-
xylazine mixture and then 
euthanize with sodium 
pentobarbital after blood 
collection 
CFA= complete Freund’s adjuvant, IFA=incomplete Freund’s adjuvant 
All blood samples collected were allowed to clot at room temperature for ≤1 h and sera 
was separated from blood cells by centrifuging at 2000g for 10 min. The serum was 
stored at -70oC. GBS protein specific antibodies in post-immunisation sera were 
assessed using ELISA (see appendix 10.5) and compared with pre-immune sera to 
determine increase in antibodies specific to the respective GBS protein antigen. 
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3.6 Bacterial surface staining and FACS 
GBS isolates were cultured on colorex strep B agar plates (MediaMage, South Africa) 
at 37oC with 5% CO2.  A single GBS positive colony was inoculated in 10 mL Todd 
Hewitt medium (Davies Diagnostics, South Africa) and allowed to grow overnight at 
37oC with shaking (230 rpm). The overnight cultures of GBS isolates were then grown 
in fresh Todd Hewitt broth at 37oC until an OD600nm
 of 0.5. The fresh GBS culture was 
washed with PBS and then fixed using PBS, 0.1% paraformaldehyde solution at 37oC 
for 1 h and at 4oC for ~16 h. The fixed bacterial cells were washed with PBS and 50 µL 
of the bacterial cells (OD600nm of 0.1) were incubated with 50 µL of PBS, 20% fetal calf 
serum and 0.1% bovine serum albumin (blocking solution) for 20 min at room 
temperature. Bacterial suspensions were then mixed with 100 µL of either pre-
immunisation or post-immunisation rabbit serum diluted 1:200 in blocking solution. 
Protein specific antibodies were allowed to bind on bacterial surface for 1 h at 4oC. 
After which the cells were centrifuged at 4000g and washed with 200 µL PBS, 0.1% 
bovine serum albumin (washing solution). Bound antibodies were detected by adding 
50 µL of anti-rabbit IgG conjugated to R-phycoerythrin diluted 1:200 in blocking 
solution and incubated for 1 h at 4oC. Unbound anti-rabbit IgG was washed with 200 µL 
of washing solution and bacterial cells re-suspended in 200 µL PBS. The bacterial cells 
were kept in the dark at 4oC. Unstained and stained bacterial cells were analyzed using 
FACS (fluorescence activated cell sorting) assay.  
The FACS Calibur instrument (BectonDickinson Bioscience, South Africa) was used to 
evaluate the accessibility of the proteins on the surface of GBS by proteins specific 
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antibodies. Unstained GBS bacterial cells were used to set the voltage and amp gain 
parameters for detection of GBS cells. The logarithmic scale was used for forward 
scatter (FSC), side scatter (SCC, threshold of 280) and R-phycoerythrin (R-PE) 
channels. Sample acquisition was performed at a rate of 300-600 events per second until 
10000 events were acquired. Analysis was performed using FlowJo software (version 
10.1r5, Tree Star Inc., CA). GBS clinical isolates were assessed for surface expression 
of Sip, gbs2106, gbs0393 and gbs1356 on the surface and the results are presented in 
chapter 8. 
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Chapter Four Characterisation of group B Streptococcus surface 
proteins 
Characterisation of group B Streptococcus surface 
proteins 
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4.1 Introduction 
 GBS surface proteins play a major role during bacterial pathogenesis, aiding in both 
host invasion and immune evasion (29). Efforts to identify highly conserved 
immunogenic GBS surface proteins as potential candidate vaccines are on-going and 
have been accelerated by the increasing number of available GBS genome sequences 
(191,208).  Comparisons among the GBS genome sequences revealed that GBS strains 
consist of a core-genome that consist of genes present in all strains (197). Of the genes 
encoded by the core-genome, 396 are surface localised proteins and thus subject of 
interest as potential universal GBS vaccines (197). 
Therefore, using the genome sequence of GBS serotype III of the NEM316 strain, in 
silico analysis was performed to identify immunogenic GBS proteins. This chapter 
discusses the selection and characterisation of GBS surface proteins that are used in 
subsequent immunological assays. This work has been published in the journal Vaccine; 
Appendix 10.7. 
4.2 Results 
4.2.1 Identification of surface localised proteins 
Using the genome sequence of GBS NEM316 strain, open reading frames (ORF) with 
characteristics of surface localisation were identified using SignalP, THMM/prodiv, 
pSORT and LipoP as described in the methods section. The complete set of predicted 
ORFs of the GBS genome were screened for protein features that are associated with 
extracellular localisation. Of the 2094 predicted proteins, 32 proteins were identified as 
surface anchored proteins and 25 as lipoproteins, Table 4.1 and appendix 10.2. The 
accuracy for selecting GBS surface proteins was verified by comparing the predicted 
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subcellular localisation of the protein with that assigned in both the curated and 
uncurated Uniprot/SwissProt proteins database of GBS NEM316. The 
Uniprot/SwissProt database had 2000/2094 predicted ORF and only 268 were assigned 
subcellular localisation. A prediction accuracy of 98% was observed using the cycle-
process to determine the subcellular localisation of the proteins. 
 
Table 4.1 Group B Streptococcus surface protein features, complete table included in appendix 10.2, 
signal peptidase I (SpI) recognises the LPxTG motif of cell wall anchored proteins and signal peptidase II 
(SpII) recognises cleavage site LxxC for lipoproteins. 
Protein name Length (aa) SignalP TMHMM pSORT LipoP 
Sip (gbs0031) 434 Yes No Extracellular SpI 
gbs0255 235 No Yes Extracellular SpI 
gbs0392 240 Yes Yes Cell wall SpI 
gbs0393 933 Yes Yes Cell wall SpI 
gbs0479 253 Yes Yes Cell wall SpI 
gbs0628 554 Yes Yes Cell wall SpI 
gbs0722 240 Yes Yes Cell wall SpI 
gbs0723 933 Yes Yes Cell wall SpI 
gbs0986 933 Yes Yes Cell wall SpI 
gbs0987 240 Yes Yes Cell wall SpI 
gbs1143 932 Yes Yes Cell wall SpI 
gbs1144 236 Yes Yes Cell wall SpI 
streptococcal C5a peptidase 
(gbs1308) 
1150 Yes Yes Cell wall SpI 
gbs1356 1634 Yes Yes Cell wall SpI 
gbs1539 192 Yes Yes Cell wall SpI 
immunogenic secreted protein 
(gbs1727) 
512 Yes Yes Cell wall SpI 
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gbs2106 225 Yes Yes Membrane SpII 
LysM domain protein (gbs2107) 179 Yes Yes Cell wall SpI 
 
4.2.2 Prediction of B cell epitopes 
The predicted surface proteins were screened for the presence of immunogenic regions 
using BepiPred, a bioinformatics tool that determines linear epitope regions within the 
protein sequence using hidden Markov models in combination with hydrophilicity 
propensity scale (206). There were 17 proteins that had an average score greater than 
the cut-off value of 0.4, Figure. 4.1. These included known virulence proteins such as 
streptococcal C5a peptidase, laminin binding protein (Lmb) and surface immunogenic 
protein (Sip). Immunogenic proteins were further narrowed to those that contain 
specific repeats of either proline or serine residues and those that had cell surface anchor 
motifs or domains, Table 4.2. The final list comprised of 10 proteins to be cloned and 
expressed for immunogenicity testing. Amongst the identified proteins; Foldase PrsA 
(gbs0827) protein which is a lipoprotein was included as a negative control for 
immunogenicity assays with the assumption that lipoproteins are mostly found 
embedded in the peptidoglycan layer and thus not easily accessible by antibodies. 
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Figure 4.1 Average B cell epitope immunogenicity score for GBS cell surface proteins as predicted using 
BepiPred software, an arbitrary threshold of 0.4 (displayed in red) was used to select for highly 
immunogenic proteins. 
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Table 4.2 Group B Streptococcus immunogenic protein containing repetitive proline/serine, LPXTG 
motif or LysM domains which were considered for subsequent cloning and purification. 
Protein name Proline Serine 
rich 
LPxTG LysM 
Sip Yes Yes No Yes 
gbs0255 No No No - 
gbs0392/0722/0987 Yes No Yes - 
gbs0393/0723/0986 No No Yes - 
streptococcal C5a peptidase Yes No No - 
gbs1356 No No Yes - 
Gbs1539 No Yes Yes - 
immunogenic secreted protein No Yes No - 
gbs2106 No Yes No - 
LysM domain protein (gbs2107) No Yes No Yes 
 
Valneva GmbH (Austria) kindly provided recombinant proteins FbsA, BibA and 
gbs0233  that were selected using the ANTIgenome technique (209).  Two BibA 
variants from strain CHO1 (ST-17) and strain NEM316 (ST-23) were provided. Amino 
acid sequence comparisons of the BibA variants revealed that the internal sequence 
fragment of BibA-NEM316 shared 16% similarity with BibA-COH1 peptide sequence, 
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Appendix 10.5.2. Therefore, for subsequent analysis the internal peptide fragment of 
BibA from GBS NEM316 strains was included together with the whole recombinant 
BibA peptide from COH1 strain. 
4.2.3 Peptide sequence conservation 
Conserved proteins among the genomes are determined as those that have ≥40% 
identity and ≥80% similarity of their sequences with a P-value ≤ 0.005. Homology of 
the selected proteins was quantified by performing a BLAST comparison of GBS 
sequences from strains A909 (Ia), 2603V/R (V), CJB111 (V), COH1 (III), 515 (Ia), 
H36B (Ib) and 18RS21 (II) that were used to define the pan-genome of GBS (197). A 
conservation index formula, 
∑  𝑆𝐼𝑖𝑛−1𝑖≥40%
𝑛−1
 , where SI is sequence identity greater than 0.4 
between the query sequence and the referent (NEM316 strain), n is available GBS 
sequences. Sip and gbs0233 proteins are highly conserved with sequence identity   
≥98% among the all GBS strains. Gbs0392 is the leased conserved protein with no 
homologous proteins in other GBS strains isolated from human samples, Figure 4.2. 
 
Figure 4.2 Representation of surface proteins conservation in GBS relative to the NEM316 strain as 
determined by 
∑ 𝑆𝐼𝑖𝑛−1𝑖>0.4
𝑛
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4.2.4 GBS protein gene cloning 
GBS genes encoding selected peptides were cloned, into E. Coli cells. Lipoprotein 
gbs0255 was omitted from cloning since an optimal primer set required to amplify the 
gene target were either too long or compromised the integrity of the expected 
recombinant protein. The peptide sequence of Gbs1356 was too large to be successfully 
amplified. Therefore, further characterisation of the protein using structural prediction 
revealed that gbs1356 consists of two domains separated by a linker peptide of residue 
632-732 (appendix 10.2).  Figure 4.3A shows the two domains of gbs1356 denoted 
gbs1356-D1 and gbs1356-0D2. Analysis using BepiPred showed that D1 had an 
average score of 0.548 compared to 0.413 of the complete protein (Figure 4.3D) and 
therefore was amplified and the recombinant clone transformed into E. coli, Figure 
4.3B. Structural superimposition of gbs1356 and D1 shows that D1 exclusively forms 
the D1 domain with a root mean square deviation of 2.421, Figure 4.3C.  
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Figure 4.3 Secondary structure prediction of gbs1356, A, complete 3D structure of gbs1356 showing the two 
domains (D1 and D2) QMEAN score of 0.71. B, secondary structure displaying the recombinant clone of the D1 
sequence. C, 3D-structure superimposition of gbs1356 and D1 showing D1 being exclusively gbs1356D1. D, B 
cell epitope distribution on gbs1356 highlighted in yellow.  
The recombinant E. coli clones were further sequenced to confirm correct in-frame sequence 
in the pET C-His vector. A total of 8 of 9 of the cloned genes were correctly inserted into the 
vector inclusive of a start codon and a his-tag coding residues on the 3’-end of ORF. 
Recombinant immunogenic secreted protein (gbs1727) had multiple point mutations 
inclusive of premature termination site and therefore omitted from subsequent production. 
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The sequencing results for the successfully cloned GBS proteins were aligned with BLAST 
nr/nt database and are included in Appendix 10.3. 
4.2.5 Protein expression and purification 
Protein expression of the cloned GBS genes was induced and the solubility of the various 
proteins accessed for optimal purification conditions. Proteins that formed inclusion bodies 
were denatured with phosphate buffer containing 8 M urea to re-solubilise them and were 
subsequently desalted to their native conformation after purification. Chromatographic 
analysis of the purified proteins was performed at 254 nm wavelength and visualised by SDS-
PAGE analysis, Figure 4.4 (corresponding data for the remaining proteins is shown in 
Appendix 10.4, Figure 10.3). High molecular weight proteins gbs0393 and gbs1356 were 
partially degraded during purification, Figure 4.4C. Table 4.3 summarises the extracellular 
localisation and immunogenicity features of the recombinant proteins produced for 
immunological testing. The immunological assay comprised of three lipoproteins; Foldases-
PrsA, gbs0233 and gbs2106, and cell-wall anchored proteins FbsA, BibA, gbs0393, gbs1356, 
gbs1539, gbs0392 together with extracellular secreted protein Sip. 
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Figure 4.4 Purified recombinant group B Streptococcus proteins; A, chromatographic analysis of eluted gbs2106 
protein, with blue line showing UV absorption at 254 nm and green line showing concentration of imidazole; B, 
SDS-PAGE visualisation of gbs2106 and foldase PrsA protein; C, LysM protein, gbs0393 and gbs1356 SDS-
PAGE visualisation. 
79 
 
Table 4.3 Subcellular localisation characteristics and putative functions of group B Streptococcus surface proteins. 
  Protein surface features Putative 
function/pathogenicity 
L
ip
o
p
ro
te
in
s 
Protein name Recombinant 
peptide Length 
(aa) 
SignalP TargetP TMHMM pSORT LipoP BepiPred 
score 
 
Foldase PsrA 
protein 
(gbs0827) 
272 Yes Secreted 0 - LXXC 0.33 Peptidyl-prolyl cis-trans 
isomerase activity 
Gbs0233 308 No Secreted 0 - LXXC -0.03 Lipoprotein, ABC transporter 
Gbs2106 189 Yes Secreted 1 - LXXC 0.57 Unknown function, 
Hypothetical lipoprotein 
C
el
l 
w
al
l 
an
ch
o
re
d
 
p
ro
te
in
s 
FbsA (gbs1087) 340 Yes Secreted 0 LPXTG - 0.55 Induces fibrinogen aggregation, 
Adhesn 
BibA-COH1 
(SAN2207) 
460 Yes Cytoplasmic 
membrane 
1 LPXTG - 0.45 Complement inhibitor, 
Adhesion 
BibA-1(gbs2018) 300 Yes Cytoplasmic 
membrane 
1 LPXTG - 0.45 Complement inhibitor, 
Adhesion 
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Gbs0393 834 Yes Secreted 2 LPXTG - 0.44 Adhesin, surface antigen protein 
Gbs1356 846 Yes Cytoplasmic 
membrane 
2 LPXTG - 0.40 Adhesin, Agglutinin receptor 
Gbs1539 156 Yes Secreted 2 LPXTG - 0.97 Unknown function 
Gbs0392 119 Yes Secreted 1 LPXTG - 0.89 Unknown funtion 
Sip 
(gbs0031) 
414 Yes Secreted 0 LysM - 0.57 Immunogenic protein 
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4.3 Discussion 
The pan-genome of GBS has a minimum of 1806 genes encoding proteins (197). 
Maione et al. identified 589 genes encoding surface proteins present in 8 GBS strains of 
serotype Ia, Ib, II, II and V of which 396 were conserved (194).  Using a representative 
genome sequence of GBS serotype III NEM316 strain and a combination of available 
bioinformatics tools, putatively immunogenic surface proteins were selected and 
produced using recombinant techniques. The recombinant proteins included cell wall 
anchored proteins Sip, gbs0392, gbs0393, gbs1356 and gbs1539 and lipoproteins 
Foldase and gbs2106. The selected proteins were supplemented with recombinant 
proteins FbsA, BibA and gbs0233 provided by Valneva Gmb (Austria). 
Sip is a highly conserved protein that is extracellular localised on the surface of GBS 
using the LysM surface anchor motif (94,210). In vitro expression of Sip is detectable at 
all growth stages suggesting that Sip is expressed throughout the life cycle of the 
bacteria. The immunogenicity of Sip has been extensively characterised and has been 
shown to be capable of conferring protection in mice pups born to immunised dams 
(94,211). Immunisation with Sip protein induces both systemic and mucosal immunity 
in the vaginal and rectal tract (212). 
The genome sequence of GBS NEM316 strains consist of 14 genetic islands of which 
four are true pathogenicity islands, comprised of genes encoding virulence surface 
proteins (213). Gbs0392 and gbs0393 are syntenic genes localised in genetic island that 
has been triplicated within the GBS NEM316 genome and annotated as chromosomal 
integrated plasmid (204,213). Gbs1356 is dimeric protein located in a true pathogenicity 
island that includes genes that encode known virulence proteins such as Lmb and C5a 
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peptidase (213). Subtractive DNA hybridisation revealed that gbs0393 and gbs1356 
homologous to a family of adhesion proteins (214). Furthermore gbs0393 and gbs1356 
were identified as highly immunogenic peptides when using cervical secretion and 
serum samples from pregnant women screened against bacteriophage displaying 
recombinant GBS proteins (96).  
Gbs1539 is a serine rich protein with repeating units flanked by either lysine or 
glutamine residues. Serine rich GBS proteins have been reported to mediate virulence in 
GBS strains (215). Moreover, analysis of differential transcription of GBS gene at 
different growth phases revealed that transcription of gbs1539 increases by >4-fold 
during transition from mid-log to stationary phase indicative of virulence capacity 
(216).  Gbs0233 and Gbs2106 are highly conserved lipoprotein consisting of the LxxC 
motif for surface localisation. The proteins were among the most immuno-reactive 
peptides identified by Meinke et al., with gbs0233 confer protection against GBS to 
40% of immunised mice (96).  
FbsA was identified as a cell wall anchored protein comprised of 16 amino acid 
repeating units that interact with host fibrinogen essential for bacterial adhesion 
(128,217). In silico analysis of GBS genomes identified BibA protein, which is a 
surface exposed adhesion protein capable of binging human C4bp (complement 4 
binding protein), thus inhibiting opsonophagocytosis  (141). Three chimeric forms of 
BibA proteins have been characterised with strains belonging to the hyper-virulence ST-
17 expressing a phylogenetically distant BibA protein (51). Heterogeneous peptide 
fragments of BibA from GBS strain COH1 (ST-17) and strain NEM316 (ST-23) were 
included in this study analysis.  
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Highly immunogenic GBS surface proteins were selected using robust computational 
algorithms. The proteins were varied according to extracellular localisation and 
heterogeneity among GBS strains. Using serological assays, the subsequent chapters 
discusses the immunogenicity of the recombinant peptides to determine their role 
possible GBS vaccine candidates.  
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Chapter Five Nat ur al  ac qui r e d Gr o up B  St r e pt o co cc us  c aps ul ar  po l ys ac c har i de  and s ur f ac e  pr o te i n ant i bo di e s  i n HIV - i nf e c t e d and H I V- u ni nf e c te d c hi l dr e n 
Natural acquired Group B Streptococcus capsular 
polysaccharide and surface protein antibodies in 
HIV-infected and HIV-uninfected children  
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5.1. Introduction 
Cases of invasive GBS disease occurring in children > 3 months of age have been 
reported. The majority of these cases were reported during the pre-IAP era, where the 
prevalence of invasive GBS disease was 4% amongst children between 1-17 years of 
age (22). Table 5.1 list studies that reported the occurrence of invasive GBS disease 
beyond infancy. These cases occur comorbid with underlying conditions associated with 
immune-suppression including HIV infection. The commonest clinical manifestations 
were pneumonia, bacteraemia with no focus and UTI. 
The prominent immuno-pathological progression of HIV infection is a continuous 
depletion and dysfunction of CD4+   T lymphocytes. Additionally, HIV infection causes 
hyper activation of B cells, hypergammaglobulinaemia and loss of memory B 
lymphocytes, hence resulting in a dysfunctional humoral immune response (218). 
Collectively immuno-pathologies associated with HIV infection increases susceptibility 
to bacterial infections such as S. pneumoniae, Haemophilus influenzae type B and GBS 
(219). There is, however, a paucity of data regarding the pathogenesis of GBS and the 
immune-suppressive role of HIV-infection that result in susceptibility to invasive GBS 
disease beyond infancy.  
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Table 5.1 Clinical manifestations of invasive group B Streptococcus disease cases occurring in children > 3 months of age with underlying conditions. 
Cases Age  Clinical manifestation Underlying conditions Year Country Ref 
3 infants who progressed to 
AIDS had positive GBS 
growth cultures from blood 
and CSF 
3.5-5 month Pneumonia, Frontal CSF space 
enlargement and seizures 
HIV infection 1983-1985 USA (220) 
18 children with GBS isolates 
from sterile sites 
15 weeks-18 
years 
Bacteraemia, meningitis, 
endocarditis and central venous 
catheter infection 
Prematurity, 
hypergammaglobulinaemia, 
diabetes mellitus, HIV and 
congenital heart disease 
1986-1993 USA (221) 
GBS isolated from a normally 
sterile sites (CSF and blood) 
were detected in 11 children  
3-31 months Respiratory distress and 
bacteraemia 
Severe malnutrition and HIV 
infection 
1997-1999 South Africa (222) 
24 children, a median age of 
8.5 years with GBS recovered 
from infectious sites 
15 weeks-12 
years 
UTI, acute tonsillitis, sepsis and 
soft tissue infection 
Diabetes mellitus, 
vesicoureteral reflux and 
autoimmune disease 
1991-2002 Taiwan (223) 
223 cases of children  
presenting with invasive GBS 
disease 
3 months-14 
years 
Bacteraemia, meningitis, 
pneumonia, septic arthritis and 
peritonitis 
Neurologic disorders. 
Immunosuppressive 
conditions, asthma, 
malignancy and renal disease 
1999-2005 USA (23) 
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Given that the GBS surface constitutes primarily of two types of antigens; 
polysaccharide encapsulating the bacteria that trigger a T lymphocyte independent 
immune response, and proteins embedded within the CPS that require secondary 
activating signals from CD4+ T lymphocytes for production of antibodies by B cells. 
The aim of this investigation was to determine whether differences in IgG titres to GBS 
CPS and surface protein between HIV-uninfected and HIV-infected children may 
possibly contribute to increased susceptibility to invasive GBS disease. This study has 
been published in the journal Vaccine; Appendix section 10.7. 
5.2. Study population 
The immunogenicity of the selected GBS surface proteins together with that of CPS of 
serotype Ia, Ib, III and V was assessed in sera collected from 77 HIV-uninfected and 68 
HIV-infected children between the age 4-7 years. These were archived samples from 
children who were enrolled in a previous study that was aimed at assessing the 
persistence of the pneumococcal conjugate vaccine (PCV) induced antibodies (224). 
Permission to use these samples without further parental consent was granted by the 
Human Research Ethics Committee of the University of Witwatersrand (Approval 
number: M121019). 
5.3. Statistical analysis 
The data was analysed using STATA software (version 13.0 Stata-Corp, Tx USA) and 
GraphPad Prism (version 5.03 GraphPad Software Inc, California USA). The IgG titres 
obtained were non-symmetric and therefore were log10 transformed for statistical 
comparisons. Statistical differences in IgG geometric mean concentration (GMC, 
µg/mL) for CPS or IgG geometric mean titres (GMT, U/mL) for proteins between HIV-
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uninfected and HIV-infected children were measured using two tailed Student’s t-test. 
Among HIV-infected children differences in IgG titres was compared between those 
who had CD4+ lymphocyte count <500 cells/µL and those who had CD4+ lymphocyte 
count ≥500 cells/µL using Mann-Whitney U test. A more conservative p value ≤ 0.01 
was considered significant to allow for multiple comparisons in lieu of undertaking any 
correction for multiple comparisons.  
5.4. Results 
Demographic information 
The demographic profiles of the HIV-infected and HIV-uninfected children were 
similar for gender and age (3.9 - 7.1 years), Table 5.2. This comprised of 55.9% males 
of which 41 were HIV-uninfected (median age=5.1 years) and 40 were HIV-infected 
(median age=5.2 years), and 44.1% females; 36 HIV-uninfected (median age=5 years) 
and 28 HIV-infected (median age 5.9 years). CD4+ lymphocyte count data was available 
for 57 of the HIV-infected children with a median of 566 cells/µl (range 0-1897 
cells/µl), including 30 (52%) with CD4+ count ≥ 500 cells/µl and 27 (47%) <500 
cells/µl. Of the HIV infected children 12 (21%, 6 males and 6 females) were on 
antiretroviral (ARV) treatment, that comprised of two nucleoside reverse transcriptase 
inhibitors and one non-nucleoside reverse transcriptase inhibitor. The median CD4+ 
count of the HIV-infected children receiving ARV treatment was 442 cells/µL (range 
255-1094 cells/µL).  
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Table 5.2 Demographic features of HIV-infected and HIV-uninfected children between the age of 4-7 
years evaluated for the prevalence of IgG anti-GBS surface antigens. 
Demographic feature HIV-infected 
(n=68) 
HIV-uninfected 
(n= 77) 
age years, median (range) 5.7 (3.9-7.1) 5.2 (3.9-6.3)  
male 40 (58.8%) 41 (53.2%) 
CD4 count cell/µL, median 
(range)  
566 (0-1897)  
<500 cells/ µL, median 
(range) 
351 (0-497)  
≥500 cells/ µL, median 
(range) 
794 (505-1897)  
HIV viral load copies/mL, 
median (range) 
37500 (25-460000)  
HAART- 56 (82.4%)  
HAART+* 12 (17.6%)  
*CD4 cell count information for four of the children receiving ARV treatment was not available 
IgG antibodies against GBS antigens 
The differences in antibody concentrations/titres between HIV-infected and HIV-
uninfected children were epitope dependent. IgG GMC (µg/ml) against CPS were lower 
in HIV-infected compared to HIV-uninfected children particularly for serotype Ib 
(0.047 vs 0.076, p=0.01) and V (1.95 vs 2.97, p = 0.005), Table 5.3. In contrast, GMTs 
were higher against the majority of the protein epitopes in HIV-infected compared to 
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HIV-uninfected children, including the lipoprotein Foldase PsrA, and the cell wall 
anchored proteins FbsA, Gbs1356, Gbs0393, Gbs1539 and Gbs0392 (p < 0.005), Figure 
5.1. Titres against the lipoprotein Gbs2106, and the lysM domain cell-wall anchored 
protein Sip were, however, significantly higher in HIV-uninfected compared to HIV-
infected children (p <0.001; Figure 5.2). 
Table 5.3 IgG geometric mean concentration (GMC, µg/ml) of group B Streptococcus capsular 
polysaccharides in HIV-uninfected and HIV-infected children between the age of 4-7 years. 
  Antigen HIV-uninfected 
GMC (95% CI) 
HIV-infected 
GMC (95% CI) 
p value 
C
ap
su
la
r 
p
o
ly
sa
cc
h
ar
id
es
 
Ia 0.078 
(0.066-0.093) 
0.061 
(0.047-0.079) 
0.1048 
 
Ib 0.755 
(0.62-0.92) 
0.472 
(0.34-0.65) 
0.0119 
 
III 0.439 
(0.38-0.51) 
0.375 
(0.32-0.44) 
0.1541 
 
V 2.971 
(2.49-3.55) 
1.952 
(1.54-2.47) 
0.0045 
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Figure 5.1 IgG geometric mean titre (log U/ml) of group B Streptococcus of GBS surface protein surface 
proteins between HIV-uninfected and HIV-infected children between the age of 4-7 years. 
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Figure 5.2 IgG geometric mean titre (log U/ml) of group B Streptococcus of GBS surface protein surface 
immunogenic protein (Sip) and gbs21016 between HIV-uninfected and HIV-infected children between 
the ages of 4-7 years. 
Multivariate regression of IgG GMC specific to GBS CPS with IgG GMT specific to 
surface proteins was performed. Statistically significant positive correlation was 
observed between IgG levels of CPS and that of surface proteins with the exception of 
Sip, FbsA and gbs1356, Table 5.4. Further evaluation of the IgG level in HIV-infected 
children revealed that IgG titres were higher in children who had CD4+ lymphocyte 
count <500 cell/µL compared to those with CD4+ lymphocyte count ≥500 cell/µL for 
proteins Foldase, gbs1356, gbs1539, gbs0233 and gbs0393, Figure 5.3. 
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Table 5.4 Multiple linear regression of the geometric mean concentration (GMC, µg/ml) of group B Streptococcus capsular polysaccharides and the geometric mean titres 
(GMT, U/ml) of surface proteins among HIV-uninfected and HIV-infected children between the age of 4-7 years. 
 Ia Ib III V 
 HIV-Uninfected HIV-Infected HIV-Uninfected HIV-Infected HIV-Uninfected HIV-Infected HIV-Uninfected HIV-Infected 
 Coeff (p value) Coeff (p value) Coeff (p value) Coeff (p value) 
FbsA 0.16 (0.423) 0.10 (0.604) 0.08 (0.644) 0.12 (0.410) 0.23 (0.307) 0.50 (0.076) 0.20 (0.307) 0.14 (0.465) 
gbs0233 0.14 (0.399) 0.35 (0.006) 0.22 (0.120) 0.26 (0.011) 0.05 (0.796) 0.67 (0.001) 0.23 (0.151) 0.41 (0.003) 
BibACOH1 0.13 (0.329) 0.30 (0.005) 0.09 (0.431) 0.18 (0.043) 0.02 (0.878) 0.46 (0.006) 0.04 (0.784) 0.36 (0.002) 
BibANEM 0.51 (0.009) 0.44 (0.001) 0.11 (0.542) 0.30 (0.004) -0.03 (0.891) 0.79 (<0.001) 0.19 (0.340) 0.55 (<0.001) 
gbs2106 0.44 (0.082) 0.64 (0.003) 0.34 (0.133) 0.48 (0.004) 0.27 (0.351) 1.21 (<0.001) 0.13 (0.607) 0.81 (<0.001) 
gbs0393 0.09 (0.443) 0.21 (0.101) 0.17 (0.083) 0.19 (0.066) 0.17 (0.180) 0.49 (0.014) 0.19 (0.093) 0.34 (0.016) 
Sip 0.10 (0.475) 0.17 (0.262) 0.20 (0.094) 0.11 (0.344) 0.05 (0.758) 0.33 (0.144) 0.13 (0.338) 0.13 (0.423) 
Foldase 0.25 (0.132) 0.29 (0.090) 0.17 (0.246) 0.32 (0.018) 0.18 (0.334) 0.72 (0.006) 0.31 (0.057) 0.49 (0.007) 
Gbs1539 0.18 (0.390) 0.24 (0.183) 0.14 (0.441) 0.19 (0.193) 0.10 (0.692) 0.61 (0.032) 0.18 (0.389) 0.35 (0.073) 
gbs1356 0.29 (0.015) 0.21 (0.104) 0.28 (0.007) 0.15 (0.142) 0.27 (0.054) 0.32 (0.103) 0.29 (0.014) 0.23 (0.096) 
gbs0392 0.36 (0.026) 0.44 (0.001) 0.24 (0.091) 0.33 (0.002) 0.43 (0.021) 0.78 (<0.001) 0.30 (0.066) 0.54 (<0.001) 
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Figure 5.3 IgG antibody titre in HIV-infected children, comparing the difference between those with 
CD4+ lymphocyte count < 500 cells/µL and those with CD4+ lymphocyte count ≥ 500 cell/µl.  
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5.5. Discussion 
Low levels of circulating antibodies to GBS polysaccharides has been  associated with 
increased risk of developing invasive GBS disease in infants (9,11,12). Increased 
bacterial infection, inclusive of GBS, occurs in HIV-infected individuals due to 
immunopathologies associated with HIV infection (225).The increased susceptibility to 
invasive GBS disease in HIV-infected children is suggested to be a consequence of 
inadequate humoral immune responses to capsular polysaccharide  (105,106). This was 
particularly evident for serotypes Ia and V, in which their respective IgG concentrations 
were shown to be lower among HIV-infected children. Also, we identified lower IgG 
titres to Sip and gbs2106 proteins. Sip has been identified as virulence factors in animal 
model studies (94), but for which an association to invasive disease in humans has not 
been established. Nonetheless, IgG titres against GBS surface antigens in both HIV-
infected and HIV-uninfected children shows that humoral immune response occurred to 
these epitopes, likely due to GBS colonisation during childhood (226). 
HIV infection causes immuno-pathogenesis associated with dysregulated and 
dysfunctional CD4+ lymphocytes, in particular, the hyper-activation of B cells and 
hypergammaglobulinaemia (218). The proper immunological response to individual 
antigens may be affected by HIV infection depending on the mechanism and pathway of 
antigen recognition by the immune system. Since protein antigens require activating 
signals from T lymphocytes to activate B cells (152), the higher protein antibody titres 
in HIV-infected compared to HIV-uninfected children to most  surface proteins may be 
a result of an aberrant response, due to hypergammaglobulinaemia that commonly 
occurs with HIV infection and frequently results in high antibody titres of  lower 
functionality (227,228). This is further corroborated by the inverse relationship between 
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antibody titres to protein antigens and CD4+ lymphocyte counts in HIV-infected 
children. Similar to these findings, serum IgG against pneumococcal surface proteins in 
HIV-infected adults were also found to be elevated compared to HIV-uninfected adults 
(229).  
The frequency of GBS colonisation remains high beyond infancy, although often occurs 
asymptomatically, however similar serotypes are isolated in both invasive cases and in 
healthy colonised individuals (221,226,230). The frequent colonising serotypes in this 
population has been reported to be Ia, Ib, II, III and V (106,221). Factors influencing 
GBS acquisition and/or transition to invasive disease are poorly understood. GBS 
colonisation information among the study participants was not available, which 
presented a limitation in our analysis, albeit increased invasive disease was reported 
amongst HIV-infected and HIV-exposed uninfected infants  (21,101) and also in 
immunocompromised children (220,221,223,225).  
Responses to the evaluated GBS proteins differed based on the localisation of the 
protein on the surface of the bacteria (lipoprotein or cell wall anchored), and also 
according to their function as indicated by shared homology of proteins with known 
function. There was no clear relationship to HIV-status between the presumed function 
of the protein or in relation to whether it was mapped to an extra cellular location. This 
was in contrast to that observed for pneumococcal protein antigens in the same study 
population, in which a selection of membrane and cell-wall associated pneumococcal 
antigens, had a distinct dichotomy with respect to HIV status, where the HIV-infected 
group had high titres associated with cell membrane anchored proteins and low titres to 
cell-wall anchored proteins and vice versa (231). The author’s hypothesised that these 
differences could have been due to some cross reactive epitopes from other bacteria in 
97 
 
HIV infected individuals due to increased gut microbial translocation in this population. 
Similarly, increased cross-reactive epitopes in HIV-infected children may also be 
responsible for the higher GMTs observed in this study despite the lack of an apparent 
dichotomy. 
The study limitations included the use of Polygam as a reference serum, which is pooled 
IgG from human adults and thus may result in an overestimation of IgG titres with 
cross-reactive antibodies induced by other species, especially for antigens that had low 
specificity. However, we conceived that since the assay was performed consistently 
throughout, any cross-reactive antibodies detected would result in a proportional 
increase and therefore would not greatly affect the difference between the study groups 
compared.  Furthermore, some of the study participants received PCV vaccine and/or 
were colonised with S. pneumoniae, albeit no cross-reactivity was evaluated between 
GBS surface antigens and pneumococcal specific antibodies. However, it is noteworthy 
that GBS specific IgG levels were not associated with PCV vaccination status or 
colonisation with S. pneumoniae in the respective children.  
The process of reverse vaccinology in vaccine design and development has been used 
successfully in identifying essential virulence factors of N. meningitidis and S. 
agalactiae which are conserved amongst several serotypes thus making them possible 
universal vaccines (193,194). Using reverse vaccinology, we were able to identify novel 
immunogenic proteins localised on the surface of GBS. This study revealed that natural 
antibody responses to GBS surface antigens are produced post-infancy, irrespective of 
HIV status. However, differences in the antigen specific titres should be investigated as 
a possible cause of a dysfunctional immune response or increased GBS colonisation in 
HIV infected children. Furthermore, characterisation of antibody avidity and 
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functionality should be evaluated to determine if the risk of invasive GBS diseases 
beyond infancy is a factor of immunosuppression resulting from a dysfunctional and 
dysregulated immune system. Should the attenuated response to these epitopes, 
particularly serotype-specific CPS and select GBS surface proteins, be responsible for 
the increased risk in susceptibility to GBS in severely immunocompromised HIV 
infected individuals, these epitopes may have potential as future vaccine candidates 
(16,174,176,177). 
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Chapter Six Nat ur al  o c c urr i ng ant i bo di e s  agai ns t  gr o up B St r e pt o co cc us  s ur f ace  pr o te i ns  i n pr e gnant  wo me n 
Natural occurring antibodies against group B 
Streptococcus surface proteins in pregnant women 
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6.1 Introduction 
Colonisation of the recto-vaginal tract of pregnant women with GBS occurs in an 
intermittent, transient and persistent manner during pregnancy (58,73). Asymptomatic 
colonisation of the gastrointestinal site has been shown to be a requisite for GBS 
colonisation in the genitourinary tract (232). GBS colonisation in the genitourinary of 
women is a predisposition to acute symptomatic infection including chorioamnionitis, 
endometritis and urinary tract infections (42). GBS colonisation of the genitourinary 
tract during pregnancy is also a key predisposing factor for developing EOD, with a 
high case fatality ratio 9.6% (2). Moreover, GBS colonisation during pregnancy is 
associated with prematurity, late miscarriages and stillbirths (233). 
Maternal immunisation during pregnancy has the potential to reduce GBS-related 
stillbirths or prematurity and also EOD and LOD in their young infants (234). Natural 
induced maternal α-C protein antibodies are capable of opsonophagocytic killing (19), 
which is associated with a lower prevalence of GBS colonisation among pregnant 
women. Therefore, a vaccine formulation which includes highly immunogenic GBS 
surface proteins capable of preventing GBS recto-vaginal colonisation, could contribute 
to reducing the risk of GBS acquisition in women, and consequently reduce vertical 
transmission of GBS to their foetus and newborns. This would ultimately reduce the 
risk of GBS associated morbidity and mortality, including that affecting the mother, 
foetus and the young infants. 
This chapter investigated natural immune responses to 11 GBS surface proteins and the 
association thereof to GBS recto-vaginal acquisition and/or clearance of colonisation.  
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6.2 Study population 
We retrospectively investigated serum samples from pregnant women who were 
previously enrolled in a study that determined the association between serotype-specific 
capsular antibody and GBS recto-vaginal colonisation in pregnant women (58). Briefly, 
the study cohort consisted of 661 asymptomatic pregnant women attending routine 
antenatal clinic visits in Soweto, South Africa during the period of August 2010 to 
August 2011 who were enrolled at 20 to 37+ weeks of gestational age. The women were 
confirmed to be HIV-uninfected and not on antibiotic treatment for at least two weeks 
prior to enrolment. The study population was documented to have a GBS acquisition 
rate of 27.9% from 20 to 37+ weeks of gestational age, with 49.6% of the women being 
colonised at least on one occasion during the study period. (58). 
GBS colonisation was determined at 20-25, 26-30, 31-35, and at 37+ week of gestation 
by culturing lower vaginal and rectal swabs in chromagenic agar and subsequenctly 
evaluated for the CAMP factor, catalase activity, hydrolysis of esculin and group B 
antigen  (58). A participant with GBS detected at either the vaginal and/or rectal swab 
was considered as colonised; and non-colonised if no growth was detected from either 
swab. In addition, sera were available from the 20-25 weeks and 37+ weeks visits and 
was stored at -70oC until assayed for the quantification of naturally induced IgG titres 
specific to GBS surface proteins.   
Paticipants were categorised according to previously determined colonisation status 
between visits as follows: women whom GBS could not be detected throughout the 
study visits were grouped as non-carriers, women who were not colonised at visit 1 but 
colonised at subsequent visits were grouped as “new-acquisition” cases. Furthermore, 
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women who were colonised with a specific GBS serotype at all study visits were 
denoted as “persistently colonised” and women who tested positive for GBS at visit 1 
(20-25 weeks of gestation age) but had negative culture results at any stage up until the 
37+ weeks gestation age visit were grouped as “transiently colonised”. Pregnant women 
that were only colonised at either the 2nd or 3rd visit were grouped as “intermittently 
colonised”.  
6.3 Statistical analysis 
Antibody titres remained skewed after log10 transformation and therefore median IgG 
antibody titres are reported. Statistical analysis was performed using STATA software 
(version 13.0 Stata-Corp, Tx USA) and GraphPad Prism (version 5.03 GraphPad 
Software Inc, California USA). Difference in IgG titres between groups was determined 
using Mann Whitney U test. Spearman’s rank test regression was performed to 
determine correlation of protein specific IgG titres with maternal age, gestational age, 
parity and gravidity. Association between colonising serotype and protein specific IgG 
titres was assessed using Kruskal-Wallis test. Multivariate quantile regression was used 
to correct for confounding variables with p value <0.2 when analysed as univariates. χ2 
and Fisher’s exact test were used to determine association between groups. Differences 
were considered significant for p-value <0.05. 
6.4 Results 
Association between IgG titres and concurrent GBS colonisation 
Among the 661 pregnant women enrolled in the study, 505 (76.1%) pregnant women 
attended all four study visits and were included in the analysis. The main reason for 
non-inclusion of the other women were relocation, withdrawal of consent or lost to 
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follow up. The demographic characteristics of the study cohort are described elsewhere 
(58). Overall, GBS colonisation was detected in 161/505 (31.9%) women at 20-25 
weeks and in 140/505 (27.7%) of gestation as detailed in Table 6.1. The predominant 
colonising serotypes were type-Ia and III, Table 6.1 (58).  
The maternal age of the women was positively correlated with IgG titres to gbs0233 
(p=0.033), foldase (p=0.02), gbs0393 (p=0.037) and Sip (p=0.03) detected in sera 
collected at 20-25 weeks of gestation age. In sera collected at 20-25 weeks of gestation 
age, gestational age was inversely correlated with IgG titres specific to FbsA (p=0.041) 
and BibA-NEM316 (p=0.02), whilst at ≥37 weeks of gestation age, an inverse 
association was detected between gestational age and IgG titres against FbsA (p=0.033). 
The women’s parity was positively correlated with antibodies against Foldase 
(p=0.045), gbs0393 (p=0.034) and gbs0392 (p=0.048) at 20-25 weeks of gestation age, 
and in sera collected at ≥37 weeks of gestation, maternal parity was correlated to FbsA 
specific IgG titres (p=0.039). The women’s number of pregnancies (gravidity) was also 
positively correlated with IgG titres against gbs0393 (p=0.009) and Sip (p=0.039) 
detected in sera collected at 20-25 weeks of gestation age. Protein specific IgG titres 
were not dependent on the colonising serotype at both 20-25 and ≥37 weeks of gestation 
age. 
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Table 6.1 Demographic characteristics of pregnant women who were either non-colonised or colonised 
with group B Streptococcus at 20-25 and ≥37 weeks of gestation. 
Demographic 20-25 week of gestation ≥37 week of gestation 
 Non-colonised 
(n=344) 
Colonised 
(n=161) 
Non-colonised 
(n=365) 
Colonised 
(n=140) 
Median age, year 
(IQR) 
25.4 (21.7-29.4) 25.5 (22.2-29.7) 25.2 (21.7-29.3) 25.6 (22.2-29.6) 
Median parity 
(range) 
0 (0-5) 1 (0-4) 0 (0-5) 1 (0-4) 
Median gravidity 
(range) 
2 (1-8) 2 (1-6) 2 (1-8) 2 (1-6) 
Miscarriage(s)     
0 293 (85.2%) 128 (79.5%) 304 (82.3%) 117 (83.6%) 
1 40 (11.6%) 30 (18.6%) 50 (13.7%) 20 (14.3%) 
≥2 11 (3.2%) 3 (1.9%) 11 (3.0%) 3 (2.1%) 
Colonisation site     
Rectal†  48 (29.8%)  46 (32.9%) 
Vaginal‡  44 (27.3%)  29 (20.7%) 
Recto-vaginal  69 (42.9%)  65 (46.4%) 
Serotype     
Ia  71 (44.1%)  50 (35.7%) 
Ib  7 (4.3%)  7 (5.0%) 
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II  13 (8.1%)  11 (7.9%) 
III  52 (32.3%)  49 (35.0%) 
IV  4 (2.5%)  2 (1.4%) 
V  13 (8.1%)  17 (12.1%) 
IX  1 (0.6%)  4 (2.9%) 
† rectal colonisation without concomitant vaginal colonisation, ‡ vaginal colonisation without 
concomitant rectal colonisation. 
Cross-sectional analysis at 20-25 weeks of gestation showed that median IgG titres 
(U/mL) for BibA protein of GBS NEM316 strain were higher in colonised (398.11) 
compared to non-colonised women; (295.12; p=0.03). A similar trend was observed at 
≥37 weeks of gestation age with elevated median IgG titres (U/mL) in colonised 
compared to non-colonised women for BibA-COH1 (309.03 vs 245.47, p=0.01), BibA-
NEM316 (380.19 vs 234.42, p=0.03), and Sip (223.87 vs 186.21, p=0.01), Table 6.2. 
These differences were, however, statistically significant only for BibA-NEM316 
(p=0.001 and Sip (p=0.001) after adjusting for cofactor variables. 
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Table 6.2 Cross-sectional comparison of median IgG antibody titres (U/ml) between non-colonised and colonised pregnant women at 20-25 and ≥37 weeks of gestation 
age. 
  20-25 weeks 37-40 weeks 
  Median IgG (IQR)   Median IgG titre (IQR)   
Protein Non-colonised 
(n=344) 
Colonised  
(n=161) 
p-
value 
Adj p-
valueα 
Non-colonised 
(n=365) 
Colonised 
(n=140) 
p-
value 
 Adj p-
valueα 
L
ip
o
p
ro
te
in
 
Gbs0233 169.82 
(91.20-389.05) 
208.93 
(104.71-371.54) 
0.21 0.10 131.83 
(81.28-309.03) 
138.04 
(81.28-234.42) 
0.90 0.90 
Gbs2106 263.03 
(128.82-524.81) 
288.40 
(131.83-478.63) 
0.92 0.90 204.17 
(91.20-398.11) 
251.19 
(147.91-363.08) 
0.17 0.17 
Foldase PsrA 213.80 218.78 0.84 0.66 173.78 194.98 0.72 0.25 
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(104.71-489.78) (117.49-457.09) (87.10-363.08) (100.00-380.19) 
C
el
l 
w
al
l 
an
ch
o
re
d
 
p
ro
te
in
s 
FbsA 104.71 
(33.88-416.87) 
93.33 
(34.67-389.05) 
0.81 0.80 83.18 
(36.31-295.12) 
85.11 
(38.02-346.74) 
0.77 0.97 
 BibA-COH1 288.40 
(138.04-524.81) 
331.13 
(169.82-575.44) 
0.05 0.57 245.47 
(125.89-446.68) 
309.03 
(165.96-602.56) 
0.01 0.24 
BibA-
NEM316 
295.12 
(120.23-630.96) 
398.11 
(190.55-691.83) 
0.03 0.21 234.42 
(104.71-478.63) 
380.19 
(173.78-616.60) 
0.03 0.001 
Gbs0393 316.23 
(158.49-645.65) 
354.81 
(194.98-616.60) 
0.35 0.62 281.84 
(141.25-562.34) 
245.47 
(128.82-489.78) 
0.19 0.10 
Sip 239.88 
(120.23-426.58) 
257.04 
(134.90-407.38) 
0.68 0.53 186.21 
(87.10-316.23) 
223.87 
(123.03-354.81) 
0.01 0.001 
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Gbs1539 181.97 
(75.86-446.68) 
213.80 
(89.13-467.74) 
0.45 0.37 147.91 
(69.18-363.08) 
151.36 
(75.86-380.19) 
0.84 0.77 
Gbs1356 269.15 
(144.54-478.63) 
295.12 
(173.78-478.63) 
0.55 0.80 213.80 
(109.65-389.05) 
218.78 
(95.50-501.19) 
0.66 0.77 
Gbs0392 245.47 
(107.15-537.03) 
269.15 
(141.25-501.19) 
0.40 0.73 186.21 
(95.50-436.52) 
213.80 
(95.50-380.19) 
0.96 0.96 
α, p value was adjusted for colonising serotype, maternal age, gestational age, parity and gravity 
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IgG titres among the pregnant women were further stratified according to the site of 
GBS colonisation. At 20-25 weeks of gestation age, median IgG titres specific to BibA-
NEM316 were significantly higher in women who were colonised in the rectum only 
(489,78 U/mL) compared to those who were non-colonised (169,82 U/mL, p=0.04 
adjusted for cofactor variables), Figure 6.1. Women who had concurrent GBS 
colonisation in the rectal and vaginal tract at 20-25 weeks of getation age had higher 
media Sip antibody titres (U/mL) compared to women who were colonised exclusively 
in the rectum (309,03 vs 204.17, p=0.019), Figure 6.1. IgG titres for the remaining GBS 
proteins were similar for non-colonised women and those who were GBS colonised at 
the rectal and/or vaginal tract, Figure 6.1.  
At ≥37 weeks of gestation age, median IgG titres were higher in women who were 
colonised in the vaginal tract only compared to women were non-colonised for proteins 
FbsA (169.82 vs 83.18, p=0.015), BibA-NEM316 (478.63 vs 234.42, p=0.001), Foldase 
(269.15 vs 173.78, p=0.034), Sip (275.42 vs 186.21, p=0.023) and gbs1539 (281.84 vs 
147.91, p=0.014). After adjusting for cofactor variables these results remained 
statistically significant for proteins BibA-NEM316 (p=0.006) and gbs1539 (p=0.031), 
Figure 6.2. 
Multivairate quantile regression analysis adjusted for cofactor variables  showed that 
GBS colonisation in vaginal tract alone was associated with higher IgG titres (U/mL) 
compared to women with only rectal colonisation for proteins Foldase (269.15 vs 91.20, 
p=0.013), gbs0233(177.83  vs 123.03, p=0.031) and gbs1539 (281.84 vs 114.82, 
p=0.001), Figure 6.2. Moreover, women with only vaginal colonisation had higher 
median IgG tires compared to women who were concurrently colonised in the rectal and 
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vaginal tract for proteins FbsA (169,82 vs 69.18, p=0.021) and BibA-NEM316 (478,63 
vs 316,23, p=0.029) after adjusting for cofactor variables, Figure 6.2.   
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Figure 6.1 IgG titres (log U/mL) against group B Streptococcus surface protein present in pregnant women who were 
either not colonised or colonised at the rectal and/or vaginal tract at 20-25 weeks of gestation age. Statistical 
comparison between groups using quantile regression, * p<0.05 and** p<0.01 adjusted for cofactor variables. Turkey 
box-and-whisker plots representing the median (line within the box), 25th and 75th percentiles (box), the 1.5 times 
interquartile distances from the 25th and 75th centiles (whiskers) and outliers (solid dots)
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Figure 6.2 IgG titres (log U/mL) against group B Streptococcus surface protein present in pregnant women who were 
either not colonised or colonised at the rectal and/or vaginal tract at ≥37 weeks of gestation age. Statistical comparison 
between groups using quantile regression, * p<0.05 and** p<0.01 adjusted for cofactor variables. Turkey box-and-
whisker plots representing the median (line within the box), 25th and 75th percentiles (box), the 1.5 times interquartile 
distances from the 25th and 75th centiles (whiskers) and outliers (solid dots).    
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Association of protein specific IgG antibody and acquisition of GBS colonisation 
To determine the association of naturally occurring GBS surface protein IgG antibodies 
and the risk of recto-vaginal GBS acquisition during pregnancy, antibody titres were 
compared between women who were persistent non-carries (255/505, 50.4%) and those 
who were negative for recto-vaginal colonisation at enrolment and subsequently 
acquired GBS colonisation during the pregnancy (54/505, 10.7%).  
Median IgG titres against all the GBS surface proteins at 20-25 weeks of gestation age 
were not statistically different between the two groups, Table 6.3 and Figure 6.3. The 
reverse cumulative plots, however, show that approximately 60% and 55% of pregnant 
women who were classified as non-carriers had predominant IgG titres against proteins 
gbs0233 and gbs1539 compared to women who subsequently acquired GBS 
colonisation following 20-25 weeks of gestation study visit, Figure 6.3. 
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Table 6.3 Median IgG titre (U/mL) against group B Streptococcus (GBS) surface proteins at 20-25 weeks 
of gestation age in pregnant women who were GBS non-carriers and those who newly acquired GBS 
recto and/or vaginal colonisation during pregnancy.  
  Non-carrier 
(n=255) 
New acquisition 
(n=54) 
 
 Protein Median IgG (IQR) Median IgG (IQR) p 
L
ip
o
p
ro
te
in
 
Gbs0233 177.83 
(93.33-407.38) 
147.91 
(79.43-229.09) 
0.09 
Gbs2106 269.15 
(134.90-524.81) 
239.88 
(123.03-537.03) 
0.79 
Foldase PsrA 223.87 
(104.71-512.86) 
186.21 
(95.50-416.87) 
0.37 
C
el
l 
w
al
l 
an
ch
o
re
d
 p
ro
te
in
s 
FbsA 104.71 
(33.88 380.19) 
97.72 
(33.88-630.96) 
0.47 
BibA-COH1 295.12 
(147.91-512.86) 
302.00 
(147.91-602.56) 
0.78 
BibA-NEM316 281.84 
(123.03-616.60) 
371.54 
(141.25-724.44) 
0.44 
Gbs0393 331.13 
(165.96-645.65) 
295.12 
(147.91-630.96) 
0.75 
Sip 239.88 
(123.03-426.58) 
263.03 
(162.18-501.19) 
0.40 
Gbs1539 194.98 
(87.10 436.52) 
91.20 
(57.54 389.05) 
0.07 
Gbs1356 269.15 251.19 0.94 
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(147.91-457.09) (147.91-562.34) 
Gbs0392 239.88 
(107.15-524.81) 
190.55 
(109.65-467.74) 
0.69 
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Figure 6.3 Reverse cumulative plots comparing IgG titres against group B Streptococcus (GBS) surface proteins 
between women who remained non-colonised throughout pregnancy (solid line) and those who were non-colonised at 
20-25 weeks of gestation age but subsequently acquired GBS colonisation (dotted line). 
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Logistic regression analysis was used to determine the IgG antibody titre threshold 
against gbs0233 and gbs1539 (estimated from the reverse cumulative plot, Figure 6.3) 
required to prevent GBS colonisation during pregnancy. Of the women who remained 
non-carriers throughout pregnancy, 46.7% (119/255) had IgG titres ≥200 U/mL against 
surface protein gbs0233 at baseline compared to 29.6% (16/54) women who newly 
acquired GBS colonisation later in pregnancy. Thus, having gbs0233 specific IgG tires 
≥200 U/mL was associated with reduced odds of acquiring GBS colonisation during 
pregnancy (adjusted OR=0.47 [95%CI: 0.25-0.89], p=0.021), Table 6.4. This strength of 
association remained similar at higher threshold, albeit not significant. 
 Similarly, for gbs1539, women who remained free of GBS recto-vaginal colonisation 
(i.e. non-carriers) were 56% more likely to have IgG titres ≥85 U/mL at baseline 
compared to women who had new-acquisition of GBS (adjusted OR=0.44 [95% CI: 
0.24-0.82], p=0.01). This strength of association between higher gbs1539 antibodies and 
risk of GBS acquisition persisted at higher thresholds of up to ≥300, albeit not 
increasing or being significant thereafter, Table 6.4. No other such association was 
found for the other GBS surface proteins. 
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Table 6.4 IgG titres against group B Streptococcus (GBS) surface proteins  gbs0233 and gbs1539 associated with prevention of acquisition of GBS colonisation. 
IgG levels 
(U/mL) 
Non-colonised 
(n=255) 
New acquisition 
(n=54) 
OR (95% CI) P value OR (95% CI)α P valueα 
Gbs0233       
≥100 185 (72.5%) 34 (63.0%) 0.64 (0.35-1.19) 0.16 0.60 (0.32-1.14) 0.12 
≥200 119 (46.7%) 16 (29.6%) 0.48 (0.26-0.91) 0.022 0.47 (0.25-0.89) 0.021 
≥300 85 (33.3%) 12 (22.2%) 0.57 (0.29-1.14) 0.11 0.59 (0.29-1.19) 0.14 
≥400 66 (25.9%) 8 (14.8%) 0.50 (0.22-1.11) 0.083 0.53 (0.23-1.18) 0.12 
≥500 51 (20.0%) 5 (9.3%) 0.41 (0.15-1.08) 0.063 0.43 (0.16-1.15) 0.092 
Gbs1539       
≥85 192 (75.3%) 30 (55.5%) 0.41 (0.22-0.75) 0.003 0.44 (0.24-0.82) 0.01 
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≥100 181 (71.0%) 26 (48.1%) 0.38 (0.21-0.69) 0.001 0.41 (0.22-0.75) 0.004 
≥200 124 (48.6%) 18 (33.3%) 0.53 (0.29-0.98) 0.04 0.54 (0.29-1.00) 0.051 
≥300 97 (38.0%) 15 (27.8%) 0.63 (0.33-1.200 0.15 0.64 (0.33-1.22) 0.18 
α, adjusted for maternal age, gestational age, parity and gravidity 
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Effect of GBS acquisition on protein specific antibody response  
Further evaluation of serum antibodies against GBS surface proteins revealed that IgG 
titres were dependent on the site where acquisition of GBS colonisation occured. Figure 
6.4 shows the number of women with newly acquired GBS colonisation in the rectal 
and/or vaginal tract by study visits. Of the women grouped as “newly acquired”, 25.9% 
(14/54) acquired GBS colonisation in the rectal tract only, 24.1% (13/54)  in vagina 
tract only and 50.0% (27/54) in recto-vaginal tract. A higher number of women newly 
acquired GBS colonisation in the vaginal tract only at ≥37 weeks of gestation age (11 of 
13, 84.6%) compared to those who newly acquired GBS colonisation in the rectal tract 
only (7 of 14, 50.0%), although this difference was not statistically  different (p=0.32).    
 
Figure 6.4 Pregnant women who newly acquired group B streptococcus colonisation after 20-25 weeks 
gestation age study visit in the rectal tract only (white bars), vaginal tract only (grey bars) and in the rectal 
and vaginal tract (black bars). 
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At ≥37 weeks  of gestation age, pregnant women who acquired GBS colonisation in the 
vaginal tract only had  higher median IgG titres (U/mL) compared to women who were 
non-carriers for GBS surface proteins BibA-NEM316 (478.63 vs 234.42, p=0.012), 
Foldase (269.15 vs173.78, p=0.036), Sip (275.42 vs 186.21, p=0.030) and gbs 1539 
(281.84 vs 147.91, p=0.049), Figure 6.5. In contrast, lower IgG titres (U/mL) were 
observed in women who newly acquired GBS colonisation at the rectal tract only at ≥37 
weeks gestational age compared to those who remained non-colonised throughout, 
inlcuding for  Foldase (128.82 vs 173.78, p=0.043), gbs0233 (123.03 vs 131.83, 
p=0.010), gbs1539 (114.82 vs 147.91, p=0.002) and gbs1356 (177.83 vs 213.80, 
p=0.019), Figure 6.5.  
Moreover, women who only acquired GBS in the vagina had higher median IgG titres 
compared to those who acquired GBS colonisation only in the rectum for proteins Sip 
(p=0.049), Foldase (p=0.0094), gbs0233 (p=0.0039), gbs0393 (p=0.027), gbs1539 
(p=0.0004) and gbs1356 (p=0.039); Figure 6.4. BibA-COH1 specific median IgG titres 
(380.19 U/mL) where higher in women who newly acquired GBS colonisation in the 
recto-vaginal tract compared to those who were persistent non-carriesr (257.04, 
p=0.041). The was no significant difference observed for the other proteins when 
comparing protein specific IgG titres in women who acquired GBS colonisation at the 
recto-vaginal tract and those who acquired GBS colonisation either in the rectal or 
vaginal tract only, Figure 6.5. 
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Figure 6.5 Comparison of median IgG titres to group B Streptococcus (GBS) proteins between pregnant women who 
were non-carriers and those who newly acquired GBS colonisation either at the rectal and/or vaginal tract at ≥37 weeks 
of gestation age. * p < 0.05, ** p < 0.01 and ** p<0.001. Turkey box-and-whisker plots representing the median (line 
within the box), 25th and 75th percentiles (box), the 1.5 times interquartile distances from the 25th and 75th centiles 
(whiskers) and outliers (solid dots). 
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Association of serum IgG and clearance of GBS recto-vaginal colonisation 
Of the 505 women included in the analysis, 69 (13.8%) had positive GBS cultured at all 
study visits (persistently-colonised), 75 (14.8%) were transiently-colonised and 52 
(10.3%) were intermittently-colonised. The pattern of GBS colonisation in women who 
were persistently-colonised differed from women who were transiently-colonised with 
GBS acccording to the site of colonisation and serotype, albeit not statistically 
significant, Table 6.5. 
To determine IgG antibody titres against GBS surface proteins associated with 
clearance of GBS colonisation during pregnancy; women who were persistently- 
colonised with GBS were compared to those who were transiently colonised. Median 
IgG titres (U/mL) among women who were persistently-colonised were higer than those 
occuring in transiently colonised women at 20-25 and ≥37 weeks of gestation age for 
the majority of proteins, Table 6.6 and Table 6.7. Multivariate analysis adjusting for 
maternal colonising serotype, maternal age, gestational age, parity and gravidity showed 
that median IgG titres were higher among persistently-colonised compared to 
transiently-colonised women  for BibA-COH1 (p=0.03), Sip (p=0.03) and gbs1356 
(p=0.04) at 20-25 weeks gestation, Table 6.6. The serum IgG titres against all the GBS 
surface proteins were not statistically different between persistently-colonised compared 
to transiently-colonised women at ≥37 weeks gestation age after adjusting for 
confounding variables, Table 6.7. 
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Table 6.5 Heat map display of serotype distribution in pregnant women who were either persistently or transiently colonised at the vaginal and/or rectal tract.  
 Vaginal Rectal Recto-vaginal 
  Persistent (n) Transient (n) Persistent (n) Transient (n) Persistent (n) Transient (n) 
Serotype V1 V2 V3 V4 V1 V2 V3 V4 V1 V2 V3 V4 V1 V2 V3 V4 V1 V2 V3 V4 V1 V2 V3 V4 
Ia 5 4 7 8 17 8 6 0 6 7 8 8 15 7 1 0 13 13 11 11 9 3 7 0 
Ib 0 0 1 1 0 0 0 0 0 0 0 0 0 1 0 0 3 3 2 1 3 0 0 0 
II 2 1 0 1 2 0 1 0 1 1 3 3 1 0 0 0 3 4 3 2 1 1 1 0 
III 3 5 5 4 4 5 2 0 10 5 7 8 6 1 2 0 17 17 15 14 6 4 2 0 
IV 1 1 1 0 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0 1 2 0 0 0 
V 1 1 0 1 3 1 2 0 2 1 0 1 2 3 1 0 1 3 3 2 4 2 2 0 
IX 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 1 2 2 0 0 0 0 
Total 12 12 14 15 26 15 11 0 20 15 19 21 24 12 4 0 37 42 36 33 25 10 12 0 
Overallα 13.2 (19.2%) 17.3 (23.1%) 18.8 (27.2%) 13.3 (17.3%) 37.0 (53.6%) 15.7 (20.9%) 
 
α, rate of GBS colonisation 
 V, study visit during pregnancy 
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Table 6.6 Comparison of median IgG titre to group B Streptococcus (GBS) surface proteins between 
pregnant women who were persistently colonised and those who were transiently colonised at 20-25 
weeks of gestation age. 
 Protein Transiently-colonised 
(n=75) 
Persistently-colonised 
(n=69) 
p value Adj p 
valueα 
L
ip
o
p
ro
te
in
 
Gbs0233 199.53 
(97.72-371.54) 
245.47 
(117.49-389.05) 
0.15 0.59 
Gbs2106 234.42 
(100.00-467.74) 
346.74 
(144.54-537.03) 
0.05 0.11 
Foldase PsrA 190.55 
(100.00-478.63) 
234.42 
(117.49-457.09) 
0.73 0.23 
C
el
l 
w
al
l 
an
ch
o
re
d
 p
ro
te
in
s 
FbsA 109.65 
(33.88-338.84) 
91.20 
(45.71 501.19) 
0.67 0.69 
BibA-COH1 288.40 
(158.49-501.19) 
436.52 
(199.53-660.69) 
0.03 0.03 
BibA-NEM316 354.81 
(141.25-741.31) 
467.74 
(213.80-691.83) 
0.35 0.29 
Gbs0393 354.81 
(194.98-676.08) 
407.38 
(251.19-602.56) 
0.60 0.17 
Sip 213.80 
(109.65-389.05) 
295.12 
(177.83-426.58) 
0.04 0.03 
Gbs1539 177.83 213.80 0.38 0.55 
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(75.86-436.52) (114.82-512.86) 
Gbs1356 263.03 
(134.90-389.05) 
354.81 
(173.78-575.44) 
0.02 0.04 
 Gbs0392 275.42 
(141.25-575.44) 
281.84 
(177.83-436.52) 
0.80 0.75 
α, adjusted for colonising serotype, gestational age, maternal age, parity and gravidity 
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Table 6.7 Comparison of median IgG titre to group B Streptococcus (GBS) surface proteins between 
pregnant women who were persistently colonised and those who were transiently colonised at ≥37 weeks 
of gestation age. 
 Protein Transient Persistent p value p valueα 
L
ip
o
p
ro
te
in
 
Gbs0233 141.25 
(75.86-275.42) 
158.49 
(97.72-323.59) 
0.20 0.71 
Gbs2106 218.78 
(93.33-407.38) 
245.47 
(123.03-346.74) 
0.73 0.56 
Foldase PsrA 158.49 
(75.86-398.11) 
194.98 
(77.62-389.05) 
0.79 0.63 
C
el
l 
w
al
l 
an
ch
o
re
d
 p
ro
te
in
s 
FbsA 79.43 
(36.31-251.19) 
85.11 
(42.66-398.11) 
0.63 0.46 
BibA-COH1 239.88 
(154.88-446.68) 
338.84 
(173.78-602.56) 
0.08 0.57 
BibA-NEM316 208.93 
(134.90-524.81) 
398.11 
(204.17-630.96) 
0.02 0.24 
Gbs0393 302.00 
(144.54-707.95) 
269.15 
(154.88-512.86) 
0.37 0.38 
Sip 199.53 
(93.33-338.84) 
223.87 
(123.03-354.81) 
0.23 0.62 
Gbs1539 125.89 
(61.66-363.08) 
177.83 
(69.18-478.63) 
0.38 0.06 
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Gbs1356 223.87 
(89.13-389.05) 
245.47 
(93.33-501.19) 
0.46 0.61 
 Gbs0392 245.47 
(97.72-575.44) 
229.09 
(104.71-398.11) 
0.65 0.56 
α, adjusted for colonising serotype, gestational age, maternal age, parity and gravidity 
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6.5 Discussion 
We observed that antibodies against a selection of GBS surface proteins were present 
throughout pregnancy irrespective of the women’s colonization status and the 
colonising serotype. This observation is consistent with the high GBS acquisition rate of 
27.9% that occurred from ≥20 weeks of gestation age onward during the study period 
(58). Also, high prevalence of GBS colonisation during pregnancy has been reported in 
other studies, being greatest in the African region (235).  The protein antibody levels 
detected were influenced by GBS colonisation status, the site of acquisition of GBS 
colonisation and gestational period.     
Humoral immunity in pregnant women with GBS colonisation has been extensively 
described for capsular polysaccharides, with serotype specific antibodies significantly 
increased in women colonised with homotypic CPS serotype (18,60,236). Similarly, 
antibody titres against Sip and pilus island proteins have been reported to be higher 
among colonised pregnant women (89,237). In our study, cross-sectional analysis at 20-
25 and ≥37 weeks of gestation revealed that IgG titres for BibA and Sip proteins were 
significantly increased in colonised compared to non-colonised women. Considering 
that this was not evaluated specifically for GBS isolates expressing the specific protein, 
this might be an under estimate of the protein’s capacity to induce natural antibody 
response.  
Changes in sera IgG titres against GBS surface proteins with advancing gestation were 
dependent on the site where GBS colonisation was detected. IgG titres against select 
GBS proteins were significantly lower in pregnant women colonised at the rectal tract 
compared to those who were only colonised at the vaginal tract at ≥37 weeks of 
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gestation. This is in contrast to Hordnes et al. (1996) who reported increased serotype-
specific capsular IgA and IgG in cervical secretion with no corresponding increase in 
serum IgG in women who had GBS colonisation at either the rectum or vaginal tract at 
17 weeks of gestation (238).  Shen et al. (2000), however reported that vaginal 
immunisation with GBS serotype III CPS conjugated to cholera toxin induced a marked 
increase in sera IgG together with mucosal IgG and IgA (239). Given that the dominant 
IgG present in cervivcal secretions and vaginal washes tends to have been derived from 
both the local and circulating plasma cells (240). This in part could explain the 
occurance of higher serum IgG titres among women who were colonised at the vaginal 
tract. 
The function of naturally induced antibodies was inferred by comparing pregnant 
women who remained non-colonised throughout the study visits to those that newly 
acquired GBS after 20-25 weeks of gestation age. Women with IgG titres ≥ 200 U/mL 
against gbs0233 were 53% less likely to acquire GBS colonisation. Similarly, having 
IgG titres ≥85 U/mL against gbs1539 reduced the odds of being colonised by 66%. 
These results suggest that increasing maternal antibodies to proteins by vaccination 
could reduce GBS acquisition and subsequently lower vertical transmission to their 
respective foetus/newborns. Similar observations were reported for antibodies against 
CPS of serotype Ia and III, with increasing IgG concentrations associated with reduced 
odds of acquiring GBS colonisation (241).  
Acquisition of GBS at the vaginal tract induced elevated serum IgG titres against select 
GBS surface proteins. This resulted in significantly lower serum IgG titres against select 
GBS surface proteins were observed in women who newly acquired GBS colonisation 
at the rectal tract compared to those that acquired GBS colonisation at the vaginal tract.  
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An increase in systemic antibody production has been reported in women where the 
vaginal tract was used as the route for immunisation (239,242). We hypothesized that 
differential protein expression may occur between the two colonisation site resulting in 
an up-regulation of specific proteins and subsequently inducing a higher immune 
response. Alternatively, the lack of serum antibody stimulation observed following 
colonisation of the rectal tract may be due to either local immune dependent suppression 
of colonisation or immunological naivety in the rectum that allows for persistent GBS 
colonisation. 
Pregnant women who were persistent GBS carriers had, overall, higher median serum 
IgG titres compared to those who cleared GBS colonisation in subsequent visits post 20-
25 weeks of gestation. Similar results were observed for IgG concentration against CPS 
of serotype Ia, III and V, however, significantly high OPA killing was reported amongst 
women who lost GBS colonisation (243). Therefore, further experiments are required to 
determine the functional activity of protein specific antibodies produced in women who 
are persistently colonised and compared to those that are transient carriers. 
Immunisation against GBS colonisation during pregnancy has the potential to reduce 
vertical transmission of the bacterium from mother to foetus/newborns, hence 
decreasing invasive GBS disease among neonates. Prevention and/or subsequent 
clearance of GBS colonisation requires a vaccine candidate capable of inducing 
neutralising antibodies at both the mucosal and systemic components (242). Identifying 
and targeting antigens that are preferentially expressed for mediating pathogenesis: 
those having dual importance in colonisation and invasive disease, may increase the 
efficacy of the vaccine against invasive disease. Moreover, these antigens may be highly 
expressed and more favourable for immune recognition for prevention of GBS 
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colonisation. Grifantini et al. identified 5 genes upregulated during Neisseria 
meningitidis adhesion, two of which were putative proteins, using DNA-microarray that 
were capable of inducing antibodies with  opsonophagocytic activity in mice (244). 
Using both known virulence proteins and in silico identified surface proteins, this study 
reports on immunogenic GBS peptides that seem to be involved during bacterial 
infection and thus further experiments are required to determine their pathogenicity. The 
peptide antigens described are capable of inducing an antibody response and exhibit 
serological potential in preventing GBS acquisition. Current evidence suggest that these 
GBS surface proteins are not involved in clearance of GBS colonisation, further 
experiments are required to determine functionality of antibodies induced.  
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Chapter Seven R ed u ced  t r a n s -pl a cen t a l  t r a ns fer  o f  a nt i bo d i es  ag a i ns t  G BS  s u r fa ce p r ot ei ns  i n  H IV - i n fect ed  mo t h er -n ew  b o r n  d y ad s 
Reduced trans-placental transfer of antibodies 
against GBS surface proteins in HIV-infected 
mother-newborn dyads 
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7.1 Introduction 
Risk factors associated with neonatal invasive GBS disease include intrapartum fever, 
premature rapture of membrane, preterm-delivery and low birth weight (245). Recently 
maternal HIV infection has been shown to increase the risk of invasive GBS disease in 
infants who have been exposed in utero  (20,21). Moreover, maternal HIV infection is 
also associated with preterm delivery and low birth weight (246), and therefore further 
increasing the burden of invasive GBS disease in HIV-exposed uninfected (HEU) 
infants. 
The increased susceptibility to bacterial and viral infections such as Streptococcus 
pneumoniae,  Streptococcus pyogenes, Haemophilus influenzae type b, Clostridium 
tetani, Bordetella pertussis and Varicella-zoster virus and measles in  HEU infants is 
partly attributable to reduced maternally derived antibodies (102–104). Similarly, 
reduced trans-placental transfer of antibodies against GBS capsular polysaccharide has 
been reported, resulting in low antibody levels that are capable of binding and 
neutralising GBS in infants (105,106). This may also contribute to the heightened 
susceptibility to invasive GBS disease amongst HEU infants (20,21). 
The aim of this study was to evaluate the effect of maternal HIV infection on trans-
placental transfer of antibodies against GBS surface proteins including BibA, Sip, 
Foldase, gbs2106, gbs0393, gbs1356, gbs1539 and gbs0392. Work included here has 
been published in The Journal of Infectious Diseases; Appendix 10.7. 
7.2 Study population 
To determine the influence of maternal HIV-infection on placental transfer of antibodies 
against GBS surface proteins, a retrospective analysis was performed in sera collected 
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from cord and maternal blood of mother-newborn pairs. The study participants were 
previously enrolled in a similar study that measured antibody concentrations specific to 
GBS CPS and proteins PI, FbsA and BibA (from hypervirulent ST-17) which are not 
included in this study analysis (106). 
Pregnant women with confirmed HIV status delivering at ≥36 weeks of gestation age 
and whose babies were ≥2.5 kg birth weight were included in the study. As part of 
routine antenatal care, CD4+ lymphocyte counts were determined for HIV-infected 
pregnant women and were used to determine ARV regimen given to each women. 
Those with CD4+ lymphocyte count ≤350 cells/µL were given triple ARV, whereas 
those who had CD4+ lymphocyte count >350   cells/µL were treated with zidovudine 
until delivery. HIV RNA-viral load was measured in blood of HIV-infected pregnant 
women using polymerase chain reaction which had a detection limit of 40 copies/mL. 
GBS colonisation was determined for the pregnant women by swabbing the lower 
vaginal and rectal tracts and inoculating selective medium. Positive GBS cultures were 
serotyped using latex agglutination. Use of the archived serum samples for this study 
was approved by the Human Research Ethics Committee of the University of 
Witwatersrand (Approval number: M140902) 
7.3 Statistical analysis 
Statistical analysis was performed using STATA software (version 13.0 Stata-Corp, Tx 
USA) and GraphPad Prism (version 5.03 GraphPad Software Inc, California USA).  
Antibody titres were log10 transformed for parametric statistical comparisons. Statistical 
differences or association between groups was measured using two tailed Student’s t-
test or χ2 and Fisher’s exact test. Confounding variables were assessed in a univariate 
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analysis and were corrected for using multivariate regression and a p value < 0.05 was 
considered statistically significant. 
Cord-maternal antibody ratio (CMR) were calculated for each mother-newborn pair and 
median CMR were compared between HIV-uninfected and HIV-infected mother-
newborn dyads using quantile regression. Relative efficiency of trans-placental transfer 
of antibodies between the two groups was measured as the difference in CMR of HIV-
uninfected and HIV-infected mother-newborn dyads and reported as a percentile. The 
association between maternal CD4+ lymphocyte count and HIV viral load with antibody 
titres and CMR was assessed using univariate quantile regression. 
7.4 Results 
Demographic characteristics 
A total of 164 mother-newborn dyads were analysed in this study. Detailed 
demographic information about the study participants is shown in Table 7.1 (106). 
Briefly, of the 164 mothers, 81 were HIV-uninfected and 83 were HIV-infected. CD4+ 
lymphocyte counts were available for 71 (85.5%) of the 83 HIV- infected women, with 
a median of 423 cells/µL (range 46-1268 cells/µL). HIV-1 RNA viral loads were 
detected in 79 HIV-infected women with a median of 96 copies/mL (range 20 to 146 
055 copies/mL). Using vaginal and rectal swabs, positive GBS growth at delivery were 
detected in 29.9% (49 of 164) women, including among 27.2% (22 of 81) HIV-
uninfected and 32.5% (27 of 83; p=0.45) HIV-infected women, supplementary Table 
S1. Serotype distribution did not differ by HIV status with the frequently colonising 
serotypes being Ia (40.8%), III (28.6%), V (18.4%),II (8.2%) and Ib (4.1%)  (106).  
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Table 7.1 Demographic characteristics of HIV-uninfected and HIV-infected pregnant women at delivery 
together with their respective HIV-unexposed and HIV-uninfected exposed infants. 
 HIV-uninfected 
(n=81) 
HIV-infected 
(n=83) 
P value 
age, years; 
median (range) 
26.0 (18.1-42.0) 30.7 (18.7-42.7) 0.0057 
Parity, median (range) 1 (0-5) 1 (0-4) 0.079 
CD4+ lymphocyte count, 
cells/µL; median (range)ǂ 
 423 (46-1268)  
<250   14 (16.8%)  
250-350  12 (14.5%)  
350-500  21 (25.3%)  
>500  24 (28.9%)  
HIV viral load, 
copies/mL; median 
(range)ɸ 
 96 (20-146055)  
<40  31 (37.3%)  
40-1000  21 (25.3%)  
1000-10000  14 (16.9%)  
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>10000  13 (15.7%)  
GBS Colonised 22 (27.2%) 27 (32.5%) 0.45 
Serotype   0.18 
Ia 12 [54.6%] 8 [29.6%] 0.47 
Ib 0 [0.0%] 2 [7.4%] 0.24 
II 2 [9.1%] 2 [7.4%] 1.00 
III 3 [13.6%] 11 [40.7%] 0.035 
V 5 [22.7%] 4 [14.8%] 0.81 
Infants    
Gender, male 45 (55.6%) 45 (54.2%) 0.86 
Gestational age, weeks; 
median (range) 
40 (36.1-44.0) 40 (36.4-43.5) 1.00 
Birth weight, grams; 
median (range) 
3130 (2510-4415) 3034 (2500-3910) 0.19 
ǂ CD4+ lymphocyte count was not recorded in 12 of the HIV-infected women. 
ɸ HIV RNA viral load was not recorded in 4 of the HIV-infected women. 
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Maternal antibodies to GBS surface proteins 
All maternal sera had detectable antibody titres for the analysed GBS surface proteins. 
IgG GMT against the GBS surface proteins analysed did not differ by GBS colonisation 
status among the women, Table 7.2. HIV-infected women had lower antibody GMT 
(U/ml) compared to HIV-uninfected women, including after adjusting for cofactor 
variables, for proteins Sip (132.42 vs 186.72, p=0.002), Foldase (162.06 vs 220.82, 
p=0.035) and other putative proteins including gbs2106 (153.62 vs 235.11, p=0.002), 
gbs0393 (258.97 vs 381.35, p=0.001), gbs1356 (156.36 vs 215.49, p=0.035), Figure 7.1. 
Similar trends were observed for gbs0392 and gbs1539 with antibody GMT being 
higher amongst HIV-uninfected compared to HIV-infected women, albeit not 
statistically significant. No significant correlation was observed between CD4+ 
lymphocyte count and HIV-1 RNA viral load with maternal antibody titres for all the 
GBS surface proteins, Table 7.3 and 7.4.  
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Table 7.2 Comparison of IgG antibody geometric mean titres (GMT) against group B Streptococcus surface protein between non-colonised and colonised pregnant 
women who were either HIV-uninfected or HIV-infected mothers.  
 HIV-uninfected  HIV-infected  
Surface 
proteins 
Non-colonised 
GMT (95%CI) 
Colonised 
GMT (95%CI) 
P 
value 
Non-colonised 
GMT (95%CI) 
Colonised 
GMT (95%CI) 
P value 
Sip 191.70 
(164.56-223.33) 
173.97 
(148.82-203.38) 
0.47 128.22 
(107.83-152.48) 
141.58 
(105.17-190.60) 
0.54 
BibA 200.13 
(157.21-254.78) 
235.12 
(149.38-370.07) 
0.51 180.36 
(143.26-227.06) 
251.09 
(171.18-368.30) 
0.13 
Foldase 220.10 
(177.61-272.75) 
222.78 
(145.24-341.71) 
0.96 151.62 
(114.95-199.98) 
186.07 
(138.05-250.80) 
0.37 
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Gbs2106 227.51 
(179.16-288.90) 
256.78 
(197.31-334.17) 
0.57 138.82 
(109.36-176.22) 
189.53 
(133.88-268.31) 
0.14 
Gbs1356 359.02 
(297.55-433.20) 
448.34 
(293.64-684.54) 
0.62 231.62 
(182.28-294.33) 
326.42 
(250.58-425.21) 
0.45 
Gbs0393 222.30 
(175.36-281.80) 
198.26 
(135.94-289.15) 
0.27 146.65 
(106.51-201.92) 
178.58 
(126.08-252.94) 
0.08 
Gbs1539 351.81 
(286.38-432.18) 
391.51 
(250.58-611.71) 
0.62 268.61 
(209.61-344.20) 
369.63 
(265.00-515.57) 
0.14 
Gbs0392 324.67 
(268.49-392.60) 
329.44 
(208.39-520.81) 
0.94 250.64 
(191.59-327.90) 
397.10 
(275.55-572.28) 
0.05 
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Figure 7.1 Reverse cumulative distributions of antibody titres against group B Streptococcus surface 
protein antigens in HIV-uninfected (solid line) and HIV-infected (dotted line) women at delivery.  
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Table 7.3 Association between group B Streptococcus specific IgG antibodies and maternal CD4+ 
lymphocyte count in HIV-infected pregnant women. 
 CD4+ cells/mL p value 
 <250 (n=14) 250-350 (n=12) 350-500 (n=21) >500 (n=24) 
Sip 160.47  
(113.08-222.89) 
116.43 
(61.36-214.19) 
149.96 
(107.42-213.24) 
136.76 
(72.47-211.64) 
0.62 
BibA 166.75 
(104.54-504.33) 
221.41 
(116.58-370.43) 
271.16 
(95.27-330.32) 
177.51 
(117.89-264.23) 
0.72 
Foldase 251.76 
(178.47-310.21) 
141.57 
(51.46-208.51) 
165.15 
(76.33-283.74) 
178.36 
(87.12-240.64) 
0.14 
gbs2106 200.48 
(124.31-361.34) 
187.74 
(61.4-382.76) 
94.03 
(61.4-382.76) 
154.78 
(91.76-213.84) 
0.37 
Gbs1356 271.59 
(180.67-541.64) 
82.42 
(38.08-257.96) 
173.89 
(38.05-257.96) 
170.5 
(78.48-205.03) 
0.54 
Gbs0393 401.36 
(192.64-
1031.36) 
187.43 
(149.35-256.83) 
230.03 
(149.35-256.83) 
283 
(104.00-492.24) 
0.77 
Gbs1539 442.58 
(144.13-853.10) 
254.09 
(97.92-290.14) 
293.36 
(97.92-290.14) 
240.89 
(163.96-518.56) 
0.66 
Gbs0392 314.42 
(197.59-433.15) 
273.32 
(152.08-521.05) 
275.11 
(152.08-521.05) 
282.85 
(108.37-582.91) 
0.64 
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Table 7.4 Association between group B Streptococcus specific IgG antibodies and maternal HIV-1 viral 
load in HIV-infected pregnant women. 
 HIV-1 viral load copies/mL  
 <40 (n=31) 40-1000 (n=21) 1000-10000 
(n=14) 
>10000 (n=13) P 
value 
Sip 149.73 
(108.35-
218.53) 
160.61 
(107.42-
216.32) 
83.82 
(56.87-116.36) 
170.35 
(130.29-
259.70) 
0.63 
BibA 222.51 
(139.44-
364.64) 
145.32 
(101.45-
228.02) 
165.93 
(60.19-330.32) 
276.77 
(122.02-
377.95) 
0.90 
Foldase 184.86 
(79.72-276.62) 
195.66 
(136.83-
283.95) 
98.76 
(46.69-180.39) 
207.6 
(136.99-
282.78) 
0.90 
gbs2106 215.07 
(94.03-361.34) 
146.92 
(95.04-209.38) 
88.66 
(46.11-157.93) 
234.18 
(92.42-359.49) 
0.17 
Gbs1356 173.89 
(93.02-346.58) 
179.57 
(85.01-237.71) 
103.27 
(35.78-248.64) 
178.83 
(150.57-
305.47) 
0.94 
Gbs0393 293.01 
(187.53-
533.49) 
283.15 
(135.19-
460.53) 
172.52 
(66.17-200.70) 
297.53 
(235.19-
455.24) 
0.60 
Gbs1539 292.6 247.58 266.77 480.69 0.18 
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(185.07-
581.09) 
(104.95-
513.25) 
(102.50-
398.00) 
(230.56-
697.13) 
Gbs0392 350.59 
(195.11-
664.54) 
312.54 
(125.79-
501.28) 
251.56 
(122.15-
302.35) 
259.41 
(184.23-
420.39) 
0.20 
 
Newborn antibodies to GBS surface proteins 
Of the 164 cord sera analysed, 18 samples had antibody titres below the detection limit 
for gbs1539, two had no detectable titres to gbs1539 and gbs0392, one each for 
gbs1539, gbs0393, Sip proteins and gbs1356. Antibody GMT in HEU newborns (n=83) 
were significantly lower compared to HIV-unexposed newborns (n=81) for all proteins 
after multivariate regression controlling for cofactor variables; including for Sip (80.37 
vs 153.70, p<0.0001), Foldase (71.07 vs 142.27, p<0.0001), BibA (127.46 vs180.42, 
p=0.026), gbs2106 (82.91 vs 205.83, p<0.0001), gbs0393 (113.50 vs 241.33, p<0.0001), 
gbs1539 (73.12 vs 138.38, p=0.016), gbs1356 (55.05 vs 104.06, p=0.001), gbs0392 
(81.70 vs 130.2, p<0.0001), Figure 7.2. 
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Figure 7.2 Reverse cumulative distributions of antibody titres against group B Streptococcus surface 
protein antigens in HIV-unexposed (solid line) and HIV-exposed uninfected (dotted line) newborn 
infants. 
Effects of HIV infection on trans-placental transfer of antibodies 
Maternal antibody titres correlated positively with cord antibody titres for all GBS 
surface proteins, R2≥0.5 and p<0.0001. Cord-maternal antibody ratios were compared 
between HIV-infected and HIV-uninfected mother-newborn dyads using quantile 
regression and adjusted for cofactor variables. Maternal HIV infection was associated 
with lower ratios of trans-placental transfer of antibodies for Sip (25.8%, p<0.001), 
Foldase (30.4%, p<0.001), gba0392 (36.5%, p=0.006), gbs0393 (32.9%, p<0.001), 
gbs1539 (39.2%, p<0.008), gbs2106 (35.7%, p<0.001) and BibA (19.4%, p=0.004), 
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Table 7.5. Antibodies to proteins gbs1539 and gbs0392 had ≤0.40 median cord-maternal 
antibody ratios irrespective of maternal HIV infection. No correlation was observed 
between cord-maternal antibody ratios with maternal CD4+ lymphocyte count and HIV-
1 RNA viral load, supplementary Table 7.6 and 7.7. 
Table 7.5 Cord-maternal ratio (CMR) of antibody titres against group B Streptococcus surface proteins in 
HIV-uninfected and HIV-infected mother-newborn dyads. 
Surface proteins  HIV-uninfected Mother-
newborn dyad median 
CMR (IQR) n=81 
HIV-infected Mother-
newborn dyad median 
CMR (IQR) n=83 
Reduction %α P valueβ 
Sip 0.819 (0.701-1.027) 0.608 (0.462-0.794) 25.8 <0.0001 
Gbs2106 0.909 (0.733-1.110) 0.584 (0.421-0.809) 35.7 <0.0001 
Gbs0393 0.641 (0.515-0.851) 0.430 (0.273-0.627) 32.9 <0.0001 
Gbs1539 0.390 (0.227-0.555) 0.237 (0.138-0.415) 39.2 0.008 
Gbs1356 0.507 (0.401-0.752) 0.319 (0.229-0.507) 37.1 <0.0001 
Gbs0392 0.397 (0.267-0.630) 0.252 (0.163-0.425) 36.5 0.006 
Foldase 0.654 (0.508-0.862) 0.455 (0.322-0.638) 30.4 <0.0001 
BibA 0.877 (0.713-1.144) 0.707 (0.500-0.850) 19.4 0.004 
α,  CMR reduction calculated as (1-CMRHIV+/CMRHIV-)×100% 
β, quantile regression p value adjusted for overall colonisation colonising serotype, maternal age, 
gestational age and parity. 
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Table 7.6 Association between group B Streptococcus specific cord-maternal IgG antibody ratios and 
maternal CD4+ lymphocyte count in HIV-infected pregnant women. 
 CD4+ lymphocyte count (cells/µL)  
Median 
(IQR) 
<250 (n=14) 250-350 
(n=12) 
350-500 
(n=21) 
>500 (n=24) P 
valueα  
Sip 0.60 
(0.44-0.90) 
0.74 
(0.57-0.88) 
0.54 
(0.46-0.67) 
0.64 
(0.44-0.84) 0.77 
BibA 0.67 
(0.54-0.81) 
0.75 
(0.44-0.84) 
0.66 
(0.56-0.83) 
0.67 
(0.47-0.91) 0.85 
Foldase 0.44 
(0.38-0.55) 
0.44 
(0.32-0.69) 
0.46 
(0.33-0.64) 
0.51 
(0.33-0.71) 0.20 
gbs2106 0.66 
(0.33-0.83) 
0.67 
(0.54-0.83) 
0.49 
(0.41-0.58) 
0.59 
(0.35-0.78) 0.83 
Gbs1356 0.39 
(0.27-0.66) 
0.40 
(0.23-0.52) 
0.29 
(0.24-0.57) 
0.32 
(0.25-0.50) 0.75 
Gbs0393 0.42 
(0.25-0.59) 
0.42 
(0.31-0.61) 
0.45 
(0.37-0.63) 
0.46 
(0.29-0.67) 0.64 
Gbs1539 0.25 
(0.19-0.42) 
0.17 
(0.13-0.32) 
0.27 
(0.16-0.44) 
0.24 
(0.11-0.39) 0.90 
Gbs0392 0.28 
(0.17-0.41) 
0.29 
(0.19-0.62 ) 
0.29 
(0.16-0.42) 
0.25 
(0.13-0.38) 0.63 
α univariate quantile regression 
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Table 7.7 Association between group B Streptococcus specific cord-maternal IgG antibody ratios and 
maternal HIV-1 viral load in HIV-infected pregnant women. 
 HIV-1 viral load copies/mL  
Median 
(IQR) 
<40 (n=31) 40-1000 (n=21) 1000-10000 
(n=14) 
>10000 (n=13) p 
valueα 
Sip 0.66 
(0.54-0.84) 
0.54 
(0.44-0.74) 
0.64 
(0.42-0.85) 
0.63 
(0.46-0.77) 0.47 
BibA 0.72 
(0.54-0.93) 
0.59 
(0.45-0.76) 
0.74 
(0.48-0.84) 
0.59 
(0.52-0.83) 0.16 
Foldase 0.43 
(0.33-0.64) 
0.46 
(0.33-0.6) 
0.49 
(0.28-0.85) 
0.43 
(0.29-0.52) 0.74 
gbs2106 0.62 
(0.46-0.84) 
0.54 
(0.35-0.77) 
0.60 
(0.43-0.88) 
0.44 
(0.33-0.61) 0.31 
Gbs1356 0.41 
(0.25-0.51) 
0.31 
(0.19-0.42) 
0.41 
(0.20-0.75) 
0.28 
(0.21-0.45) 0.64 
Gbs0393 0.49 
(0.36-0.68) 
0.40 
(0.24-0.48) 
0.38 
(0.32-0.71) 
0.35 
(0.23-0.49) 0.36 
Gbs1539 0.24 
(0.14-0.4) 
0.16 
(0.11-0.34) 
0.33 
(0.18-0.68) 
0.32 
(0.14-0.42) 0.66 
Gbs0392 0.29 
(0.17-0.59) 
0.30 
(0.13-0.42) 
0.22 
(0.17-0.42) 
0.22 
(0.18-0.36) 0.79 
α univariate quantile regression 
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7.5. Discussion 
We observed 19% to 39% reduction in the concentration of trans-placental transfer GBS 
surface proteins antibodies in HIV-infected compared to HIV-uninfected mother-
newborn dyads. Low antibody GMT in HIV-infected mothers together with reduced 
efficiency of trans-placental transfer of antibodies resulted in lower antibody GMT in 
HEU infants compared to HIV-unexposed infants. The results of this study are similar 
to that reported for antibody against H. influenzae type b, B. pertussis, tetanus and S. 
pneumoniae in HIV-infected compared to HIV-uninfected mother-newborn dyads 
(104). 
A reduction in trans-placental transfer of antibodies against GBS capsular 
polysaccharide for the predominantly invasive serotype Ia, II, III and V has been noted 
previously (106). Maternally derived serotype specific capsular antibodies against these 
invasive serotypes play an important role in providing protection to neonates (176). It is 
therefore likely that the impediment of materno-foetal antibody transfer against GBS 
surface proteins together with antibodies against GBS CPS during intrauterine HIV 
exposure may in part contribute to the increased risk of developing invasive GBS 
disease in infants.  
GBS surface proteins Sip and BibA, have been previously reported to confer protection 
in newborn pups challenged with a lethal dose of GBS, when born to mice dams 
immunised with the respective protein (51,211). The virulence and immunological role 
of the other evaluated GBS proteins are unknown as these proteins were identified 
computationally; however, these proteins have emerged in other studies as potential 
GBS virulence factors. Using subtractive DNA hybridisation, gbs1356 and gbs0393 
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were shown to be homologous to a family of adhesion proteins that play a role in 
binding of GBS to host epithelial cells (214).   
IgG1, primarily induced by protein antigens, is efficiently transported across the 
placenta compared to IgG2 induced by CPS. Therefore, maternal immunisation using a 
protein-based vaccine might result in higher trans-placental transfer of antibody 
concentrations to provide protection against invasive GBS disease in newborns (107). 
Considerations, however, should be taken in selecting highly immunogenic proteins 
antigens that are capable of crossing the placenta and provide protection to both the 
mother and the infant. Antibodies to the highly conserved proteins such as Sip, 
expressed by all GBS isolates, BibA, existing in three different allelic forms (51), and 
gbs2106 protein were efficiently transferred across the placenta in the absence of 
maternal HIV infection.  
The prevalence of GBS colonisation in HIV-infected women is similar to HIV-
uninfected women, including for countries where there is a higher burden of HIV 
infection (235), including observed in our study population. Antibody GMT did not 
differ by colonisation status or colonising serotype amongst HIV-uninfected and HIV-
infected mothers for the investigated GBS surface protein antigens.  Acquisition of GBS 
colonisation occurs frequently during pregnancy (235), and therefore difference in IgG 
level that may result from GBS colonisation cannot be detected using a cross-sectional 
study (92). Other limitations of the study include use of Polygam as reference serum 
which does not allow quantification of absolute antibody concentrations comparable to 
other study populations. 
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Given that HEU infants are at high risk of invasive GBS due to reduced maternally 
derived antibodies, increasing maternal antibodies by vaccination has the potential to 
reduce the risk of invasive GBS disease. HIV-infected women, however, were reported 
to have lower antibody concentrations specific to CPS following immunisation with a 
polysaccharide-protein glycoconjugate based vaccine (176). The poor immunogenic 
response in HIV-infected women may be circumvented by adapting an alternate dosing 
schedule, dosing strength. Since it appears that the antibody response induced by 
proteins Sip, gbs2106, gbs1356, gbs0393 and Foldase are attenuated by HIV-infection, 
this might contribute to the increased susceptibility to invasive GBS disease in HEU 
infants. Further investigations are required to assess the association of antibody to these 
proteins in relation to risk for invasive GBS disease in neonates. 
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Chapter Eight A ss o c i a ti o n  o f N a tu r a l  Ind u ced  An t i bo d i es  a g a i ns t  G r o up  B  St r ep to co ccu s  Su r fa ce P r ot ei n s a n d  In va s i ve Di s ea s e i n  N eo n at es  an d  Ea r ly  In fa n cy 
Association of Natural Induced Antibodies against 
Group B Streptococcus Surface Proteins and 
Invasive Disease in Neonates and Early Infancy 
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8.1 Introduction 
There were approximately 6.3 million deaths reported in children ≤ 5 years of age in 
2013, with 44% of the cases occurring during the neonatal period (1). GBS is the 
leading cause of neonatal pneumonia, septicaemia and meningitis, with a case fatality 
ratio between 2-20% (1,2,37,38). The use of intrapartum antibiotic prophylaxis (IAP) 
following universal or risk based screening of GBS in pregnant women has proven 
effective in reducing EOD by 70-90% in high income countries (6,247). Such a 
strategy, however, is unlikely to be feasible in low-income countries due to cost and 
logistical constrains.  
Alternatively, maternal vaccination for prevention of invasive GBS disease is supported 
by studies reporting reduced risk of neonates developing invasive GBS disease when 
born to mothers with high antibody concentration against GBS capsular polysaccharides 
(CPS) (9–14). Phase I/II clinical trials have shown that such a vaccine is safe and 
immunogenic when administered to pregnant women (15–17). The immunogenicity of 
these CPS vaccines were enhanced by conjugating them to immunogenic protein 
carriers. Given that serotype Ia, Ib, II III and V account for >80% of neonatal GBS 
disease, substituting the conjugate protein with a conserved immunogenic GBS protein 
may further increase serotype coverage and thus confer broad-spectrum, including 
serotype-independent protection.   
In this chapter we investigated the association of maternal antibody titres to GBS 
surface proteins BibA, Sip, Foldase, gbs2106, gbs1356 gbs0393, gbs1539 and gbs0392 
and invasive GBS disease in neonates born to GBS colonised women, irrespective of 
serotype. 
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8.2 Study population 
We  retrospectively analysed serum samples  from mothers and young infants (<90 days 
age) previously enrolled in a case-control study investigating the association of capsular 
antibody to serotype-specific invasive GBS disease (14). Briefly, infants <90 days of 
age with GBS cultured from either blood, cerebrospinal fluid or other normally sterile 
sites were enrolled into the study, and their mothers.  Healthy young infants without 
invasive GBS disease were enrolled as the control group, matched for maternal HIV 
status, maternal age (±2.5 years), gestational age (≥37 weeks or ± 2 weeks for preterm), 
and age of disease onset in the cases (<6 days for EOD or ±14 days for LOD). Lower 
vaginal and rectal swabs were collected form the mothers at enrolment to determine 
GBS colonisation and the colonising serotypes. 
8.3 Statistical analysis 
The data was analysed using STATA software (version 13.0 Stata-Corp, Tx USA) and 
GraphPad Prism (version 5.03 GraphPad Software Inc, California USA). IgG antibody 
titres occurring in both mothers and infants were log10 transformed for parametric 
statistical comparisons and reported as geometric mean titres (GMT, U/mL). Student’s 
t-test was used to compare the differences in IgG antibody titres between colonised 
women of healthy infants (controls) and those with invasive GBS disease (cases); and 
similarly so in the infants. Confounding variables were adjusted using multivariate 
regression. χ2, Fischer’s exact test and logistic regression were used to determine 
maternal antibody titres associated with protection against invasive GBS disease in 
infants.  P-value < 0.05 was considered statistically significant. 
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8.4 Results 
We included 182 women colonised with GBS in the recto-vaginal tract. Of those, 66 
were mothers to infants who developed invasive GBS disease (cases: 36 EOD and 30 
LOD) and 116 mothers of healthy infants (matched controls: 52 EOD and 64 LOD), 
Table 8.1. The distribution of colonising GBS serotypes differed between case and 
control mothers, with the predominant serotypes being Ia (40.9% vs 37.9%) and III 
(39.4% vs 28.4%), p=0.042, Table 8.1. The frequency of premature rupture of amniotic 
membrane (PROM; ≥18h) was higher among women of cases (16.7%) compared to 
controls (6.0%, p<0.001), Table 8.1. Other risk factor characteristics including maternal 
HIV status, premature delivery and birth weight were similar between cases and 
controls. 
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Table 8.1 Demographic characteristics of group B Streptococcus colonised mothers of asymptomatic 
infants (controls) and infants with invasive GBS disease (cases). 
 Cases (n=66) Controls (n=116) P value 
Maternal    
Median age. years (range) 27.5  
(16.2-39.7) 
27.3 
(16.1-39.7) 
0.98 
Median parity (range) 1 (0-5) 1 (0-6) 0.32 
Median gravidity (range) 2 (1-5) 2 (1-7) 0.16 
PROM≥18 h 11 (16.7%) 7 (6.0%) <0.001 
Colonising serotype   0.042 
Ia 27 (40.9%) 44 (37.9%)  
Ib 3 (4.5%) 4 (3.4%)  
II 1 (1.5%) 16 (13.8%)  
III 26 (39.4%) 33 (28.4%)  
IV 1 (1.5%) 0  
V 7 (10.6%) 14 (12.1%)  
Co-colonisedǂ 1 (1.5%) 5 (4.3%)  
HIV-infected. n 35 (53.0%) 51 (44.0%)  0.24 
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HIV-infected Median CD4. 
cells/µL (IQR) 
n=33 
387 (280-559) 
n=50 
384 (265-519) 
0.81 
Infant    
Gestational age (weeks) 39.1  
(28.0-40.2) 
38.6  
(36.3-40.2) 
0.82 
preterm 22 (33.3%) 33 (28.4%)  
term 44 (66.6%) 83 (71.6%)  
Birth weight grams (IQR) 2887.5 
(2140.0-3200.0) 
3002.5 
(2645.0-3400.0) 
0.053 
<2500 19 (28.8%) 23 (19.8%)  
≥2500 47 (71.2%) 93 (80.2%)  
Invasive GBS disease onset   0.21 
EOD 36 (54.5%) 52 (44.8%)  
LOD 30 (45.5%) 64 (55.2%)  
PROM = premature rupture of membrane 
ǂ colonised with more than one GBS serotype, 
Antibodies against GBS surface proteins 
Significantly lower IgG GMT against Sip protein were detected in women of cases 
(164.94 U/mL) compared to those of controls (218.90 U/mL, p=0.019), Table 8.2. 
Maternal antibody titres against the remaining GBS surface proteins were similar 
between mothers of cases and controls, Table 8.2. IgG GMT (U/mL) measured in 
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infants’ sera were lower in cases compared to controls for proteins Sip (54.49 vs 104.36, 
p<0.001), Foldase (51.16 vs 79.78, p=0.025), gbs2106 (54.35 vs 85.76, p=0.022) and 
gbs0393 (94.68 vs 140.43, p=0.029), Table 8.3.  
Table 8.2 IgG antibodies geometric mean titres (GMT, U/mL) against group B Streptococcus surface 
proteins in colonised women of infants with invasive disease (cases) or healthy controls. 
Protein Case (n=66) 
IgG GMT (95% CI) 
Control (n=116) 
IgG GMT (95% CI)  
P valueα 
BibA 257.43 
(187.03-354.33) 
222.55 
(184.00-269.17) 
0.41 
Sip 164.94 
(132.03-206.04) 
218.90 
(192.57-248.82) 
0.019 
Foldase 199.72 
(149.95-266.02) 
240.86 
(202.90-285.92) 
0.23 
gbs2106 160.90 
(133.30-194.21) 
184.96 
(156.12-219.12) 
0.31 
gbs0393 436.38 
(337.76-563.78) 
436.84 
(375.31-508.45) 
0.97 
gbs1356 218.82 
(168.58-284.02) 
236.22 
(201.39-277.06) 
0.53 
gbs1539 406.18 
(317.72-519.27) 
432.55 
(361.08-518.18) 
0.54 
gbs0392 373.31 
(310.90-448.25) 
390.59 
(332.13-459.34) 
0.61 
α, adjusted for colonising serotype and PROM≥18h 
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Table 8.3 IgG antibodies geometric mean titres (U/mL) against group B Streptococcus surface proteins in 
infants with invasive group B streptococcus disease (cases) or healthy infants delivered by colonised 
mothers (controls). 
Protein Case (n=66) 
IgG GMT (95% CI) 
Control (n=116) 
IgG GMT (95% CI)  
P valueα 
BibA 79,14 
(55,56-112,74) 
94,28 
(74,55-119,22) 
0.51 
Sip 54,49 
(40,76-72,86) 
104,36 
(88,19-123,49) 
<0.001 
Foldase 51,16 
(37,24-70,29) 
79,78 
(64,64-98,45) 
0.025 
gbs2106 54,35 
(40,68-72,62) 
85,76 
(68,73-107,00) 
0.022 
gbs0393 94,68 
(72,05-124,41) 
140,43  
(115,71-170,44) 
0.029 
gbs1356 46,13 
(33,08-64,32) 
65,06 
(52,55-80,56) 
0.088 
gbs1539 70,42 
(50,03-99,14) 
97,59 
(77,60-122,71) 
0.11 
gbs0392 77,13 
(59,63-99,75) 
87,40 
(71,75-106,46) 
0.45 
α, adjusted for colonising serotype and PROM≥18 h. 
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Antibody titres associated with EOD and LOD 
Antibody titres in mothers and infants were further stratified based on EOD and LOD 
cases and their respective controls groups. No statistcal difference was observed for IgG 
GMT between mothers of EOD case and controls, Figure 8.1. Mothers of infants who 
developed LOD had significantly lower IgG GMT (U/mL) against protein Sip (170.35 
[95% CI: 120.93-239.97]) compared to those of controls (255.64 [95% CI: 218.36-
299.29], p=0.029), Figure 8.2. Similarly, IgG GMT against gbs2106 was lower in 
mothers of infants with LOD (133.42 [95% CI: 100.54-177.06]) compared to those of 
controls (205.25 [95% CI:165.81-254.08], p=0.018), Figure 8.2. 
Infants who developed EOD had significantly lower IgG GMT (U/mL) compared to 
control infants for Sip (65.48 vs 145.43, p<0.001), Foldase (50.45 vs 109.87, p=0.005), 
gbs0393 (106.29  vs 221.81, p=0.006) and gbs1356 (45.34 vs 94.52, p=0.01), Figure 
8.2. Similarly, infanst with LOD had lower IgG GMT (U/mL) compared to control 
infants for Sip (43.72 vs 79.69, p=0.040) and gbs2106 (30.46 vs 65.35, p=0.003), Figure 
8.2. 
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Figure 8.1 IgG antibody titres against group B Streptococcus surface protein in colonised mothers and their respective infants who either remained healthy or who 
developed early-onset GBS disease (EOD), p-value was adjusted for maternal colonising serotype and premature rupture of membrane >18 h. 
163 
 
 
 
Figure 8.2 IgG antibody titres against group B Streptococcus surface protein in colonised mothers and infants and their respective infants who either remain healthy or 
who developed late onset GBS disease (LOD), p-value was adjusted for maternal colonising serotype and premature rupture of membrane >18 h. 
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Maternal antibody levels associated with protection against invasive GBS disease  
Given that antibody titres against GBS surface proteins Sip, Foldase, gbs2106, gbs1356 
and gbs0393 differed depending on invasive GBS disease status, antibody levels in 
mothers associated with reduced odds of delivering an infant that develop invasive GBS 
disease were determined for these proteins. Using the reverse cumulative distribution, 
the lowest maternal antibody titre against Sip associated with reduced likelihood of 
having an infant that develops invasive GBS disease was 150 U/mL (OR = 0.44, 
p=0.01). Increasing maternal antibodies against Sip was associated with decreasing 
odds of their infants developing invasive GBS disease, Figure 8.4 and Table 8.4.  
IgG GMT ≥200 U/mL for Foldase protein were observed to occur in 42.4% (28/66) of 
mothers with infants that developed invasive GBS disease, significantly less compared 
to 59.5% (69/116) maternal control counter parts. Increasing maternal antibodies against 
Foldase, however, was not associated with reduced odds of invasive GBS disease in 
infants, Figure 8.3 and Table 8.4. Similarly, 68.2% (45/66) women with infants that 
developed invasive disease had antibody titres ≥99 U/mL for gbs2106 protein, 
significantly less compared to 83.6% (97/116) mother of controls (OR=0.42, p=0.016), 
Figure 8.3 and Table 8.4.  No association was observed for maternal antibodies against 
gbs1356 and gbs0393 with reduced odds of delivering infants who develop invasive 
GBS disease, Figure 8.3 and Table 8.4. 
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Figure 8.3 Reverse cumulative plots of IgG titre (U/mL) against group B Streptococcus (GBS) surface protein 
antigens in mothers who delivered either infants who remained healthy (blue) or those who developed invasive 
GBS disease (red). 
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Table 8.4 IgG antibody titre threshold against group B Streptococcus surface proteins in colonised mothers who 
delivered infant who were either healthy or developed invasive GBS disease. 
IgG levels 
(U/mL) 
Case 
(n=66) 
Control 
(n=116) 
OR (95% CI) P valueα 
Sip     
≥100 51 (77.3%) 102 (87.9%) 0.47 (0.21-1.04) 0.059 
≥150 36 (54.5%) 85 (73.3%) 0.44 (0.23-0.83) 0.01 
≥200 25 (37.9%) 70 (60.3%) 0.40 (0.22-0.75) 0.004 
Foldase     
≥100 49 (74.2%) 94 (81.0%) 0.67 (0.33-1.39) 0.28 
≥200 28 (42.4%) 69 (59.5%) 0.50 (0.27-0.93) 0.027 
≥300 18 (27.3%) 42 (36.2%) 0.66 (0.34-1.28) 0.22 
gbs2106     
≥99 45 (68.2%) 97 (83.6%) 0.42 (0.21-0.86) 0.016 
≥100 45 (68.2%) 94 (81.0%) 0.50 (0.25-1.01) 0.050 
≥200 14 (21.2%) 38 (32.8%) 0.55 (0.27-1.12) 0.097 
Gbs0393     
≥100 64 (97.0%) 115 (99.1%) 0.28 (0.025-3.13) 0.27 
≥200 52 (78.8%) 96 (82.8%) 0.77 (0.36-1.66) 0.51 
≥300 45 (68.2%) 76 (655%) 1.13 (0.59-2.15) 0.71 
Gbs1356     
≥70 57 (86.4%) 110 (94.8%) 0.35 (0.12-1.02) 0.04 
≥100 54 (81.8%) 101 (87.1%) 0.67 (0.29-1.53) 0.34 
≥300 24 (36.4%) 46 (39.7%) 0.87 (0.47-1.62) 0.66 
 
 
α, p value was determined using either χ2 or Fisher’s exact test. 
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In vitro expression of proteins on the surface of GBS 
The expression of Sip, gbs2106, gbs1356 and gbs0393 on the surface of GBS were assessed 
by flow cytometry. Using the GBS strains from which the protein genes were cloned, Sip, 
gbs2106 and gbs0396 were shown to be expressed on the surface of GBS, with ≥6-fold 
higher antibody binding in antigen specific sera compared to pre-immunisation sera (control), 
Figure 8.4. Control sera in rabbits immunised with either Sip or gbs1356 had a high binding 
signal relative to unstained bacterial cells. This reduced the resolution power to infer 
expression of antigens on the surface of GBS (appendix 10.6). Antibody binding on the 
surface of GBS was 6-fold higher when using Sip specific post-immunisation sera despite the 
high binding signal of the relative control sera, and therefore was used to assess expression of 
Sip on GBS clinical isolates together with gbs2106 and gbs0393.  
 
Figure 8.4 Expression of proteins on the surface of group B Streptococcus (serotype III NEM316 strain). 
Binding of antibodies using antigen specific rabbit sera (red) compared to the corresponding pre-immunisation 
sera (blue) was detected by flow cytometry to access expression of each protein on the surface of GBS. 
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GBS isolates from mothers who delivered infants ≥37 weeks of gestation age were assessed 
for surface expression of proteins Sip, gbs2106 and gbs0393. The demographic 
characteristics were similar between mothers of cases and controls whose colonising isolates 
were analysed, Table 8.5. Of the 82 GBS isolates screened (39 from cases and 43 from 
control), Sip was expressed in 77.3%, 64.7% and 69.8%% GBS strains isolated from mothers 
of EOD, LOD and control infants respectively, Figure 8.5. Gbs2106 protein was expressed by 
all GBS strains isolated from mothers of EOD and LOD infants. Gbs0393 protein was 
expressed in 95.5%, 82.4% and 86.0% in GBS strains isolated from mothers of EOD, LOD 
and control infants, Figure 8.5. 
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Figure 8.5 Distribution of surface proteins on group B Streptococcus isolates from mothers of infants who 
remained healthy (white) or those that developed EOD (grey) and LOD (black). 
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Table 8.5 Demographic characteristics for mothers colonised with group B Streptococcus isolates expressing either Sip, gbs2106 or gbs0393 on the surface. 
 Sip gbs2106 gbs0393 
 Cases (n=28) Controls (n=30) Cases (n=39) Controls (n=38) Cases (n=35) Controls (n=37) 
Median Age (range) 25.8 (19.4-36.8) 25.1 (18.3-35.8) 27.5 (19.4-36.8) 25.3 (18.3-33.5) 26.8 (19.4-36.8) 25.9 (18.3-35.8) 
Median Parity 
(range) 
1 (0-3) 0 (0-3) 1 (0-3) 0 (0-3) 1 (0-3) 0 (0-3) 
Median Gravidity 
(range) 
2 (1-5) 1.5 (1-5) 2 (1-5) 2 (1-5) 2 (1-5) 2 (1-5) 
PROM≥18 h 5 (17.9%) 1 (3.3%) 5 (12.8) 2 (5.3%) 5 (14.3%) 2 (5.4%) 
serotype       
Ia 14 (50.0%) 13 (43.3%) 17 (43.6%) 14 (36.8%) 17 (48.6%) 17 (45.9%) 
Ib 2 (7.1%) 1 (3.3%) 2 (5.1%) 2 (5.3%) 2 (5.7%) 2 (5.4%) 
II 1 (3.6%) 0 1 (2.6%) 1 (2.6%) 1 (2.9%) 1 (2.7%) 
III 6 (21.4%) 11 (36.7%) 14 (35.9%) 16 (42.1%) 10 (28.6%) 12 (32.4%) 
V 5 (17.9%) 5 (16.7%) 5 (12.8%) 5 (13.2%) 5 (14.3%) 5 (13.5%) 
HIV-infected 13 (46.4%) 10 (33.3%) 20 (51.3%) 12 (31.6%) 19 (54.3%) 12 (32.4%) 
Median Gestation 
age (IQR) 
40.0 (38.5-40.6) 39.3 (38.5-40.5) 40.0 (39.0-40.5) 40.0 (39.0-40.4) 40.0 (38.6-40.6) 39.5 (39.0-40.3) 
Median Birth 
weight, kg (IQR) 
2.96 (2.80-3.24) 3.08 (2.86-3.45) 3.04 (2.84-3.38) 3.11 (2.92-3.50) 3.01 (2.80-3.39) 3.11 (2.93-3.45) 
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In vitro protein expression and protective antibody titres 
Antibody levels against Sip, gbs2106 and gbs0393 were compared between women of 
cases and controls colonised with GBS expressing the respective protein. IgG GMT 
against gbs2106 were lower in case mothers (160.89 [95%CI: 125.02-207.05]) 
compared to control mothers (248.65 [95% CI: 197.41-313.19], p=0.019), Figure 8.6. 
The odds of invasive GBS disease in the infant was lower for mothers carrying GBS 
strain expressing gbs2106 with antibody levels ≥100 (OR=0.11 [95% CI: 0.02-0.54], 
p=0.002).  No statistical difference was observed when comparing IgG GMT between 
case and control women colonised with GBS strains expressing Sip (202.26 [95% 
CI:138.64-295.07] vs 268.05 [95% CI: 205.02-350.47], p=0.099) and gbs393 (490.58 
[95% CI: 327.28-735.36] vs 370.46 [95% CI: 289.25-474.47], p=0.30), however, 
antibody titres among mothers of controls was higher than those of cases for Sip, Figure 
8.6. Antibody titres against Sip and gbs2106 in infants with EOD or LOD were 
significantly lower compared to their respective controls, Figure 8.7. 
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Figure 8.6 Reverse cumulative distribution of antibody titres against Sip, gbs2106 and gbs0393 proteins 
in group B Streptococcus (GBS) colonised women who had infant (<90 days of age) that either remained 
healthy (blue) or developed invasive GBS disease (red). 
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Figure 8.7 Comparison of IgG against GBS surface in infants born to mothers colonised with GBS stain 
expressing the respective protein between those who developed EOD or LOD and their corresponding 
controls.  
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8.5 Discussion 
GBS continues to be the leading infectious cause of neonatal morbidity and mortality 
(2). The low incidence of GBS disease requires a large sample populations to prove 
efficacy of a vaccine and ultimately impeding vaccine licensure (248). An alternative 
pathway sought to expedite vaccine licensure is to establish maternal antibody levels 
associated with reduced risk of invasive GBS disease in infants. In this study we show 
that increasing maternal antibodies against GBS surface proteins Sip and gbs2106 result 
in reduced odds of developing invasive GBS disease in infants. These results suggest a 
possible contribution of these antigens in protecting against invasive GBS disease. 
Infants born to mothers with low circulating antibodies against GBS capsular 
polysaccharides have an increased risk of developing invasive GBS disease. Protective 
antibody thresholds specific for CPS of serotype Ia, III, V and VIII have been reported, 
with variation among the studies due to lack of standardisation of the assay methods 
used (11–14,18,249).  
We report here that maternal antibodies ≥150 U/ml for GBS surface proteins Sip 
reduces the odds of delivering infants with invasive GBS by 66%. Infants who 
developed EOD or LOD in turn had lower antibody titres against Sip compared to 
controls. Sip has been previously shown to confer protection to mice pups born to dams 
immunised with Sip (94,212). Therefore, increasing maternal antibodies by vaccination 
may protect against both EOD and LOD. In vitro expression of Sip on the surface of 
GBS was detected in 70.7% of GBS isolates analysed, however, it has been reported 
that Sip is a highly conserved protein expressed in all GBS proteins (250). The lower 
rate of detection of Sip in our isolates may be due to the low sensitivity of our assay 
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caused by the high background exhibited in the pre-immunisation sera. This may have 
resulted in underestimation of antibody protection conferred by Sip proteins. 
Women carrying GBS strains expressing gbs2106, with antibody titres ≥100U/ml, 
reduced the odds of their infants developing invasive GBS disease by 90%. Infants who 
developed EOD and LOD had lower antibody titres against gbs2106. Furthermore, 
gbs2106 was expressed in 93.9% of the GBS isolates analysed and occurred in all of 
EOD and LOD cases, thus highlights the antigen’s role during GBS pathogenesis. 
The characteristics of an ideal GBS vaccine candidate is that the antigen (i) must be 
highly immunogenic, (ii) antigen specific antibodies must efficiently cross the placenta, 
(iii) confer protection to both the mother and infant, (iv) antibodies must persist 
throughout infancy and (iv) possess a broad-spectrum target against disease causing 
GBS serotypes. Using the ANTIgenome technique, Sip and gbs2106 were shown to be 
highly immunogenic GBS proteins (96). Furthermore, in the absence of maternal HIV-
infection, both proteins were efficiently transferred across the placental as discussed in 
the previous chapter. Manning et al. reported that antibodies against Sip in infants 
persist throughout infancy with a halve life of 43.9 days being detected up until 6 
months of age (89). In this study, antibodies specific to Sip and gbs2106 were capable 
of binding to the surface of 70% and 89% GBS isolates irrespective of serotype. 
Moreover, increasing maternal antibodies were associated with reduced odds of 
delivering infants that develop invasive GBS disease. Therefore, Sip and gbs2106 fulfil 
most if not all criteria for an ideal GBS vaccine warranting inclusion as future vaccine 
candidates. A standardised assay, however, is required for evaluating serological 
surrogate markers correlated with protection against invasive GBS disease that would 
be comparable to other study populations. 
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Chapter Nine Concluding Remarks 
Concluding Remarks 
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9.1 Conclusion 
In this study we used reverse vaccinology techniques to identify GBS surface proteins 
that could possibly be considered as vaccine candidates. Using robust computational 
algorithms, 7 immunogenic proteins predicted to be localised on the surface of GBS 
were recombinantly produced and subjected to serological testing together with 
virulence proteins, BibA, FbsA and gbs0233 provided by Vulneva Gmb Austria.  
Increased susceptibility to invasive GBS disease beyond infancy was explored by 
comparing serum IgG titres between HIV-infected and HIV-uninfected children. Our 
findings were that HIV-infection attenuated antibody response against capsular 
polysaccharides and surface proteins Sip and gbs2106, which could play a role in 
susceptibility to GBS disease. Other factors such as immune-exhaustion as a result of 
chronic HIV infection may also contribute to GBS susceptibility as demonstrated by the 
inverse relationship observed between CD4+ lymphocyte count and antibody levels 
amongst HIV infected children, indicative of hypergammaglobulinemia.  
Recto-vaginal GBS colonisation in pregnant women is a strong risk factor of invasive 
GBS disease in infants. A high GBS acquisition rate of 27.9% was reported to occur 
during the last trimester of pregnancy in our study setting. Here, we show that GBS 
protein specific antibody titres might be used a relative measure of immunity against 
GBS acquisition. High antibody titres against gbs0233 and gbs1539 were associated 
with reduced odds of acquisition of GBS colonisation. Moreover, a longitudinal study 
evaluating GBS colonisation during pregnancy reported decreasing vaginal carriage 
overtime. Our data reveal heightened antibody responses against GBS surface proteins 
following acquisition of GBS colonisation in the vagina, whilst an attenuated antibody 
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response was observed when colonised at the rectum. Thus, we hypothesised that 
colonisation at the anorectal tract likely results in immunological tolerance or ignorance 
of GBS which may favour persistent colonisation.  
Maternal HIV infection increases the risk of infants developing invasive GBS disease. 
The mechanism for this is partly attributable to reduced efficiency to transfer antibodies 
against GBS surface proteins across the placenta as reported here. Twenty-nine percent 
of pregnant women in our study population were reported to be HIV infected. The 
incidence of their infants developing invasive GBS disease was 2-fold greater than 
infants born to HIV-uninfected women, highlighting an urgent requirement for 
intervention.  
Sero-epidemiological data against GBS capsular polysaccharides suggest that 
immunisation of women during pregnancy with the major serotypes (Ia, Ib, II, III and 
V) could reduce 50-90% of invasive GBS cases. Similarly, in this study we show that 
increasing maternal antibodies against Sip and gbs2106 will reduce 66-90% of invasive 
GBS disease cases in infants. Sip and gbs216 proteins are highly conserved proteins and 
have the potential to confer serotype-independent protection. Moreover, proteins can be 
inexpensively produced in large amounts using recombinant cloning techniques and are 
immunogenic without being conjugated to other molecules. Altogether this information 
warrants further considerations of these proteins as GBS vaccine candidates.  
9.2 Future prospects 
The in silico method used to select putatively immunogenic peptides in this study was a 
bioinformatics tool that incorporates hidden Markov models and propensity scale 
methods (hydrophilicity scores) to identify linear B cell epitopes. Since B cell activation 
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and subsequent antibody production requires secondary stimulatory signals from T cells 
to initiate B cell clonal expansion producing both memory and active B cells. The 
presence of T cell epitopes in protein antigens is essential for mounting an effective 
immunological response. Hence, in silico selection of proteins inclusive of epitopes 
with high affinity to HLA class II should be incorporated in reverse vaccinology. This 
will circumvent limitations that arise when using a running window propensity scale to 
identify B cell epitopes which is biased against peptides with large molecular weight 
containing discontinuous epitopes. 
GBS asymptomatically colonises epithelial cells of the lower gastrointestinal and 
genitourinary tract of women. Transition to pathogenic infection entails utilisation of 
virulence factors that either interact with components of the host extracellular matrix 
(invasion) or evade immunological recognition, Figure 9.1. In this study we observed 
that acquisition of GBS colonisation at the vagina induced a heightened antibody 
response compared to acquisition of colonisation in the rectum. Given that colonisation 
of the anorectal tract is perceived as the requisite for colonisation in the vagina, these 
data suggest that differential protein expression may occur when colonising the vaginal 
tract. Thus, future studies should investigate the transcriptomic profile of GBS 
depending on the site where colonisation occurs. This information may highlight 
antigens involved at different pathogenic stages that are essential vaccine targets.  
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Figure 9.1 Pictorial depiction of group B Streptococcus postulated mechanisms for host invasion and 
immune evasion. A, thick capsular polysaccharide masks surface proteins to avoid opsonisation and B, 
capsular polysaccharide synthesis decreases during adhesion and invasion by binding to of host epithelial 
cells surface markers. 
In this study, women who were colonised with GBS throughout pregnancy had high 
antibodies against GBS surface proteins compared to women who cleared GBS 
colonisation. Recto-vaginal colonisation of GBS during pregnancy occurs either in a 
persistent, transient or intermittent manner and mechanisms for this are poorly 
understood. Adherence of GBS strains to either the epithelial cells of the genitourinary 
tract or the gastrointestinal tract are dependent on both the colonising serotype and GBS 
proteins expressed on the surface (251). GBS strains of serotype III have an adherence 
capacity higher than that of serotype Ia, and with those expressing alp genes encoding 
alp2 and Rib proteins having a higher propensity to adhere to epithelial cells of the 
lower gastrointestinal tract (251). Moreover, persistence of GBS in the genital tract is 
mediated by strains with a higher affinity for cervical epithelial cells compared to the 
ones in the vaginal cells (252). Therefore, establishment of persistent GBS colonisation 
is dependent on an intricate interaction among innate immunity, adaptive immunity, site 
of colonisation, and the colonising serotype together with surface proteins expressed on 
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GBS strains. Therefore, complementary functional assays that measure killing activity 
of antibodies induced by proteins are essential in establishing immunity associated with 
clearance of GBS colonisation.  
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Chapter Ten Appendices 
Appendices 
  
182 
 
10.1 Ethics approval letters 
This thesis entails retrospective use of archived human serum samples to measure 
antibody titres specific to GBS surface proteins and capsular polysaccharides. Prior to 
enrolment on the original studies, signed informed consent was obtained from all study 
participants and from legal guardians in cases where minors were to be enrolled. Table 
10.1 lists the study cohorts from which serum samples were taken. Use of the sera for 
this research thesis was approved by the Human Research Ethics Committee and the 
approval letters are included below. 
To evaluate in vitro surface expression of GBS proteins, white New Zealand female 
rabbits were immunised with purified recombinant peptides to generate protein specific 
antibodies. The Animal Ethics Screening Committee (AESC) of the University of 
Witwatersrand approved the use of animals for generating polyclonal antibodies against 
GBS surface proteins Sip, gb2106, gbs0393 and gbs1356. The approval letter is 
attached below with AESC approval number:2015/05/20/B.    
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Table 10.1 Description of study cohorts used in fulfilment of study objects approved by the Human Research Ethics Committee (HREC). 
HIV-uninfected and HIV–infected children (HREC number: M121019) 
Original study  Age Sample size Description 
Durability of antibody responses to an 
investigational 9-valent PCV (HREC 
#M970916) 
4-7 years 145 HIV-uninfected and HIV-infected children who were 
participants of a phase 3 PCV efficacy trial. 
GBS non-colonised and colonised pregnant women (HREC number: M12019) 
GBS correlates of protection trial 
(HREC #M090937) 
16-42 years  661 Pregnant women between 20-37+ weeks of gestation age 
who were enrolled in  a study to determine antibodies 
against capsular polysaccharides correlated to prevention 
and/or clearance of GBS colonisation. 
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HIV-uninfected and HIV-infected mother newborn dyads (HREC number: M140902 
Effects of maternal HIV infection on 
trans-placental transfer of GBS 
antibodies (HREC #M120905) 
Infants: <24h 
Mothers: 
 18-42 yeas 
164 Maternal and cord blood taken in HIV-uninfected and HIV-
infected pregnant women ≥37 week of gestation age. 
Infants GBS disease status (HREC number: M140902) 
Clinical and Immunological 
epidemiology of invasive GBS in South 
Africa: A case control study (HREC 
#M120963) 
Infants: ≤ 90 
days 
Mother:  
16-40 years 
 
183 GBS colonised pregnant women who delivered infants that 
subsequently developed invasive GBS disease (cases) or 
infants that remained health  
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10.2 In silico predicted GBS surface proteins 
Table 10.2 provides the full list of GBS proteins in NEM316 strain that were predicted 
to be either lipoproteins or cell wall anchored proteins. 
Table 10.2 Extracellular localisation of group B streptococcus NEM316 proteins classified according to 
their predicted sub-cellular localisation. 
Lipoproteins Cell wall Proteins 
hypothetical protein gbs0086 hypothetical protein gbs0391 
hypothetical protein gbs0113 hypothetical protein gbs0392 
hypothetical protein gbs0144 hypothetical protein gbs0393 
hypothetical protein gbs0184 cell wall surface anchor family protein 
lipoprotein hypothetical protein gbs0451 
hypothetical protein gbs0233 hypothetical protein gbs0470 
hypothetical protein gbs0397 hypothetical protein gbs0479 
hypothetical protein gbs0419 hypothetical protein gbs0619 
hypothetical protein gbs0440 cell wall surface anchor family protein 
hypothetical protein gbs0473 hypothetical protein gbs0629 
hypothetical protein gbs0727 hypothetical protein gbs0632 
hypothetical protein gbs0778 hypothetical protein gbs0721 
hypothetical protein gbs0796 hypothetical protein gbs0722 
foldase protein PrsA hypothetical protein gbs0723 
hypothetical protein gbs0918 cell wall surface anchor family protein 
hypothetical protein gbs0937 hypothetical protein gbs0966 
hypothetical protein gbs0942 hypothetical protein gbs0986 
hypothetical protein gbs0957 hypothetical protein gbs0987 
hypothetical protein gbs0982 hypothetical protein gbs0988 
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phosphate ABC transporter 
phosphate-binding protein 
hypothetical protein gbs1087 
hypothetical protein gbs1057 hypothetical protein gbs1143 
hypothetical protein gbs1216 hypothetical protein gbs1144 
laminin-binding surface protein hypothetical protein gbs1145 
hypothetical protein gbs1463 hypothetical protein gbs1288 
hypothetical protein gbs1489 streptococcal C5a peptidase 
hypothetical protein gbs1501 hypothetical protein gbs1356 
hypothetical protein gbs1577 hypothetical protein gbs1403 
peptidyl-prolyl cis-trans isomerase, 
cyclophilin-type 
hypothetical protein gbs1474 
hypothetical protein gbs1589 hypothetical protein gbs1477 
hypothetical protein gbs1632 cell wall surface anchor family protein 
hypothetical protein gbs1659 cell wall surface anchor family protein 
hypothetical protein gbs1689 amidase family protein 
hypothetical protein gbs1810 hypothetical protein gbs1919 
hypothetical protein gbs1908 bifunctional 2',3'-cyclic nucleotide 2'-
phosphodiesterase/3'-nucleotidase precursor 
protein 
hypothetical protein gbs1926 hypothetical protein gbs2008 
hypothetical protein gbs1953 hypothetical protein gbs2022 
hypothetical protein gbs2033 
hypothetical protein gbs2106 
 
Protein domain prediction 
Cloning of large proteins is a laborious task with a low success rate. Recognising 
domains within a protein that are able to adopt a conformation that is similar to the one 
they fold into when they are part of the complete protein would be ideal in truncating 
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proteins and cloning their constituents. The isolated domain peptides are easier to clone 
based on their smaller molecular weight and would subsequently fold into 
macromolecules that resemble a part of the parent peptide. Native gbs1356 has a 
molecular weight of 181 KDa, which is processed to 171 KDa by cleaving off the signal 
peptide and C-terminal residues posterior to LPXTG motif during cell wall anchoring. 
Cloning and expression of such a large protein was infeasible and therefore 
distinguishable domains were identified using DLP (domain linker peptide) with a 
linker peptide predicted between residues 579-679. The smooth value score was 3.472 
for the linker peptide; significantly above the 0.0 threshold, highlighting the presence of 
two domains denoted as gbs1356D1 and gbs1356D2. The prediction of a second linker 
peptide was rationalised as a false positive since it occurred within 40 residues from the 
C-terminal (253).  
 
Figure 10.1 Domain linker prediction for gbs1356 showing linker peptide at between residues 632-732 
with a smooth value of 2.879. The second predicted linker peptide is 40 residues from the C-terminal and 
therefore invalid. 
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10.3 Recombinant genes cloning 
The genes encoding the selected GBS surface proteins were amplified using the PCR 
conditions detailed in Methods chapter 3.2. The PCR conditions were optimised for 
each gene encoding target protein. Table 10.3 describes the optimal temperature and 
time that was used to clone each respective GBS protein. The 5’ and 3’ end of the 
primer set to amplify specific genes were flanked with DNA base pairs homologous to 
cloning vector regions that enable homologous recombination. The annealing conditions 
of the PCR reaction did not incorporate the flanking regions required for homologous 
recombination. 
Table 10.3 Polymerase chain reaction conditions for amplifying genes encoding group B Streptococcus 
surface proteins.  
Protein name Length (bp)* Annealing 
temperature (oC) 
Elongation Time 
(min) (1min/1Kb) 
Foldase protein 830 50.3 1 
Surface immunogenic protein 1221 51.5 1.5 
gbs0392 588  54.9 0.5 
gbs0393 2517 53.3 2.5 
gbs1356-D1 2553 53.1 2.5 
Gbs1539 484 53.1 0.5 
Immunogenic secreted protein 1368 51.7 1.5 
gbs2106 582 52.2 0.5 
LysM domain protein 444 53.2 0.5 
* gene length excludes the signal peptide region and cell wall anchoring motif 
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The amplified DNA genes were cloned into pETite plasmid vector (Lucigen, USA) 
encoding C-terminal His-tag and kanamycin resistant genes, Figure 10.2. The specific 
primer set for each GBS protein was designed to exclude the signal peptide region 
together with the surface anchoring motif (LxxC or LPxTG). Amplified genes were 
inserted into the vector using homologous flanking regions as according to the 
manufactures instructions.  
 
Figure 10.2 Schematic representation of the pETite vector displaying the origin of replication (Ori), 
repressor of primer (ROP), kanamycin resistant gene (Kan) the ribosomal binding site (RBS) and the 6 
histidine tag (HIS6). 
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Selected GBS surface protein gene amplicons are listed in Table 10.4. The gene length 
included the homologous flanking regions and the peptide length includes the 
recombinant peptide together with the 6×Histidine tag on the C-terminal. 
Table 10.4 Group B Streptococcus surface protein amplified gene properties. 
Protein name Gene length 
(bp) 
Vector size Pepetide 
length (Da) 
Foldase protein (gbs0827) 1010 3063 30,388.41 
Sip (gbs0031) 1401 3454 45,419.37 
gbs0392 770 2823 20,399.70 
gbs0393 2699 4752 91,639.05 
gbs1356-D1 2735 4788 94,820.20 
Cell wall protein 666 2179 16,921.68 
gbs2106 764 2817 20,645.82 
LysM domain protein (gbs2107) 626 2679 16,091.58 
 
Protein encoding genes cloned into the pETite vector were sequenced using forward and 
revers primers to determine correct and in-frame insertion of recombinant gene. The 
sequencing result of the recombinant GBS genes (query) was aligned with GBS 
NEM316 strain gene sequences from NCBI nucleotide BLAST database to show correct 
recombinant gene inserts as shown below (reverse sequence not included). 
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Gbs0392 
Score =   994 bits (538),  Expect = 0.0 
 Identities = 545/552 (99%), Gaps = 0/552 (0%) 
 Strand=Plus/Minus 
 
Query  1      GTCATCCCMGTAGAMCMAGCAGTACCATCTACTGAAGTGGTCACACCACCAAACYCWKTA  60 
              |||||||| ||||| | ||||||||||||||||||||||||||||||||||||| |  || 
Sbjct  81061  GTCATCCCAGTAGACCCAGCAGTACCATCTACTGAAGTGGTCACACCACCAAACTCAGTA  
81002 
 
Query  61     GATCCTAGTTTACCAACTGATACAACAGATCCTAGCACCCCAGTAGTACCTGAGAAACTA  
120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  81001  GATCCTAGTTTACCAACTGATACAACAGATCCTAGCACCCCAGTAGTACCTGAGAAACTA  
80942 
 
Query  121    CCAGACACCTCAAAACCAGCAGAGCCAGAAACACCAAAAGAAGAGCTACCAGCGCCAGTG  
180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  80941  CCAGACACCTCAAAACCAGCAGAGCCAGAAACACCAAAAGAAGAGCTACCAGCGCCAGTG  
80882 
 
Query  181    GATCCGACAACTCCATCAGCTGGCAAAGAAGACAAACAAGAAACTGTTCCAGGTCAGGCT  
240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  80881  GATCCGACAACTCCATCAGCTGGCAAAGAAGACAAACAAGAAACTGTTCCAGGTCAGGCT  
80822 
 
Query  241    GAAACGCCTaaagaagaagtaaaacctgaaaaccctaagtctagtgaagacaagaaaaaa  
300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  80821  GAAACGCCTAAAGAAGAAGTAAAACCTGAAAACCCTAAGTCTAGTGAAGACAAGAAAAAA  
80762 
 
Query  301    gaagaaCTTGTCCCAGATAATGTTTCAAAAGACATTATTGACAAGGTGGATACCACTACA  
360 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  80761  GAAGAACTTGTCCCAGATAATGTTTCAAAAGACATTATTGACAAGGTGGATACCACTACA  
80702 
 
Query  361    GGTGAAGTGGTCTTTAAACCGATTCCAGTCACACCAGACAAAACAGTTATCGGTACTAAG  
420 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  80701  GGTGAAGTGGTCTTTAAACCGATTCCAGTCACACCAGACAAAACAGTTATCGGTACTAAG  
80642 
 
Query  421    GACAGTCAGGTGATTATTCGTGACCAWGCAGGCCGTACACAAGTCGTTACCCCTGAGAGC  
480 
              |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Sbjct  80641  GACAGTCAGGTGATTATTCGTGACCAAGCAGGCCGTACACAAGTCGTTACCCCTGAGAGC  
80582 
 
Query  481    CTTGGTGGCCACGTTAATCCTAATGGAACCGTTACACTTAAAGATGCTACAGGTGCTGAA  
540 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  80581  CTTGGTGGCCACGTTAATCCTAATGGAACCGTTACACTTAAAGATGCTACAGGTGCTGAA  
80522 
 
Query  541    AAGACGCTCCCA  552 
              |||||||||||| 
Sbjct  80521  AAGACGCTCCCA  80510 
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Gbs0393 
Score =  4567 bits (2473),  Expect = 0.0 
 Identities = 2477/2481 (99%), Gaps = 0/2481 (0%) 
 Strand=Plus/Minus 
 
Query  56     GCTGTTACMMCCACACCTGCAGTTAATCATGCGACAACTACTGATGCACAAGCTGATTTA  
115 
              ||||||||  |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  80140  GCTGTTACAACCACACCTGCAGTTAATCATGCGACAACTACTGATGCACAAGCTGATTTA  
80081 
 
Query  116    GCTAATCAAACACAAGCTGTTAAAGATGTTACTGCAAAAGCACAAGCTAATACACAAGCT  
175 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  80080  GCTAATCAAACACAAGCTGTTAAAGATGTTACTGCAAAAGCACAAGCTAATACACAAGCT  
80021 
 
Query  176    ATTAAAGATGCTACTGCTGAAAATGCAAAAATTGATGCTGAAAACAAAGCAGAGGCAGAG  
235 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  80020  ATTAAAGATGCTACTGCTGAAAATGCAAAAATTGATGCTGAAAACAAAGCAGAGGCAGAG  
79961 
 
Query  236    CGTGTTGCAAAAGAAAACAAGGAAGGTCAAGCAGCCGTAGATGCACGTAACAAAGCAGGT  
295 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79960  CGTGTTGCAAAAGAAAACAAGGAAGGTCAAGCAGCCGTAGATGCACGTAACAAAGCAGGT  
79901 
 
Query  296    CAAGCAGCCGTAGATGCACGTAATAAAGCGAAACAGCAAGCGCAAGACGATCAAAAAGCA  
355 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79900  CAAGCAGCCGTAGATGCACGTAATAAAGCGAAACAGCAAGCGCAAGACGATCAAAAAGCA  
79841 
 
Query  356    AAAATTGATGCTGAAAACAAAGCAGAGTCTCAACGTGTAAGTCAGTTAAATGCACAAAAT  
415 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79840  AAAATTGATGCTGAAAACAAAGCAGAGTCTCAACGTGTAAGTCAGTTAAATGCACAAAAT  
79781 
 
Query  416    AAAGCAAAAATTGACGCAGAAAATAAAGATGCGCAAGCTAAAGCAAATGCGACTAATGCA  
475 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79780  AAAGCAAAAATTGACGCAGAAAATAAAGATGCGCAAGCTAAAGCAAATGCGACTAATGCA  
79721 
 
Query  476    CAATTACAAAAAGATTATCAAGCTAAATTAGCGGAAATCAAATCAGTTGAAGCTTATAAT  
535 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79720  CAATTACAAAAAGATTATCAAGCTAAATTAGCGGAAATCAAATCAGTTGAAGCTTATAAT  
79661 
 
Query  536    GCAGGTGTACGTCAACGTAATAAAGATGCACAAGCTAAAGCAGATGCGACTAACGCACAG  
595 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79660  GCAGGTGTACGTCAACGTAATAAAGATGCACAAGCTAAAGCAGATGCGACTAACGCACAG  
79601 
 
Query  596    TTACAAAAAGACTATCAAGCTAAATTAGCACTTTATAATCAAGCTCTAAAAGCTAAAGCA  
655 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
196 
 
Sbjct  79600  TTACAAAAAGACTATCAAGCTAAATTAGCACTTTATAATCAAGCTCTAAAAGCTAAAGCA  
79541 
 
Query  656    GAAGCAGATAAACAGTCTATTAATAATGTTGCTTTTGATATCAAAGCTCAAGCTAAAGGT  
715 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79540  GAAGCAGATAAACAGTCTATTAATAATGTTGCTTTTGATATCAAAGCTCAAGCTAAAGGT  
79481 
 
Query  716    GTTGATAACGCTGAATATGGAAACTCAATCATGACTGCAAAAACTAAACCTGACGGAAGT  
775 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79480  GTTGATAACGCTGAATATGGAAACTCAATCATGACTGCAAAAACTAAACCTGACGGAAGT  
79421 
 
Query  776    TTCGAGTTTAACCATGATATGATCGATGGTGTGAAGACAATCGGCTATGGGAAATTGACA  
835 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79420  TTCGAGTTTAACCATGATATGATCGATGGTGTGAAGACAATCGGCTATGGGAAATTGACA  
79361 
 
Query  836    GGTAAAGTTAATCATCATTATGTTGCTAACAAGGATGGCTCTGTGACAGCATTTGTTGAT  
895 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79360  GGTAAAGTTAATCATCATTATGTTGCTAACAAGGATGGCTCTGTGACAGCATTTGTTGAT  
79301 
 
Query  896    TCTGTCACTCTTTACAAGTACGAGTATCGTAATGTTGCTCAAAATGCTGCTGTTAACCAA  
955 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79300  TCTGTCACTCTTTACAAGTACGAGTATCGTAATGTTGCTCAAAATGCTGCTGTTAACCAA  
79241 
 
Query  956    AATATTGTATTTAGAGTTTTAACAAAAGATGGTCGTCCTATTTTTGAAAAAGCTCATAAT  
1015 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79240  AATATTGTATTTAGAGTTTTAACAAAAGATGGTCGTCCTATTTTTGAAAAAGCTCATAAT  
79181 
 
Query  1016   GGTAACAAAACTTTTGCAGAAACTTTAAACAAAACTTTACAACTCAATCTTAAATATGAG  
1075 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79180  GGTAACAAAACTTTTGCAGAAACTTTAAACAAAACTTTACAACTCAATCTTAAATATGAG  
79121 
 
Query  1076   CTTAAACCACATGCTTCCAGCGGTAACGTCGAAGTCTTTAAGATTCATGATGACTGGGTA  
1135 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79120  CTTAAACCACATGCTTCCAGCGGTAACGTCGAAGTCTTTAAGATTCATGATGACTGGGTA  
79061 
 
Query  1136   CATGACACACATGGGTCTGCTTTAGTGTCTTATGTTAATAATAATGATGCTGTTCCTAAT  
1195 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79060  CATGACACACATGGGTCTGCTTTAGTGTCTTATGTTAATAATAATGATGCTGTTCCTAAT  
79001 
 
Query  1196   GTGGTCATCCCAGAACGGCCAACTCCACCAAAGCCAGTGAAAGTTACACCTGAAGCAGAA  
1255 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  79000  GTGGTCATCCCAGAACGGCCAACTCCACCAAAGCCAGTGAAAGTTACACCTGAAGCAGAA  
78941 
 
Query  1256   AAACCAGTACCTGAAAAGCCAGTTGAGCCTAAATTGGTAACGCCTACATTAAAAACTTAT  
1315 
197 
 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78940  AAACCAGTACCTGAAAAGCCAGTTGAGCCTAAATTGGTAACGCCTACATTAAAAACTTAT  
78881 
 
Query  1316   ACTCCAGTCAAATTTATTCCGCGAGAATACAAACCAGAACCAATCACCCCTGAGACGTTT  
1375 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78880  ACTCCAGTCAAATTTATTCCGCGAGAATACAAACCAGAACCAATCACCCCTGAGACGTTT  
78821 
 
Query  1376   ACCCCTGAGAAATTTACTCCAGCTCAACCAAAAGTGAAACCACATGTGTCTATTCCTGAA  
1435 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78820  ACCCCTGAGAAATTTACTCCAGCTCAACCAAAAGTGAAACCACATGTGTCTATTCCTGAA  
78761 
 
Query  1436   AAGATTAACTACTCAGTTAGTGTTCATCCTGTTTTAGTTCCAGCTGCTAATCCTTCAAAA  
1495 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78760  AAGATTAACTACTCAGTTAGTGTTCATCCTGTTTTAGTTCCAGCTGCTAATCCTTCAAAA  
78701 
 
Query  1496   GCTGTCATTGATGAAGCAGGTCAATCTGTTAATGGTAAAACCGTATTACCAAATGCAACA  
1555 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78700  GCTGTCATTGATGAAGCAGGTCAATCTGTTAATGGTAAAACCGTATTACCAAATGCAACA  
78641 
 
Query  1556   TTAGACTATGTTGCTAAACAAAACTTTAGTCAATACAAAGGTATTAAAGCTTCTGCAGAA  
1615 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78640  TTAGACTATGTTGCTAAACAAAACTTTAGTCAATACAAAGGTATTAAAGCTTCTGCAGAA  
78581 
 
Query  1616   GCGATCGCAAAAGGTTTTGCATTTGTAGATCAACCAAATGAAGCGTTAGCTGAATTGACT  
1675 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78580  GCGATCGCAAAAGGTTTTGCATTTGTAGATCAACCAAATGAAGCGTTAGCTGAATTGACT  
78521 
 
Query  1676   GTTAAGTCTATCAAAGCATCTAATGGTGATGATGTATCAAGCTTGTTAGAAATGCGTCAT  
1735 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78520  GTTAAGTCTATCAAAGCATCTAATGGTGATGATGTATCAAGCTTGTTAGAAATGCGTCAT  
78461 
 
Query  1736   GTTTTATCAAAAGATACTTTAGACCAAAAACTTCAATCTCTTATTAAAGAGGCAGGAATT  
1795 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78460  GTTTTATCAAAAGATACTTTAGACCAAAAACTTCAATCTCTTATTAAAGAGGCAGGAATT  
78401 
 
Query  1796   AGTCCAGTTGGTGAGTTTTACATGTGGACTGCAAAAGATCCACAAGCTTTTTATAAAGCT  
1855 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78400  AGTCCAGTTGGTGAGTTTTACATGTGGACTGCAAAAGATCCACAAGCTTTTTATAAAGCT  
78341 
 
Query  1856   TATGTTCAAAAAGGACTAGATATCACTTATAATCTATCCTTTAAAATCAAAGCTAACTTT  
1915 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78340  TATGTTCAAAAAGGACTAGATATCACTTATAATCTATCCTTTAAAATCAAAGCTAACTTT  
78281 
 
198 
 
Query  1916   ACTAAAGGTCAAATCAAAAATGGTGTTGCACAGATTGATTTTGGGAATGGATATACAGGT  
1975 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78280  ACTAAAGGTCAAATCAAAAATGGTGTTGCACAGATTGATTTTGGGAATGGATATACAGGT  
78221 
 
Query  1976   AATATTGTAGTCAATGATGTTACTGTTCCAGAAGTACATAAGGATATACTTGATAAAGAG  
2035 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78220  AATATTGTAGTCAATGATGTTACTGTTCCAGAAGTACATAAGGATATACTTGATAAAGAG  
78161 
 
Query  2036   GATGGTAAATCAATTAATAATAGTACGGTTAAGTTAGGTGATGAAGTGACCTACAAACTT  
2095 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78160  GATGGTAAATCAATTAATAATAGTACGGTTAAGTTAGGTGATGAAGTGACCTACAAACTT  
78101 
 
Query  2096   GAAGGATGGGTTGTACCAGCAAACCGTGGTTACGATCTTTTTGAATACAAATTTGTGGAT  
2155 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78100  GAAGGATGGGTTGTACCAGCAAACCGTGGTTACGATCTTTTTGAATACAAATTTGTGGAT  
78041 
 
Query  2156   CAATTACAACACACACATGATCTTTACTTACGTGATAAAGTGGTCGCTAAAGTTGATGTG  
2215 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78040  CAATTACAACACACACATGATCTTTACTTACGTGATAAAGTGGTCGCTAAAGTTGATGTG  
77981 
 
Query  2216   ACATTAAAAGATGGTACAGTCATTAAAAAAGGGACTAATTTAGGAGAGTACACAGAAACA  
2275 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  77980  ACATTAAAAGATGGTACAGTCATTAAAAAAGGGACTAATTTAGGAGAGTACACAGAAACA  
77921 
 
Query  2276   GTTTACAACAAAACGACAGGTCATTATGAGCTTGCCTTTAAAAAAGAGTTTTTAGCTAAG  
2335 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  77920  GTTTACAACAAAACGACAGGTCATTATGAGCTTGCCTTTAAAAAAGAGTTTTTAGCTAAG  
77861 
 
Query  2336   GTTTCTCGTGAATCAGAATTTGGTGCAGATGATTTTATTGTAGTTAAACGTATTAAGGCA  
2395 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  77860  GTTTCTCGTGAATCAGAATTTGGTGCAGATGATTTTATTGTAGTTAAACGTATTAAGGCA  
77801 
 
Query  2396   GGTGATGTTTACAATACTGCTGATTTATATGTTAATGGATATAAAGTTAAGTCAGAAGCA  
2455 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  77800  GGTGATGTTTACAATACTGCTGATTTATATGTTAATGGATATAAAGTTAAGTCAGAAGCA  
77741 
 
Query  2456   GTTGTGACTCATACTACTGAGAAATCAAAACCAGTTGAACCACAAAAAGCAACTCCAAAA  
2515 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  77740  GTTGTGACTCATACTACTGAGAAATCAAAACCAGTTGAACCACAAAAAGCAACTCCAAAA  
77681 
 
Query  2516   RCTCCRGCTAAAGGACTGCCA  2536 
               |||| ||||||||||||||| 
Sbjct  77680  GCTCCAGCTAAAGGACTGCCA  77660 
199 
 
Gbs1356-D1 
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Query  40     GTAGGGAGAACTGTTGCGACAAGTGTACAGACGGAAACGAATCCTGCAACAAATTTAAAA  99 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  95303  GTAGGGAGAACTGTTGCGACAAGTGTACAGACGGAAACGAATCCTGCAACAAATTTAAAA  
95244 
 
Query  100    GAAAATCAGCCAAGTCCGATTGCGGAACAAAAAGATAGTCTTGCAGCAACCGGTMAATCA  
159 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  95243  GAAAATCAGCCAAGTCCGATTGCGGAACAAAAAGATAGTCTTGCAGCAACCGGTCAATCA  
95184 
 
Query  160    ACTGGAACGGTGACAGTCACTGTTCCACATGATAAGGTGACACAAGCTGTCGATAAGGCA  
219 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  95183  ACTGGAACGGTGACAGTCACTGTTCCACATGATAAGGTGACACAAGCTGTCGATAAGGCA  
95124 
 
Query  220    AAGACCGAAGGAATAAAAGCAGTACAAGACAAGCCGATGGACTTAGGCAATACAGTATCC  
279 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  95123  AAGACCGAAGGAATAAAAGCAGTACAAGACAAGCCGATGGACTTAGGCAATACAGTATCC  
95064 
 
Query  280    GCAGCTGAAACCAGCCAACAACTCAAAAAGGCAGAAGAAGATGCCACAAACCAAACAACA  
339 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  95063  GCAGCTGAAACCAGCCAACAACTCAAAAAGGCAGAAGAAGATGCCACAAACCAAACAACA  
95004 
 
Query  340    ACTATTTCTAAAACTGTTGAAATCTACAAGTCTGATAAAGCAACTTATGAAGCTGAAAAG  
399 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  95003  ACTATTTCTAAAACTGTTGAAATCTACAAGTCTGATAAAGCAACTTATGAAGCTGAAAAG  
94944 
 
Query  400    AAGTGGGTAGAGAAGCGTAATGAAGAGTTAACTGCTGCTTATGATAAGGCAGAACAAACA  
459 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94943  AAGTGGGTAGAGAAGCGTAATGAAGAGTTAACTGCTGCTTATGATAAGGCAGAACAAACA  
94884 
 
Query  460    GGGACTGGCTTAAACCATTCGGTTGATACGACTGTTTCAGAATTGAAGTCGCAAGACCAA  
519 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94883  GGGACTGGCTTAAACCATTCGGTTGATACGACTGTTTCAGAATTGAAGTCGCAAGACCAA  
94824 
 
Query  520    AACGCTCATGTGACCGTGAACACACAAACAGTAAAATCAGGAGATGGGACGAGTGTTTCA  
579 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94823  AACGCTCATGTGACCGTGAACACACAAACAGTAAAATCAGGAGATGGGACGAGTGTTTCA  
94764 
 
Query  580    GGCTATCAGGAGTACGTCAAGTCTGTTGCGGCCATTGATAAGAAGAATAAAGCGAACTTA  
639 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94763  GGCTATCAGGAGTACGTCAAGTCTGTTGCGGCCATTGATAAGAAGAATAAAGCGAACTTA  
94704 
200 
 
 
Query  640    GCTGATTATCGGACTAAGAAACAAGCCGCAGACGCTGTTGTGGCTAAGAATCAACTCATT  
699 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94703  GCTGATTATCGGACTAAGAAACAAGCCGCAGACGCTGTTGTGGCTAAGAATCAACTCATT  
94644 
 
Query  700    CAAAAAGAGAATGAAGCTGGGCTTGCTAAGGCAAAAGCAGAAAATGAAGCGATTGACAGA  
759 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94643  CAAAAAGAGAATGAAGCTGGGCTTGCTAAGGCAAAAGCAGAAAATGAAGCGATTGACAGA  
94584 
 
Query  760    CGGAATAAAGAAGGGCAAAAAGCTGTTGATGAAGCAAATAAGGCTGGGCAAGCCGCAGTA  
819 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94583  CGGAATAAAGAAGGGCAAAAAGCTGTTGATGAAGCAAATAAGGCTGGGCAAGCCGCAGTA  
94524 
 
Query  820    GAGCAAGCGAACCAAGAAAAACAAAAACAGGCCGCAAACCGTGCTTTTGAAATTGCGACA  
879 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94523  GAGCAAGCGAACCAAGAAAAACAAAAACAGGCCGCAAACCGTGCTTTTGAAATTGCGACA  
94464 
 
Query  880    ATTACCAAACGGAATAAAGAAAGAGAAGAAGTCGCAAAGAAAGAAAATGCAGCGATTGAT  
939 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94463  ATTACCAAACGGAATAAAGAAAGAGAAGAAGTCGCAAAGAAAGAAAATGCAGCGATTGAT  
94404 
 
Query  940    GCTTATAATGCGAAAGAATGGATCCGCTATAAGCGGGATTTAGCAAACATCTCAAAAGGG  
999 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94403  GCTTATAATGCGAAAGAATGGATCCGCTATAAGCGGGATTTAGCAAACATCTCAAAAGGG  
94344 
 
Query  1000   GAGGAAGGCTACATTTCAGAAGCCCTTGCGCAGGCTCTAGATTTAAATCATGGCGAACCG  
1059 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94343  GAGGAAGGCTACATTTCAGAAGCCCTTGCGCAGGCTCTAGATTTAAATCATGGCGAACCG  
94284 
 
Query  1060   CAGGTCAAACATGGTGCAGGTACTCGAAATCCAGATCGAATCATTTCAAAGGGAGATGCC  
1119 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94283  CAGGTCAAACATGGTGCAGGTACTCGAAATCCAGATCGAATCATTTCAAAGGGAGATGCC  
94224 
 
Query  1120   ATGTTGGGTGGCTATTCTAACATTCTTGATTCAACGGGTTTCTTTGTCTACAATCACTTT  
1179 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94223  ATGTTGGGTGGCTATTCTAACATTCTTGATTCAACGGGTTTCTTTGTCTACAATCACTTT  
94164 
 
Query  1180   AAAACAGGTGAAACGCTGAACTTTACCTATCAAAATCTGAAGCATGCACGTTTTGATGGG  
1239 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94163  AAAACAGGTGAAACGCTGAACTTTACCTATCAAAATCTGAAGCATGCACGTTTTGATGGG  
94104 
 
Query  1240   AAGAAAATTACAGCCATAACTTATGATATTACCAATCTGGTTTCACCAACTGGAACCAAT  
1299 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
201 
 
Sbjct  94103  AAGAAAATTACAGCCATAACTTATGATATTACCAATCTGGTTTCACCAACTGGAACCAAT  
94044 
 
Query  1300   GCGGTGCAGTTAGTTGTTCCAAACGACCCAACAGAAGGCTTTATTGCTTATCGCAATGAT  
1359 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  94043  GCGGTGCAGTTAGTTGTTCCAAACGACCCAACAGAAGGCTTTATTGCTTATCGCAATGAT  
93984 
 
Query  1360   GGCGCTGGAAATTGGCGGACAGATAAGATGGAGTTCCGTGTCAAAGCTCGGTATTTCTTA  
1419 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93983  GGCGCTGGAAATTGGCGGACAGATAAGATGGAGTTCCGTGTCAAAGCTCGGTATTTCTTA  
93924 
 
Query  1420   GAAGACGGTTCACAAGTGACCTTTACTAAAGAAAAACCAGGTGTCTTTACCCACTCGTCA  
1479 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93923  GAAGACGGTTCACAAGTGACCTTTACTAAAGAAAAACCAGGTGTCTTTACCCACTCGTCA  
93864 
 
Query  1480   CTCAATCATAATGATATTGGGCTTGAATATGTTAAAGACTCATCAGGTAAATTTGTTCCT  
1539 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93863  CTCAATCATAATGATATTGGGCTTGAATATGTTAAAGACTCATCAGGTAAATTTGTTCCT  
93804 
 
Query  1540   ATTCATGGTTCAAGTGTGCAAGTAACCAATGAGGGCTTAGCCCGTTCGTTAGGTTCAAAC  
1599 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93803  ATTCATGGTTCAAGTGTGCAAGTAACCAATGAGGGCTTAGCCCGTTCGTTAGGTTCAAAC  
93744 
 
Query  1600   CGAGCGAGTGACTTGAAGTTGCCAGAAGAATGGGATACGACTTCTAGTCGCTATGCTTAT  
1659 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93743  CGAGCGAGTGACTTGAAGTTGCCAGAAGAATGGGATACGACTTCTAGTCGCTATGCTTAT  
93684 
 
Query  1660   AAAGGAGCGATTGTATCAACAGTCACATCGGGGAATATTTATACCGTAACCTTTGGCCAA  
1719 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93683  AAAGGAGCGATTGTATCAACAGTCACATCGGGGAATATTTATACCGTAACCTTTGGCCAA  
93624 
 
Query  1720   GGAGATATGCCAACCCAAGTGGGAGGGAAGACCTATTGGTTTGCTTTAAATACTTTGCCA  
1779 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93623  GGAGATATGCCAACCCAAGTGGGAGGGAAGACCTATTGGTTTGCTTTAAATACTTTGCCA  
93564 
 
Query  1780   GTCGCAAAAACAGTGACTCCCTACAATCCAAAGACTCATGTAAGACCACAGCTGGATCCA  
1839 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93563  GTCGCAAAAACAGTGACTCCCTACAATCCAAAGACTCATGTAAGACCACAGCTGGATCCA  
93504 
 
Query  1840   GTTCCTGAACCGATAAAAGTTACACCAGAAACTTATACTCCTAAAATCTTTACTCCTGAA  
1899 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93503  GTTCCTGAACCGATAAAAGTTACACCAGAAACTTATACTCCTAAAATCTTTACTCCTGAA  
93444 
 
Query  1900   AAACCAGTAACCTTTACTCCAAAATCAGTAGAAAAAGTGCCCCAACCTAGTTTGACCTTA  
1959 
202 
 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93443  AAACCAGTAACCTTTACTCCAAAATCAGTAGAAAAAGTGCCCCAACCTAGTTTGACCTTA  
93384 
 
Query  1960   ACAAAAGTCACACTACCAACAAATCTGAAGCTAGAACCATTACCCAAAGCTCCACAAAAG  
2019 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93383  ACAAAAGTCACACTACCAACAAATCTGAAGCTAGAACCATTACCCAAAGCTCCACAAAAG  
93324 
 
Query  2020   CCAACCGTTCATTACCACGATTACCTCTTAACCACAACACCCGCTATCGCAAAAGAAGTG  
2079 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93323  CCAACCGTTCATTACCACGATTACCTCTTAACCACAACACCCGCTATCGCAAAAGAAGTG  
93264 
 
Query  2080   ATGAATGTTGACAAAGTTAATCTTCATGGTAAACAGGTGGCTAAGGATTCCACTGTTATT  
2139 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93263  ATGAATGTTGACAAAGTTAATCTTCATGGTAAACAGGTGGCTAAGGATTCCACTGTTATT  
93204 
 
Query  2140   TATCCCTTGACAGTAGATGTTTTATCTCCAAATCGTTCCAAGATAACCAGTCTTATCTTT  
2199 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93203  TATCCCTTGACAGTAGATGTTTTATCTCCAAATCGTTCCAAGATAACCAGTCTTATCTTT  
93144 
 
Query  2200   GAAGATTATCTGCCTGCTGGTTATGCGTTTGATATGACGAAGACACAAGCGGAGAATAGC  
2259 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93143  GAAGATTATCTGCCTGCTGGTTATGCGTTTGATATGACGAAGACACAAGCGGAGAATAGC  
93084 
 
Query  2260   GACTATGACTTAACCTTTGATAAAAATAAGAACTTTGTGACCTTGAAAGCGAAAGATAGC  
2319 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93083  GACTATGACTTAACCTTTGATAAAAATAAGAACTTTGTGACCTTGAAAGCGAAAGATAGC  
93024 
 
Query  2320   TTACTTCAAACGTTGAATAAAGAGTTAAACAAGTCTTATCAACTGTCTGCTCCAAAACTT  
2379 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  93023  TTACTTCAAACGTTGAATAAAGAGTTAAACAAGTCTTATCAACTGTCTGCTCCAAAACTT  
92964 
 
Query  2380   TATGGTTCAGTTCAAAATGATGGGGCGACTTATTCTAATAGCTATAAACTCCTTATTAAC  
2439 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92963  TATGGTTCAGTTCAAAATGATGGGGCGACTTATTCTAATAGCTATAAACTCCTTATTAAC  
92904 
 
Query  2440   AAGGACACCCCAAACACCTATACGGTTATTTCAAACGTAGTTAGAATTCGGACTCCAGGA  
2499 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92903  AAGGACACCCCAAACACCTATACGGTTATTTCAAACGTAGTTAGAATTCGGACTCCAGGA  
92844 
 
Query  2500   GACGGTGAAACGACCAGCCGAATCCGGCCTAAAAAGGACAATGAAAATGCGGACGGT  2556 
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92843  GACGGTGAAACGACCAGCCGAATCCGGCCTAAAAAGGACAATGAAAATGCGGACGGT  92787 
  
203 
 
Gbs1539 
Score =   826 bits (447),  Expect = 0.0 
 Identities = 447/447 (100%), Gaps = 0/447 (0%) 
 Strand=Plus/Minus 
 
Query  1      GCTGATACAAGTGATAAGAATACTGACACGAGTGTCGTGACTACGACCTTATCTGAGGAG  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92787  GCTGATACAAGTGATAAGAATACTGACACGAGTGTCGTGACTACGACCTTATCTGAGGAG  
92728 
 
Query  61     AAAAGATCAGATGAACTAGACCAGTCTAGTACTGGTTCTTCTTCTGAAAATGAATCGAGT  
120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92727  AAAAGATCAGATGAACTAGACCAGTCTAGTACTGGTTCTTCTTCTGAAAATGAATCGAGT  
92668 
 
Query  121    TCATCAAGTGAACCAGAAACAAATCCGTCAACTAATCCACCTACAACAGAACCATCGCAA  
180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92667  TCATCAAGTGAACCAGAAACAAATCCGTCAACTAATCCACCTACAACAGAACCATCGCAA  
92608 
 
Query  181    CCCTCACCTAGTGAAGAGAACAAGCCTGATGGTAGAACGAAGACAGAAATTGGCAATAAT  
240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92607  CCCTCACCTAGTGAAGAGAACAAGCCTGATGGTAGAACGAAGACAGAAATTGGCAATAAT  
92548 
 
Query  241    AAGGATATTTCTAGTGGAACAAAAGTATTAATTTCAGAAGATAGTATTAAGAATTTTAGT  
300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92547  AAGGATATTTCTAGTGGAACAAAAGTATTAATTTCAGAAGATAGTATTAAGAATTTTAGT  
92488 
 
Query  301    AAAGCAAGTAGTGATCAAGAAGAAGTGGATCGCGATGAATCATCATCTTCAAAAGCAAAT  
360 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92487  AAAGCAAGTAGTGATCAAGAAGAAGTGGATCGCGATGAATCATCATCTTCAAAAGCAAAT  
92428 
 
Query  361    GATGGGAAAAAAGGCCACAGTAAGCCTAAAAAGGAACTTCCTAAAACAGGAGATAGCCAC  
420 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  92427  GATGGGAAAAAAGGCCACAGTAAGCCTAAAAAGGAACTTCCTAAAACAGGAGATAGCCAC  
92368 
 
Query  421    TCAGATACTGTAATAGCATCTACGGGA  447 
              ||||||||||||||||||||||||||| 
Sbjct  92367  TCAGATACTGTAATAGCATCTACGGGA  92341 
  
204 
 
Gbs2106 
Score =   998 bits (540),  Expect = 0.0 
 Identities = 543/546 (99%), Gaps = 0/546 (0%) 
 Strand=Plus/Minus 
 
Query  1      GCAGATAAAGTTCGCGTAGCCaaaaaatcaaaaaTGACTAAGGCGACATCTAAAYCWWAA  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||| |  || 
Sbjct  73484  GCAGATAAAGTTCGCGTAGCCAAAAAATCAAAAATGACTAAGGCGACATCTAAATCAAAA  
73425 
 
Query  61     GTAGAAGATGTAAAACAGGCTCCAAAACCTTCTCAGGCATCTAATGAAGCCCCAAAATCA  
120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73424  GTAGAAGATGTAAAACAGGCTCCAAAACCTTCTCAGGCATCTAATGAAGCCCCAAAATCA  
73365 
 
Query  121    AGTTCTCAATCTACAGAAGCTAATTCTCAGCAACAAGTTACTGCGAGTGAAGAGGCAGCT  
180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73364  AGTTCTCAATCTACAGAAGCTAATTCTCAGCAACAAGTTACTGCGAGTGAAGAGGCAGCT  
73305 
 
Query  181    GTAGAACAAGCAGTTGTAACAGAAAACACCCCTGCTACCAGTCAGGCACAACAAGCTTAT  
240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73304  GTAGAACAAGCAGTTGTAACAGAAAACACCCCTGCTACCAGTCAGGCACAACAAGCTTAT  
73245 
 
Query  241    GCTGTTACTGAGACAACTTATAGACCTGCTCAACACCAGACGAGTGGCCAAGTATTGAGT  
300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73244  GCTGTTACTGAGACAACTTATAGACCTGCTCAACACCAGACGAGTGGCCAAGTATTGAGT  
73185 
 
Query  301    AATGGAAATACTGCAGGGGCTATTGGCTCAGCAGCTGCAGCACAAATGGCTGCTGCAACA  
360 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73184  AATGGAAATACTGCAGGGGCTATTGGCTCAGCAGCTGCAGCACAAATGGCTGCTGCAACA  
73125 
 
Query  361    GGAGTCCCTCAGTCTACTTGGGAACATATTATTGCCCGTGAATCAAATGGTAATCCTAAT  
420 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73124  GGAGTCCCTCAGTCTACTTGGGAACATATTATTGCCCGTGAATCAAATGGTAATCCTAAT  
73065 
 
Query  421    GTTGCTAATGCCTCAGGAGCTTCAGGACTTTTCCAAACGATGCCAGGTTGGGGTTCAACA  
480 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73064  GTTGCTAATGCCTCAGGAGCTTCAGGACTTTTCCAAACGATGCCAGGTTGGGGTTCAACA  
73005 
 
Query  481    GCTACAGTTCAGGATCAAGTTAATTCAGCTATTAAAGCTTATCGTGCTCAAGGTTTATCA  
540 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73004  GCTACAGTTCAGGATCAAGTTAATTCAGCTATTAAAGCTTATCGTGCTCAAGGTTTATCA  
72945 
 
Query  541    GCTTGG  546 
              |||||| 
Sbjct  72944  GCTTGG  72939 
205 
 
LysM domain protein (gbs2107) 
Score =   750 bits (406),  Expect = 0.0 
 Identities = 407/408 (99%), Gaps = 0/408 (0%) 
 Strand=Plus/Minus 
 
Query  1      ACCGTGAAATCAGGTGATACCTTATCAGCTATTGCTAAAAATCATAAAACTACGGTACAA  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  74171  ACCGTGAAATCAGGTGATACCTTATCAGCTATTGCTAAAAATCATAAAACTACGGTACAA  
74112 
 
Query  61     GAGTTAGTGTCTCTCAATAGTATCAGTAACGCTGATGTCATCAGTATAGGTGATGTTTTA  
120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  74111  GAGTTAGTGTCTCTCAATAGTATCAGTAACGCTGATGTCATCAGTATAGGTGATGTTTTA  
74052 
 
Query  121    AAATTGGATAATTCTAAAGCTAGTCAAGCAGAAGCAAAATCTCAACCAACAATTGAAAAT  
180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  74051  AAATTGGATAATTCTAAAGCTAGTCAAGCAGAAGCAAAATCTCAACCAACAATTGAAAAT  
73992 
 
Query  181    TCAATGAATTCTTCATCAAATTTGAGTTCAAGTGATTCAGCCGCMAAAGAAGAAATAGCT  
240 
              |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||| 
Sbjct  73991  TCAATGAATTCTTCATCAAATTTGAGTTCAAGTGATTCAGCCGCAAAAGAAGAAATAGCT  
73932 
 
Query  241    CGTCGTGAATCAAATGGTAGTTATACTGCACAGAATGGACAATATTATGGAAGATATCAA  
300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73931  CGTCGTGAATCAAATGGTAGTTATACTGCACAGAATGGACAATATTATGGAAGATATCAA  
73872 
 
Query  301    CTGTCTCAATCTTACCTAAATGGCGACTTATCTCCTGAAAATCAAGAAAAAGTAGCGGAC  
360 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73871  CTGTCTCAATCTTACCTAAATGGCGACTTATCTCCTGAAAATCAAGAAAAAGTAGCGGAC  
73812 
 
Query  361    AATTATGTGGTTTCTCGTTACGGATCTTGGTCGGCAGCGCTATCATTT  408 
              |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  73811  AATTATGTGGTTTCTCGTTACGGATCTTGGTCGGCAGCGCTATCATTT  73764 
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Foldase PrsA protein (gbs0827) 
Score =  1465 bits (793),  Expect = 0.0 
 Identities = 794/795 (99%), Gaps = 0/795 (0%) 
 Strand=Plus/Plus 
 
Query  1      GTTGTTACMATGAAGGGCGACACTATCACAGTCTCTGATTTTTATGATCAAGTAAAAACA  60 
              |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  66812  GTTGTTACAATGAAGGGCGACACTATCACAGTCTCTGATTTTTATGATCAAGTAAAAACA  
66871 
 
Query  61     TCAAAAGCTGCACAACAATCAATGCTTACATTGATCCTCTCACGTGTTTTTGATACACAG  
120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  66872  TCAAAAGCTGCACAACAATCAATGCTTACATTGATCCTCTCACGTGTTTTTGATACACAG  
66931 
 
Query  121    TATGGTGATAAAGTTTCAGATAAAAAAGTATCAGAAGCTTATAATAAGACAGCTAAAGGC  
180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  66932  TATGGTGATAAAGTTTCAGATAAAAAAGTATCAGAAGCTTATAATAAGACAGCTAAAGGC  
66991 
 
Query  181    TATGGTAATTCATTTTCAAGCGCACTTTCACAAGCAGGTTTGACTCCAGAAGGTTACAAA  
240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  66992  TATGGTAATTCATTTTCAAGCGCACTTTCACAAGCAGGTTTGACTCCAGAAGGTTACAAA  
67051 
 
Query  241    CAACAAATTCGCACAACTATGCTTGTGGAATATGCTGTAAAAGAAGCAGCTAAGAAAGAA  
300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67052  CAACAAATTCGCACAACTATGCTTGTGGAATATGCTGTAAAAGAAGCAGCTAAGAAAGAA  
67111 
 
Query  301    TTAACAGAAGCAAACTATAAAGAAGCATATAAAAACTATACTCCTGAAACTTCTGTACAA  
360 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67112  TTAACAGAAGCAAACTATAAAGAAGCATATAAAAACTATACTCCTGAAACTTCTGTACAA  
67171 
 
Query  361    GTAATCAAATTGGATGCAGAAGATAAAGCTAAATCTGTCCTTAAAGATGTAAAGGCTGAT  
420 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67172  GTAATCAAATTGGATGCAGAAGATAAAGCTAAATCTGTCCTTAAAGATGTAAAGGCTGAT  
67231 
 
Query  421    GGAGCTGATTTTGCAAAGATTGCAAAAGAAAAAACAACAGCTACTGATAAAAAAGTTGAG  
480 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67232  GGAGCTGATTTTGCAAAGATTGCAAAAGAAAAAACAACAGCTACTGATAAAAAAGTTGAG  
67291 
 
Query  481    TATAAATTTGATTCTGCAGGGACAAGCCTCCCTAAAGAAGTTATGTCAGCAGCCTTTAAG  
540 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67292  TATAAATTTGATTCTGCAGGGACAAGCCTCCCTAAAGAAGTTATGTCAGCAGCCTTTAAG  
67351 
 
Query  541    CTAGATAAAAATGGTGTTTCAGATGTGGTTTCAACGGTTGATTCAACAACTTATAAAACA  
600 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67352  CTAGATAAAAATGGTGTTTCAGATGTGGTTTCAACGGTTGATTCAACAACTTATAAAACA  
67411 
207 
 
 
Query  601    AGTTACTACATCATTAAAGTAACTGATAAGACAGAGAAAAAATCTGATTGGAAATCTTAC  
660 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67412  AGTTACTACATCATTAAAGTAACTGATAAGACAGAGAAAAAATCTGATTGGAAATCTTAC  
67471 
 
Query  661    AAAAATCGCTTAAAAGAAGTTATTCTTAAGGATAAAACAAGCGATAGATCCTTCCAAAAT  
720 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67472  AAAAATCGCTTAAAAGAAGTTATTCTTAAGGATAAAACAAGCGATAGATCCTTCCAAAAT  
67531 
 
Query  721    AAAGTGATTTCAAAAGCCTTAGAAAAAGCTAACGTTAAGATTAAAGATAAAGCATTTGCA  
780 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67532  AAAGTGATTTCAAAAGCCTTAGAAAAAGCTAACGTTAAGATTAAAGATAAAGCATTTGCA  
67591 
 
Query  781    GGCATCTTATCACAA  795 
              ||||||||||||||| 
Sbjct  67592  GGCATCTTATCACAA  67606 
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Surface immunogenic protein (gbs0031) 
Score =  2255 bits (1221),  Expect = 0.0 
 Identities = 1221/1221 (100%), Gaps = 0/1221 (0%) 
 Strand=Plus/Plus 
 
Query  41     GCACAAGAAACAGATACGACGTGGACAGCACGTACTGTTTCAGAGGTAAAGGCTGATTTG  
100 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  47593  GCACAAGAAACAGATACGACGTGGACAGCACGTACTGTTTCAGAGGTAAAGGCTGATTTG  
47652 
 
Query  101    GTAAAGCAAGACAATAAATCATCATATACTGTGAAATATGGTGATACACTAAGCGTTATT  
160 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  47653  GTAAAGCAAGACAATAAATCATCATATACTGTGAAATATGGTGATACACTAAGCGTTATT  
47712 
 
Query  161    TCAGAAGCAATGTCAATTGATATGAATGTCTTAGCAAAAATAAATAACATTGCAGATATC  
220 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  47713  TCAGAAGCAATGTCAATTGATATGAATGTCTTAGCAAAAATAAATAACATTGCAGATATC  
47772 
 
Query  221    AATCTTATTTATCCTGAGACAACACTGACAGTAACTTACGATCAGAAGAGTCATACTGCC  
280 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  47773  AATCTTATTTATCCTGAGACAACACTGACAGTAACTTACGATCAGAAGAGTCATACTGCC  
47832 
 
Query  281    ACTTCAATGAAAATAGAAACACCAGCAACAAATGCTGCTGGTCAAACAACAGCTACTGTG  
340 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  47833  ACTTCAATGAAAATAGAAACACCAGCAACAAATGCTGCTGGTCAAACAACAGCTACTGTG  
47892 
 
Query  341    GATTTGAAAACCAATCAAGTTTCTGTTGCAGACCAAAAAGTTTCTCTCAATACAATTTCG  
400 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  47893  GATTTGAAAACCAATCAAGTTTCTGTTGCAGACCAAAAAGTTTCTCTCAATACAATTTCG  
47952 
 
Query  401    GAAGGTATGACACCAGAAGCAGCAACAACGATTGTTTCGCCAATGAAGACATATTCTTCT  
460 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  47953  GAAGGTATGACACCAGAAGCAGCAACAACGATTGTTTCGCCAATGAAGACATATTCTTCT  
48012 
 
Query  461    GCGCCAGCTTTGAAATCAAAAGAAGTATTAGCACAAGAGCAAGCTGTTAGTCAAGCAGCA  
520 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48013  GCGCCAGCTTTGAAATCAAAAGAAGTATTAGCACAAGAGCAAGCTGTTAGTCAAGCAGCA  
48072 
 
Query  521    GCTAATGAACAGGTATCACCAGCTCCTGTGAAGTCGATTACTTCAGAAGTTCCAGCAGCT  
580 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48073  GCTAATGAACAGGTATCACCAGCTCCTGTGAAGTCGATTACTTCAGAAGTTCCAGCAGCT  
48132 
 
Query  581    AAAGAGGAAGTTAAACCAACTCAGACGTCAGTCAGTCAGTCAACAACAGTATCACCAGCT  
640 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
209 
 
Sbjct  48133  AAAGAGGAAGTTAAACCAACTCAGACGTCAGTCAGTCAGTCAACAACAGTATCACCAGCT  
48192 
 
Query  641    TCTGTTGCCGCTGAAACACCAGCTCCAGTAGCTAAAGTAGCACCGGTAAGAACTGTAGCA  
700 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48193  TCTGTTGCCGCTGAAACACCAGCTCCAGTAGCTAAAGTAGCACCGGTAAGAACTGTAGCA  
48252 
 
Query  701    GCCCCTAGAGTGGCAAGTGTTAAAGTAGTCACTCCTAAAGTAGAAACTGGTGCATCACCA  
760 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48253  GCCCCTAGAGTGGCAAGTGTTAAAGTAGTCACTCCTAAAGTAGAAACTGGTGCATCACCA  
48312 
 
Query  761    GAGCATGTATCAGCTCCAGCAGTTCCTGTGACTACGACTTCACCAGCTACAGACAGTAAG  
820 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48313  GAGCATGTATCAGCTCCAGCAGTTCCTGTGACTACGACTTCACCAGCTACAGACAGTAAG  
48372 
 
Query  821    TTACAAGCGACTGAAGTTAAGAGCGTTCCGGTAGCACAAAAAGCTCCAACAGCAACACCG  
880 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48373  TTACAAGCGACTGAAGTTAAGAGCGTTCCGGTAGCACAAAAAGCTCCAACAGCAACACCG  
48432 
 
Query  881    GTAGCACAACCAGCTTCAACAACAAATGCAGTAGCTGCACATCCTGAAAATGCAGGGCTC  
940 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48433  GTAGCACAACCAGCTTCAACAACAAATGCAGTAGCTGCACATCCTGAAAATGCAGGGCTC  
48492 
 
Query  941    CAACCTCATGTTGCAGCTTATAAAGAAAAAGTAGCGTCAACTTATGGAGTTAATGAATTC  
1000 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48493  CAACCTCATGTTGCAGCTTATAAAGAAAAAGTAGCGTCAACTTATGGAGTTAATGAATTC  
48552 
 
Query  1001   AGTACATACCGTGCGGGAGATCCAGGTGATCATGGTAAAGGTTTAGCAGTTGACTTTATT  
1060 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48553  AGTACATACCGTGCGGGAGATCCAGGTGATCATGGTAAAGGTTTAGCAGTTGACTTTATT  
48612 
 
Query  1061   GTAGGTACTAATCAAGCACTTGGTAATAAAGTTGCACAGTACTCTACACAAAATATGGCA  
1120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48613  GTAGGTACTAATCAAGCACTTGGTAATAAAGTTGCACAGTACTCTACACAAAATATGGCA  
48672 
 
Query  1121   GCAAATAACATTTCATATGTTATCTGGCAACAAAAGTTTTACTCAAATACAAACAGTATT  
1180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48673  GCAAATAACATTTCATATGTTATCTGGCAACAAAAGTTTTACTCAAATACAAACAGTATT  
48732 
 
Query  1181   TATGGACCTGCTAATACTTGGAATGCAATGCCAGATCGTGGTGGCGTTACTGCCAACCAC  
1240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48733  TATGGACCTGCTAATACTTGGAATGCAATGCCAGATCGTGGTGGCGTTACTGCCAACCAC  
48792 
 
Query  1241   TATGACCACGTTCACGTATCA  1261 
              ||||||||||||||||||||| 
210 
 
Sbjct  48793  TATGACCACGTTCACGTATCA  48813 
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10.4 Recombinant protein purification 
Overexpressed GBS proteins were purified using Fast Perfomance Liquid 
Chromatography (ATKA FPLC, GE-Healthcare) and visualised by SDS-PAGE 
analysis. Figure 10.3 depict the un-purified lysate and the pure protein eluted from the 
Ni2+ affinity column. All proteins were successfully purified, however, gbs0393 and 
Tgbs1356 partially degraded. Proteins BibA-COH1, BibA-NEM316, FbsA and gbs0233 
were kindly provided by Valneva Austria GmbH. 
212 
 
 
Figure 10.3 SDS-PAGE visualisation of purified group B Streptococcus recombinant proteins 
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10.5 Multiplex Luminex assay validation and standardisation 
Protein specific IgG titres in serum collected from study participants were measured 
using the Bio-plex 200 Luminex system (BioRad, USA). The method is comparable to 
an ELISA immunological assay, however, the Luminex system is capable of 
simultaneous quantification of antibodies targeting different antigens. This is achieved 
by using a dual laser, flow cytometric principle that identifies fluorescent micro-beads 
conjugated with the antigen and simultaneously quantifying bound antibodies. 
Quantification of the bound antibodies is based on an indirect antibody capture 
immunoassay where a secondary antibody (anti-human IgG) tagged with a fluorophore 
is used as a signal reporter. Data is measured as the fluorescent intensity relative to 
antigen-antibody concentration.  
This section describes the validation of the multiplex Luminex assay for the 
quantification of IgG titres specific to GBS surface proteins Sip, BibA-COH1, BibA-
NEM316, Foldase, gbs0233 gbs0392, gbs0393, gbs1356, gbs1539 and 2106. The 
optimal protein concentration for conjugating to the microbeads and the specificity of 
the reference serum (Polygam) were established for each protein antigen included in the 
assay. Intra-assay reproducibility was monitored using pooled sera of participants with 
high IgG titres (high titres control) and those that had low IgG titres (low titres control).  
10.5.1 Quantification of optimal protein concentration 
To determine the optimal protein concentration for conjugating to the microbeads, 
antibodies against proteins BibA-COH1, FbsA, Foldase, gbs0233, gbs0392 and gbs0393 
were measured using Polygam. The concentrations of the purified recombinant proteins 
were determined using Pierce® BCA Protein Assay Kit (ThermoScientific, USA) 
214 
 
according to manufacturer’s instructions. Proteins were diluted in PBS solution into 5 
dilutions of 125 µg/mL, 100 µg/mL, 75 µg/mL, 50 µg/mL and 25 µg/mL protein 
concentrations. Proteins were coupled to unique micro-beads as described in the 
methods section 3.4.1. A singleplex assay was performed for each protein dilution using 
1:100 Polygam dilutions and fluorescence intensity (FI) was measured, Figure 10.4. 
Protein concentration of 50 µg/mL was established as the optimal conjugating 
concentration and used in subsequent Luminex immunoassays. 
 
Figure 10.4 Quantification of optimal protein concentration for conjugating to micro-beads. 
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10.5.2 Cross-reactivity and specificity of reference serum 
Cross-reactivity of BibA-NEM316 and BibA-COH1 
GBS recombinant proteins supplied by Vulneva Gmb Austria of gbs2018 (BibA)-
NEM316 a variant of BibA of strain COH1 had a sequence identity of 43%. Sequence 
comparisons of BibA protein from NEM316 and COH1 strains have highly identical 
flanking sequences. Heterogeneity occurs within internal regions of the two proteins 
that may have a significant role in pathogenicity and immunogenicity (51). To include 
both BibA variants in a multiplex assay; fragment peptide of BibA-NEM316 inclusive 
of the variable region that showed least identity with BibA-COH1 was selected based 
on multiple sequence alignment as depicted below. 
(gbs2018COH1:gbs2018-1) Aligned. Score: 16 
(gbs2018COH1:gbs2018-A) Aligned. Score: 22.5806 
(gbs2018COH1:gbs2018-C) Aligned. Score: 88.6792 
 
gbs2018COH1      MDSPDTLKVEKLGKLKDVKSVHELTPISIPNELKGAKEQALSSIISHPNITNSEVDKLAS 
gbs2018-C_       ------------------------------------------------------------ 
gbs2018-A        ------------------------------------------------------------ 
gbs2018-1        ------------------------------------------------------------ 
 
 
gbs2018COH1      DYSFRINTSNDVNDVKRLLNEFYNAVARKQLDTNSADYRSKIDNISTTGLAIALEAKEIY 
gbs2018-C_       ------------------------------------------------------------ 
gbs2018-A        ------------------------------------------------------------ 
gbs2018-1        ----------------------MATHAKVSDQELGKQSRRSQDIIKSLGFLSSDQKDILV 
 
 
gbs2018COH1      EANKSILPHRYKDSVGTYVNSFEERRSPGKFNIWNGQEGFNAAQKLLEDVKKLLLELQNL 
gbs2018-C_       ------------------------------------------------------------ 
gbs2018-A        ------------------------------------------------------------ 
gbs2018-1        KSISSSKDSQLILKFVTQAT---------QLNNAESTKAKQMAQNDVALIKNISPEVLEE 
 
 
gbs2018COH1      TKNNKPNIQVPKQAPTEAAKPALSPEALTRLTTWYNQAKDLLKDDQVKDKYVDILSVQKA 
gbs2018-C_       -MEAKPNIQVPKQAPTEAAKPALSPEALTRLTTWYNQAKDLLKDDQVKDKYVDILAVQKA 
gbs2018-A        ---------MDTSSGISASIPHKKQVNLGAVTLKNLISKYRGND--------------KA 
gbs2018-1        YKEKIQRASTKSQVDEFVAEAKKVVNSNKETLVNQANGKKQEIAKLENLSNDEMLRYNTA 
..    .: .                .*                   .* 
 
gbs2018COH1      VDQAYDHVEEGKFITTDQANQLANKLRDALQSLELKDKKVAKPVAKGTYDVKYVDTEGKE 
gbs2018-C_       VDQAYDHVEEGKFITTDQANQLANKLRDALQSLELKDKKVAKPEAK-------------- 
gbs2018-A        IAILLSRVNDFNRASQDTLPQLINSTEAEIRNILYQG----------------------- 
gbs2018-1        IDNVVKQYNEGKLNITAAMNALNSIKQAAQEVAQKNLQKQYAKKIER------------- 
:    .: :: :         * .  .   .    : 
 
gbs2018COH1      VAKSRHFEGEEGAAFVTSAKEVAGYKLVRTEGAVSNVFTAGAQVRTYVYEKVKPEVKPDV 
gbs2018-C_       -----------------------------------------------------PEAKPEA 
gbs2018-A        ------------------------------------------------------------ 
gbs2018-1        --------------------------------------------------------ISSK 
 
 
gbs2018COH1      KPEAKPEAKPEVKPDVKPEAKPEAKPEVKSDVKPEAKPEAKPEAKPEVKPDVKPEAKPEA 
gbs2018-C_       KPEAKPEAKPEAKPEAKPEAKPDVKPEAKPDVKPEAKPEAKPEAKSEAKPEAKLEAKPEA 
gbs2018-A        ------------------------------------------------------------ 
gbs2018-1        GLALSKKAKEIYEKHKSILPTPGYYADSVGTYLNRFRDKQTFGNRSVWTGQSGLDEAKKM 
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gbs2018COH1      KPATKKSVNTSGNLVAKKAIENKKYSKKLPSTLEHHHHHH 
gbs2018-C_       KPATKKSVNTSGNLAAKKAIENKKYSKKLPSTLEHHHHHH 
gbs2018-A        ---------------------QIGKQNKPSVTLEHHHHHH 
gbs2018-1        LDEVKKLLKELQDLTRGTKEDKKPDVKPEAKPLEHHHHHH 
 
An ELISA competitive inhibition assay was performed to determine the degree of 
cross-reactivity between BibA from COH1 strain and the internal fragment BibA 
peptide form NEM316. Firstly, optimal coating concentration for each antigen was 
measured to determine the sensitivity of the assay. A 2-fold serial dilution of 20 µg/mL 
of protein antigen (20 µg/mL-0.002 µg/mL) in 100 µL PBS, 0.05% NaN3 was absorbed 
on to Nunc maxisorb 96 well microtitre flat bottomed plates (ThermoScientific, 
Denmark) at 37oC for 5 h and then overnight at 4oC. Unbound protein antigen was 
washed 4 times with PBS, 0.05% Tween20 (washing buffer) and the binding sites were 
blocked by adding 300 µL/well of PBS, 10% fetal bovine serum (blocking buffer) and 
incubated at 37oC for 1 h. After blocking, the plate was washed 4× with washing buffer. 
Antigen specific antibodies in Polygam (pooled IgG) sera diluted 1:100, 1:200, 1:400 
and 1:1800 in blocking buffer was added 100 µL/well and allowed to bind to the 
respective antigen at 37oC for 2 h. Unbound antibodies were washed 4× with washing 
buffer and bound IgG was detected by adding 100 µL/well of goat anti-human IgG 
conjugated with alkaline phosphatase (Jackson ImmunoResearch, USA) diluted 1:2000 
in blocking buffer at 37oC for 2 h. Unbound antibodies was removed by washing 4× 
with washing buffer and 2× with distilled water. Signal was developed by adding 100 
µL/well of 1 mg/mL of p-nitrophenol phosphate disodium (Sigma-Aldrich), with signal 
allowed to develop for 1 h at room temperature. Absorbance was measured at 405nm 
using MultiSkan II plus plate reader (LabSystems). Optimal plate coating concentration 
was determined to be 2.5 µg/mL and 5µg/mL for BibA-COH1 and BibA-NEM316 
respectively, Figure 10.5 
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Figure 10.5 Sensitivity ELISA assay to determine optimal protein concentration for absorption of BibA-
COH1 and BibA-NEM316 to microtitre plate. 
  
The Competitive inhibition ELISA assay for BibA-COH1 and BibA-NEM1 was 
performed similar to the sensitivity ELISA assay with the exception that 2-fold diluted 
Polygam (1:100-1:64000) was mixed with 20 µg/mL of either BibA-COH1 or BibA-
NEM316 prior adding to bound antigen on the plate. Absorbance signal detected from 
homologous and heterologous inhibition was compared to uninhibited Polygam. There 
was no significant cross-reactivity observed between the two peptides and therefore no 
quantitation inference was expected during multiplex immunoassay of the two antigens, 
Figure 10.6.  
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Figure 10.6 ELISA competitive inhibition assay, A, homologous inhibition of BibA-1 peptide and B, 
homologous inhibition of BibA-COH1  protein, error bars are indicative of standard error of the mean. 
Cross-reactivity of GBS surface protein in multiplex assay 
Comparisons of a singleplex and multiplex assays were conducted for each GBS surface 
protein to determine variation of IgG binding signal in the presence of multiple 
analytes. A strong positive correlation (R2>0.9) was detected for all evaluated GBS 
proteins between the singleplex and multiplex assay, Figure 10.7.   
Specificity of the reference serum (Polygam) to GBS surface proteins was determined 
by performing a competitive inhibition assay. A multiplex Luminex was conducted as 
described in the methods section, with the exception that 5 µg of GBS protein antigen 
was incubated with 1:100 Polygam dilution at RT for 1 h prior being probed in a 
multiplex assay. The specificity of polygamy to each protein was determined by 
comparing mean fluorescent intensity (MFI) detected for each protein in the presence 
and absence of inhibiting protein. Homologous and heterologous percentage inhibition 
was calculated as (
MFI−MFIinh
MFI
) × 100%, where MFIinh is the binding intensity of 
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Polygamy in the presence of inhibiting protein. Table 10.5 includes the specificity for 
each protein included in the multiplex. 
 
  
Figure 10.7 Comparisons of IgG binding signal by multiplex (blue) and singleplex (red) immunoassay. 
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Table 10.5 Specificity absorption assay for Group B Streptococcus surface proteins, homologous 
inhibition is indicated in light grey,  and heterologous cross-reactivity ≥ 20% is marked as dark-grey. 
 Foldase Gbs0392 FbsA Gbs1539 Gbs0393 Gbs2106 BibA-
NEM316 
BibA-
COH1 
Gbs1356 sip Gbs0233 
Foldase 76.3 5.8 11.6 -60.5 13.7 2.9 -8.3 -2.4 16.9 3.4 -29.1 
Gbs0392 5.1 80.7 -2.9 -21.3 20.3 -10.8 -7.3 -7.1 0.3 -0.7 -2.9 
FbsA -19 -20.2 99.9 -10.9 -14 -5.1 -6.9 1.9 -31.4 -6.6 9.6 
Gbs1539 -20.4 9.7 -10.4 80.3 -36 -18.1 -10.2 16.7 3.2 -18.4 -8.4 
Gbs0393 18.3 24.1 13.5 -20.1 99.9 11.3 1.5 9.5 54 11.4 18.2 
Gbs2106 17.1 1.5 2.4 9. 6.7 97.8 -9.6 -5.6 2 -9 16.4 
BibA-
NEM316 
19.1 -13.9 4.3 28.6 18.9 9.1 93.2 28.2 19.9 11 -19.8 
BibA-
COH1 
12 -23.8 -1.6 8.9 12.1 0.7 0 95.2 3.5 -1.2 -39.7 
Gbs1356 39.4 -12.4 0.3 53.7 33.5 9.7 6.6 6.8 95 10.5 -24 
sip 30.9 -12.1 -8.1 8.3 18.6 -4.9 -1.9 -3.4 39 86.8 -40.3 
Gbs0233 0.1 -30.3 -6.4 16.1 -.2.3 -5.4 13.4 -5.5 -18.4 -13.2 31.9 
 
Quality control of the multiplex Luminex assay 
In-house reference sera was prepared by screening IgG titres against GBS proteins in 
serum from pregnant women with or without GBS colonisation. Sera with high IgG 
titres against the GBS surface proteins were pooled together and used as high-titred 
control (HC). Similarly, sera with low IgG titres against the proteins were pooled 
together and used as low-titred control (LC). Inter-asssay reproducibility of the assay 
was determined by constructing Levey-Jenning plots using HC and LC mean 
fluorescence intensity (MFI) for each assay run, Figure 10.8.  Assay runs that had HC 
and LC values outside  ±2SD limits were repeated. 
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Figure 10.8 Levey-Jennings plot of high and low titre sera against group B Streptococcus surface proteins included in 
multiplex Luminex assay. The lines represent the mean (blue), ±2SD (green) and ±3SD (red). 
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10.6 Generation of specific antibodies to GBS recombinant proteins 
Polyclonal antibodies specific to GBS surface proteins Sip, gbs2106, gbs0393 and 
gbs1356 were generated using rabbits. Purified recombinant protein was emulsified in 
either complete or incomplete Freund’s adjuvant and administered subcutaneously in 
three doses as described in the methods sections. Immunisation of the Sip and gbs1356 
recombinant proteins differed from the proposed immunisation schedule due to 
development of inflammation or consolidated granuloma on the injection site as a result 
of using complete Freund’s adjuvant.  
Rabbit immunised with Sip recombinant protein developed a consolidated granuloma 
after primary immunisation and therefore administration of the 1st booster dose was 
delayed by 14 days to allow the rabbit to recover after consulting with a veterinarian. 
Similarly, rabbit immunised with gbs1356 had inflammation at the injection site after 
primary immunisation and administration of the 1st booster dose was delayed by 7 days. 
Table 10.6 describes the amended immunisation schedule for the two respective protein 
antigens. 
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Table 10.6 Amended immunisation schedule for rabbits that had adverse reaction following 
administration of antigen emulsified in complete Freund’s adjuvant. 
Sip gbs1356 
Day Event Day Event 
1 Collection of control serum 1 Collection of control serum 
1 Primary Immunisation 1 Primary Immunisation 
28 Collection of test sera 28 Collection of test sera 
42 1st Booster Immunisation 35 1st Booster Immunisation 
49 Collection of test sera 42 Collection of test sera 
56 2nd Booster Immunisation 49 2nd Booster Immunisation 
70 Exsanguination 63 Exsanguination 
   
IgG antibodies against the GBS surface proteins were measured following 
immunisation of rabbits using ELISA assays. The optimal coating concentration for 
each antigen was measured to determine the sensitivity of the assay (described in 
section 10.5). A 5-fold serial dilution of 5 µg/mL of protein antigen (5 µg/mL, 1 µg/mL, 
0.2 µg/mL, 0.04 µg/mL and 0.008 µg/mL) was absorbed on to microtitre plates. Protein 
specific antibodies in pre-immunisation and post-immunisation sera (diluted 1:200, 
1:600 and 1:1800) were measured using goat anti-rabbit IgG conjugated with alkaline 
phosphatase (Jackson Immunology, USA) and signal was developed by adding p-
nitrophenol phosphate disodium (Sigma). Absorbance was measured at 405nm using 
MultiSkan II plus plate reader (LabSystems). 
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Sip and gbs1356 specific IgG antibodies had the highest signal when using 1:200 
dilutions of post-immunisation sera bound to 5 µg/mL of antigen, Figure 10.8. 
Similarly, for gbs2106 and gbs0393, 1:200 dilutions of sera showed saturation of IgG 
specific antibody level at 1.0 µg/mL of protein antigen, Figure 10.9. 
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Figure 10.9 Sensitivity assay of post-immunisation sera following immunisation with surface immunogenic protein (Sip), gbs2106, gbs0393 and gbs1356. 
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The antibody kinetics for each antigen was measured to determine seroconversion in the 
respective immunised rabbits. Protein concentration that yielded the highest signal, Sip 
(5 µg/mL), gbs2106 (1.25 µg/mL), gbs0393 (1.25 µg/mL) and gbs1356 (5 µg/mL) were 
absorbed onto plate overnight at 4oC. The assay was performed similar to the sensitivity 
assay using 1:200 and 1:800 dilutions of the pre- and post-immunisation sera. 
Figure 10.10 displaying the antibody kinetics for Sip and gbs1356 whereby the highest 
response was achieved after the primary injection. The subsequent booster doses 
marginally increased IgG antibodies level. A similar immune response was observed for 
gbs2106 and gbs0393, Figure 10.11. A seroconversion >30-fold was achieved for each 
respective antigen post-immunisation.  
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Figure 10.10 IgG response against group B Streptococcus recombinant proteins surface immunogenic 
protein (Sip) and gbs1356.  
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Figure 10.11 IgG response against group B Streptococcus recombinant proteins gbs2106 and gbs0393.  
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Cross-reactivity of the post-immunisation sera was evaluated among the immunising 
protein antigens. Highest cross-reactivity of 19% was observed between Sip and 
gbs1356, Figure 10.12.  
 
Figure 10.12 Cross-reactivity IgG antibodies from rabbits immunised with either surface immunogenic 
protein (Sip), gbs2106, gbs0393 or gbs1356. 
In vitro expression on of proteins on the surface of GBS 
Anti-GBS surface protein sera generated in rabbits were used to assess in vitro 
expression of Sip, gbs0393, gbs1356 and gbs2106 on the surface of GBS as described in 
the methods section. GBS NEM316 of serotype III from which the recombinant 
peptides were cloned was used a control. The target protein was defined as expressed on 
the surface of GBS when antibody binding from post-immunisation serum were 2-fold 
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
Sip 5µg/ml gbs2106
1.25µg/ml
gbs0393
1.25µg/ml
gbs1356 5µg/ml
A
b
so
rb
an
ce
 (
4
0
5
 n
m
)
Protein concentration
Sip
gbs2106
gbs0393
gbs1356
232 
 
higher compared to pre-immunisation serum as measured by their median fluorescence 
intensity (FI). Amongst the evaluated proteins, post-immunisation with >2-fold IgG 
binding to the surface of GBS compared to that of control sera was detected for Sip, 
gbs2106 and gbs0393 proteins. The fluorescence intensity (FI) signal detected on GBS 
when probing with pre-immunisation sera from rabbits immunised gbs0393 and 
gbs2106 were similar to that detected for unstained bacteria, Figure 10.13. Whilst, for 
Sip and gbs1356 proteins, pre-immunisation FI values were higher compared to 
unstained bacterial cells, which inevitably reduced the resolution power for inferring 
surface localisation of proteins. Antibody binding on the surface of GBS was 6-fold 
higher when using Sip specific post-immunisation sera despite the high binding signal 
of the relative pre-immunisation sera, and therefore Sip was characterised as exposed on 
the surface of GBS, Figure 10.13.  
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Figure 10.13 Evaluation of in vitro expression of proteins on the surface of group B  Streptococcus 
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10.7 Manuscripts in press 
This work entails serological analysis of GBS surface proteins in four different study 
cohorts, separated into chapters 5-8. The manuscript entitled “Natural acquired group 
B Streptococcus capsular polysaccharides and surface protein antibodies in HIV-
infected and HIV-uninfected children” comprises of the work included in chapters 4 
and 5. The second manuscript which is entitled “Reduced trans-placental transfer of 
antibodies against group B Streptococcus surface proteins in HIV-infected mother-
newborn dyads” comprises of work described in chapter 7. Reprints of both 
manuscripts are included below. 
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